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Overlaid pressure and intensity plots demonstrate the calculation of 
the effective pumping pressure (Peff) and the emptying rate (ER). 
Typical pack flow that is present before the beginning of flow 
occlusion (bottom left) is recovered after occlusion (bottom right). 
To quantify the point at which packet flow was restored, the time at 
which the magnitude of the power spectral density function (PSD) 
recovered to a specified value was calculated as described in the 
methods section.  
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right). To quantify the point at which packet flow was restored, the 
time at which the magnitude of the power spectral density function 
(PSD) recovered to a specified value was calculated as described in 
the methods section. 
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restoration pressure on the forelimb were significantly different from 
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variability from measurements taken on the tail. Error bars represent 
SEM.  
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pressure increase (*- denotes significant difference between control 
and GTNO, p<0.05) (^- denotes significant difference between 
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frequency (p<0.05). (F) Due to the valve malformations in the 
lymphatics of LEC-DKO mice, the lymphatics are unable to prevent 
backflow, and thus results in a negative emptying rate (p<0.01). (G) 
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(A) C57BL/6 mice exhibit significant weight gain on a 60% fat diet 
compared to chow fed controls (p<0.0001). (B) Representative NIR 
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vessels. (C) Representative intensity tracking showing differences in 
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mice. (D) Obesity causes significantly lower packet frequency 
(p<0.05). (E-G) No statistically significant differences were 
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Error bars represent SEM. 
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Figure 14 Graphical representation of the study design. 67 
Figure 15 (A) High fat diet induces significant weight gain in male C57BL6J 
mice (p < 0.0001). (B) Following lymphedema induction via ablation 
of a collecting lymphatic vessel and the dermal lymphatics the distal 
tissues exhibit progressive swelling that subsequently subsides. The 
tails of control and obese mice were not found to differentially swell. 
Error bars represent SEM. (*, denotes significant difference between 
control and obese, p < 0.05)Representative NIR images taken at the 
wound site 5-minutes after tracer injection at the distal tip of the tail. 




located on the lateral aspects of the tail. 1 week after ligation chow 
fed control animals exhibit uptake of fluorophore in the intact 
lymphatic vessel that subsequently transits the wound site. This was 
delayed in obese animals. However, this difference is attenuated by 
the 10-week time point. 
Figure 16 Representative NIR images taken at the wound site 5-minutes after 
tracer injection at the distal tip of the tail. Pre-surgery images depict 
the two collecting lymphatic vessels located on the lateral aspects of 
the tail. 1 week after ligation chow fed control animals exhibit uptake 
of fluorophore in the intact lymphatic vessel that subsequently 
transits the wound site. This was delayed in obese animals. However, 
this difference is attenuated by the 10-week time point.  
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arrival time.  Significant differences in arrival time between control 
and obese animals we observed pre-surgery in addition to 7 and 56 
days post-surgery. Induction of lymphedema via single vessel 
ligation surgery resulted in significant delays in arrival time 
compared to pre-surgical baseline for both the control and obese 
groups. Error bars represent SEM. (n=8, control) (n=6, obese) (*, 
denotes significant difference between control and obese; †, denotes 
significant difference between control value and the baseline pre-
surgical control value; ‡, denotes significant difference between 
obese value and the baseline pre-surgical obese value, p < 0.05).  
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vessels. Ten weeks post-surgery, after swelling has subsided, the 
wounded collecting lymphatic vessels were observable; however, 
they remained obstructed by the wound. Tracer was observed 
extravasating from the collecting lymphatic vessels into the 
“honeycomb” network of initial lymphatic vessels. (B) 
Representative intensity tracking from the control imaging segments 
depicts the presence of discrete fluorescent packets pre-surgically 
with a subsequent absence at later time points. 
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Figure 19 Functional measurements, obtained via NIR imaging, indicate that 
obesity adversely impacts the functional response of the intact 




frequency of fluorescent pulsations within the vessel, exhibited 
significant differences between control and obese groups. (B) Packet 
transport, the integral of the packet frequency signal over time, was 
used to evaluate fluorescence transport driven by intrinsic lymphatic 
contractions. (C) Effective pumping pressure was used to evaluate 
the maximal pressure generated by the collecting vessel to overcome 
occlusion. Error bars represent SEM. (n=8, control) (n=6, obese) (*, 
denotes significant difference between control and obese; †, denotes 
significant difference between control value and the baseline pre-
surgical control value; ‡, denotes significant difference between 
obese value and the baseline pre-surgical obese value, p < 0.05). 
Figure 20 (A) Representative 3D 2nd harmonic generation images of collecting 
lymphatic collagen microstructure from control and obese mice. (B) 
Collagen fibers were found to be significantly wavier in obese mice 
compared to control. (C) Representative image depicting the 
calculation of the collagen waviness ratio computed from the total 
length of the collagen fiber and the end-to-end length. (*, denotes 
significant difference between control and obese, p < 0.05). 
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Figure 21 Representative immunofluorescent images of collecting lymphatic 
vessels labeled for α-SMA (red) and Prox-1 (blue). Confocal images 
of isolated collecting lymphatic vessels were used to produce 3D Z-
stack renderings of the α-SMA/Prox-1 structure. 
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Figure 22 Topical tacrolimus ointment was used to treat a subset of obese mice 
(n=5) beginning at day 14 post-surgery. (A) Treatment with 
tacrolimus ointment did not differentially impact absolute tail 
swelling; however, this is likely caused by the tacrolimus treated 
group exhibiting significantly greater swelling prior to the start of 
treatment. (B) Treatment with tacrolimus ointment resulted in a 
significant reduction in tail swelling when compared to start of 
treatment values at day 14. Red arrows indicate the beginning of 
tacrolimus treatment at the 14-day time point. Error bars represent 
SEM. (n=8, control) (n=6, obese) (n=5, obese + tacro) (¢, denotes 
significant difference between obese + tacro and control; ¥, denotes 
significant difference between obese + tacro and obese, p < 0.05). 
84 
Figure 23 Treatment with tacrolimus ointment did not differentially impact the 
fluorescence arrival time to the wound site following injection of 
fluorophore. Red arrows indicate the beginning of tacrolimus 
treatment at the 14-day time point. Error bars represent SEM. (n=8, 
control) (n=6, obese) (n=5, obese + tacro) (¢, denotes significant 
difference between obese + tacro and control; ¥, denotes significant 




Figure 24 Tacrolimus ointment protects against the declines in collecting 
lymphatic function caused by obesity after induction of lymphedema 
as assessed by NIR imaging. (A) Tacrolimus treatment for a subset 
of obese mice increased lymphatic packet frequency to levels similar 
to control with significant differences between the obese group 
manifesting at 56-days post-surgery. (B) Tacrolimus treatment was 
not found to significantly improve lymphatic packet transport. (C) 
Tacrolimus treatment protected against the declines in pumping 
pressure caused by obesity with significant differences from the 
untreated group being observed at days 28 and 42. Red arrows 
indicate the beginning of tacrolimus treatment at the 14-day time 
point. Error bars represent SEM. (n=8, control) (n=6, obese) (n=5, 
obese + tacro) (¢, denotes significant difference between obese + 
tacro and control; ¥, denotes significant difference between obese + 
tacro and obese; Ø, denotes significant difference between obese + 
tacro and baseline day 0 value, p < 0.05) 
86 
Figure 25 (A) Graphical depiction of the study design. On day -1, pre-surgery 
MRI was used to map the lymphatic anatomy of the hind limbs in 
sheep. On day 0 pre-surgical NIR imaging was used to evaluate 
baseline lymphatic function. Immediately after imaging, the caudal 
lymphatic vessel on one of the hind limbs was ligated in order to 
create a lymphatic injury, while the contra-lateral limb was left 
intact. Follow-up NIR imaging was used to evaluate changes in 
lymphatic function of the vessels on the intact and wounded limbs at 
days 7, 14, 28, and 42. (B) Evans blue was injected intradermally 
and uptake by the lymphatic vessels was visualized with the skin 
removed. Two primary collecting lymphatic vessels (cranial and 
caudal) run along the lateral aspect of the hind limb and serve to drain 
fluid from the distal portions of the limb. During surgery on Day 0, 
the caudal vessel was ligated whereas the cranial vessel was left 
intact. (C) NIR imaging was used to guide and confirm ligation of 
the caudal lymphatic vessel. Pre-ligation images exhibit fluorophore 
uptake by the vessel. After ligation, and excision of a 2 cm segment 
of vessel, NIR imaging confirmed the absence of fluorescence 
transport by the vessel. (D) Circumferential measurements taken at 
the mid tarsus on the hind limb was used to identify the presence or 
absence of swelling due to the injury. No significant swelling of the 
tissue was observed. Error bars represent SEM. 
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Figure 26 (A) MRI imaging of the lymphatic anatomy of the hind limbs was 
conducted one day pre-surgery and 42 days after surgery. Pre-
surgical MRI shows the two primary collecting lymphatic vessels 
that drain the hind limbs. These two vessels run in parallel and both 
drain to the popliteal lymph node. At 42 days post-surgery the caudal 
vessel is absent from the MR images on the wounded leg. (B) NIR 




lymphatic ligation. Pre-surgical images show both the cranial and 
caudal collecting lymphatics intact. Immediately after ligation of the 
caudal collecting lymphatic, an absence of fluorophore transport 
confirmed successful ligation and excision of the vessel. (C) The 
diameter of the cranial vessel on the control and wounded leg was 
measured distal to the wound site using the MR images before and 
42 days after surgery. Values were normalized by the pre-surgical 
average diameter of the respective vessel. (****, p < 0.0001). 
Figure 27 NIR lymphatic imaging was used to non-invasively evaluate 
lymphatic functional changes in response to the lymphatic injury. 
NIR imaging data was collected from the intact vessels on both the 
control (n=5) and wounded (n=5) legs. (A) Packet frequency, the 
frequency of fluorescent pulsations within the vessel, exhibited 
significant differences between intact vessels on the control and 
wounded legs at day 28 post-surgery. (B) The percent difference 
between the packet frequencies of the control and wounded leg 
depict a decline due to the surgery. (C) Effective pumping pressure 
(Peff), was used to evaluate the maximal pressure generated by the 
collecting vessel to overcome occlusion. Significant differences in 
Peff were observed at day 28. (D) Packet transport, the integral of 
the packet frequency signal over time, was used to evaluate 
fluorescence transport driven by intrinsic lymphatic contractions. 
Significant differences in packet transport were observed at day 28. 
Error bars represent SEM. (*, significant difference between control 
and wounded, p < 0.05; ¥, significant difference between baseline 
value at Day 0, p < 0.05). 
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Figure 28 Intact lymphatic vessels were isolated from the control and wounded 
legs to evaluate changes in the stretch response due to the surgery. 
Vessel segments were cannulated and exposed to a range of 
transmural pressures. (A) Wire myography was used to evaluate the 
contractile force of isolated lymphatic vessels (non-pressurized) and 
exhibited significant increases in the contractile force of vessels from 
the wounded leg (n=4 control, n=4 wounded). (B) Vessel segments 
from the wounded leg exhibited higher contraction frequencies than 
control segments (n=4 control, n=4 wounded). (C) The amplitude of 
lymphatic contractions did not significantly differ between the 
control and wounded groups (n=4 control, n=4 wounded). (D) 
Lymphatic tone was not significantly different in vessel segments 
collected from the wounded leg (n=4 control, n=4 wounded). Error 
bars represent SEM and open circles represent individual data points 
(*, significant difference between control and wounded, p < 0.05; †, 
significant difference between control and control baseline at 1.5 




between wounded and wounded baseline at 1.5 cmH2O transmural 
pressure, p < 0.05) 
Figure 29 Diameters of vessels from the control and wounded leg were 
measured during the isolated vessel procedures at 5 cmH2O 
transmural pressure and 0 cmH2O axial pressure gradient. There was 
no observed statistically significant difference in the outer diameters 
of the vessels between the control or wounded leg. Error bars 
represent SEM. 
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Figure 30 Intact lymphatic vessels were isolated from the control and wounded 
legs to evaluate changes in the flow response to the surgery. Vessel 
segments were cannulated and exposed to a range of transaxial 
pressure gradients. 100uM LNAME was used to inhibit endothelial 
nitric oxide synthase (eNOS). (A) The frequency of lymphatic 
contraction was slightly increased for isolated vessels collected from 
the wounded leg when compared to control. The addition of LNAME 
inhibits intrinsic contraction of vessels from the wounded leg. 
However, control vessels exhibit a differential response; increasing 
contractile frequency in response to LNAME (n=3 control, n=5 
wounded). (B) Lymphatic contraction amplitude was decreased in 
response to imposed flow. Vessels from the wounded limb exhibited 
lesser degree amplitude loss with the addition of L-NAME (n=3 
control, n=5 wounded) (C) Lymphatic muscle tone of vessels from 
the wounded leg was decreased compared to control. Isolated 
lymphatic vessels from the wounded leg exhibit a little response to 
application of LNAME compared to control vessels (n=3 control, 
n=5 wounded). (D) The vessel from the wounded leg exhibited less 
of a contractile response to shear stress than vessels from the control 
leg (n=1 control, n=1 wounded). Error bars represent SEM and open 
circles represent individual data points (*, significant difference 
between control and wounded, p < 0.05; †, significant difference 
between control and control baseline at 0 cmH2O axial pressure 
gradient, p < 0.05; ‡, significant difference between wounded and 
wounded baseline at 0 cmH2O axial pressure gradient, p < 0.05) 
118 
Figure 31 Fractional pump flow and ejection fraction were derived from 
isolated vessel diameter tracings. (A) Fractional pump flow of 
vessels from the wounded leg and control leg as a function of 
transmural pressure. (B) Ejection fraction as a function of transmural 
pressure. (C) Fractional pump flow at varying axial pressure 
gradients with an average transmural pressure of 6 cmH2O with and 
without the addition of L-NAME. (D) Ejection fraction at varying 
axial pressure gradients with an average transmural pressure of 6 
cmH2O with and without the addition of L-NAME. (*, significant 
difference between control and wounded, p < 0.05; †, significant 




transmural pressure, p < 0.05; ‡, significant difference between 
wounded and wounded baseline at 1.5 cmH2O transmural pressure, 
p < 0.05) 
Figure 32 Comparative protein expression profiling of control vs wounded 
lymphatic muscle cells together with the molecular and cellular 
pathways predicted by IPA.  (A) Un-biased, non-clustered heat map 
generated in “perSPECtives” using the normalized weighted spectral 
counts highlights the change in the protein expression profiles in the 
“wounded” relative to the “control” lymph muscle cells.  (B) The 
main canonical pathways affected by the top 105 genes with higher 
than twofold expression level in the “wounded” vs “control” 
samples, subjected to the analysis by IPA algorithm.  The % of total 
molecules up- (red color) or downregulated (green color) in each 
pathway together with the corresponding log (-p value) are 
displayed.  (C) Protein networks significantly regulated (p< 0.05) in 
the “wounded” relative to the “control” lymph muscle cells are 
displayed as IPA predicted diseases and cellular functions using the 
z score (down-regulated corresponding to z<-1.5 and blue color; up-
regulated, corresponding to z>+1.5 and orange color). The size of 
each rectangle is proportional with the value of the z score associated 
to a specific pathway.  Increased organismal injury, cell death, small 
molecules and lipids metabolism and cellular movement are the main 
diseases and cellular pathways characterizing the “wounded” 
system. 
121 
Figure 33 Protein networks significantly regulated (p < 0.05) in the wounded 
relative to the control lymph muscle cells.  The proteins with at least 
two-fold changed in the expression profiles were analyzed by 
Ingenuity Pathways Analysis (IPA, Ingenuity Systems) to determine 
the cellular pathways impacted by the wounded conditions relative 
to the control in the lymph muscle cells. (A) The functional networks 
with the highest scores were predicted by IPA to be related to the 
increased cellular movement of fibroblasts, smooth muscle cells and 
leukocytes in the wounded cells as compared with control.  The 
wounded conditions are prone to experience a significant in the 
networks associated with the fibrosis, reactive oxygen species (B) 
and cell proliferation (C).  The proteins in red and green had a 
significantly up- or down-regulated expression (p < 0.05), 
respectively.  The shape of symbols denotes the molecular class of 
the proteins. A solid line indicates a direct molecular interaction, 
whereas a dashed line indicates an indirect molecular interaction. 
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Figure 34 Vessels from the wounded leg displayed structural and mechanical 
changes caused by the ligation surgery. (A) The lymphatic valves of 
vessel segments from the wounded leg were prolapsed upon 




column- transverse, right column- axial) exhibited atrophy of the 
musculature surrounding the vessel compared to control. 
Additionally, vessel segments from the wounded leg appear to have 
an increase in matrix surrounding the vessel. (C) Biaxial testing was 
conducted on isolated vessel segments at various axial stretches and 
transmural pressures. Wounded vessels exhibited increases in vessel 
compliance compared to control. The biaxial data was fit to a 
constitutive model to calculate material parameters that capture 
pressure-diameter behavior (details in theory). 
Figure 35 Isolated vessel function and mechanical properties were utilized to 
inform a computational model, which was used to elucidate how the 
structural and functional changes caused by the surgery would affect 
intrinsically driven flow. (A) Biaxial testing data was used to inform 
a computational model that predicts active and passive wall stress as 
a function of circumferential stretch. Testing data suggests an 
increase in the passive and active compliance of the vessels from the 
wounded leg. (B) (Left) Mechanical parameters coupled with ex-
vivo isolated vessel frequencies were used to simulate predicted 
lymph flow rates as a function of pressure generation. Our 
computational model suggests that vessel segments from the 
wounded leg may exceed the flow rate of control by increasing 
contraction frequency and contractile force. (Right) Pressure-volume 
curves for these simulations. (C) (Left) Mechanical parameters 
coupled with in-vivo contraction frequencies assessed via NIR 
imaging at day 42. Our computational model suggests that, in an in-
vivo context, vessel segments from the wounded leg may have 
decreased intrinsically driven lymph flow rates. (Right) Pressure-







The lymphatic system is composed of a network of vessels, nodes, and accessory 
organs that is present in most soft tissues of the body. The lymphatics play a vital role in 
maintaining tissue fluid homeostasis, trafficking immune cells from the periphery to the 
nodes, and transporting dietary lipids from the intestines to the blood stream. Unlike the 
blood vasculature, the lymphatic system does not have a central pump. Instead, transport 
is promoted by collecting lymphatic vessels that are composed of a series of contractile 
segments separated by one-way valves. When the normal function of the lymphatics is 
compromised a disease called lymphedema may develop, which is characterized by tissue 
fluid retention, fibrosis, and adipose accumulation. Unfortunately, lymphedema is a 
relatively common complication of cancer therapies that damage the lymphatic 
vasculature, such as lymph node dissections and radiation treatment.  
Despite being integral driver of lymphatic transport, relatively little is known about 
how collecting lymphatic function and remodeling may influence the development of 
lymphedema. This work demonstrates the development of novel near-infrared imaging 
methods with the ability to quantify and phenotype collecting lymphatic failure during 
lymphatic disease. These methods provide biological insight into the functional and 
remodeling response of the collecting lymphatic vessels to surgical disruption of lymphatic 
drainage pathways. Specifically, we demonstrate that diet-induced obesity adversely 
impacts collecting lymphatic contractility and pump function during lymphedema in a 
mouse model. Further, in a clinically relevant sheep model, we demonstrate that the 
uninjured vessel can compensate in vivo by altering its intrinsic functional response and 
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structure; however, through this process, the collecting lymphatic muscle experiences 
increased oxidative stress due to increased contractility. The results of this work 
demonstrate that functional adaptations of the collecting lymphatic vessels may influence 








CHAPTER 1. INTRODUCTION AND BACKGROUND 
 In this chapter I will begin with an introduction to the lymphatic system and discuss 
the essential roles that it plays in physiology. I will subsequently introduce lymphedema 
and discuss current research that contributes to our understanding of the disease and its 
progression. I will then focus on our current understanding of the collecting lymphatic 
vessel’s role in lymphedema and the techniques developed to quantify this contribution. 
Finally, I will give an overview of the specific aims that have motivated my work. 
1.1 Lymphatic Physiology 
 The lymphatic system is a network of vessels, nodes, and accessory organs that 
plays essential roles in regulating tissue fluid homeostasis, trafficking immune cells, and 
transporting dietary lipids (209). The lymphatic vasculature is present in most soft tissues 
of the body and is responsible for transport of between 4-8 liters of fluid per day back to 
the blood circulation (178). This fluid, called lymph, originates from the interstitial spaces 
of the body, where capillary beds continuously extravasate water, small solutes, and ions 
in accordance with the hydrostatic and oncotic pressure gradients described by Starling’s 
equation (119). While nearly 90% of this extravasated fluid is reabsorbed at the pre-venous 
end of the capillary beds, a fraction of the remaining 10% is transported by the lymphatics 
as lymph. 
Lymphatic transport begins when lymph is absorbed by lymphatic capillaries, 
called initial lymphatics, that infiltrate the capillary beds and are tethered by anchoring 
filaments to the extra-cellular matrix (18). The initial lymphatics are blind-ended structures 
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typically composed of a single endothelial cell layer that is highly permeable to 
macromolecules. These initial lymphatics converge and transport fluid to the collecting 
lymphatic vessels that possess smooth muscle cells, capable of tonic and phasic 
contraction, in addition to one-way valves to prevent backflow (251). The afferent 
collecting lymphatics subsequently transport fluid to the lymph nodes, which play an 
essential role in antigen presentation to residing lymphocytes (243). Efferent collecting 
vessels exit the nodes and progressively converge to form the collecting lymphatic ducts 
that drain to the largest lymphatic vessel in the body, called the thoracic duct. The thoracic 
duct ultimately expels its contents into the blood circulation via the left subclavian vein 
(148).  
 The collecting lymphatic vessels are composed of laminar layers in a manner 
similar to veins and arteries. The internal layer is composed of lymphatic endothelial cells 
(LECs) adhered to a basement membrane (129). LECs are highly specialized and possess 
a number of lymphatic specific markers that differentiate them from blood endothelial cells 
(168, 238). These include VEGF-R3, the receptor for vascular endothelial growth factor 
type C (VEGF-C) (1, 97, 160); Prox-1, the homeobox gene product involved in the 
developmental regulation of the lymphatic system (90, 100); LYVE-1, a hyaluronan 
receptor (181, 200); and podoplanin (PDPN), a glomerular podocyte membrane 
mucoprotein (33, 240). The outer layers of the lymphatic vessels  are composed of elastin, 
surrounded by lymphatic smooth muscle cells (LMCs), and collagen (129).  Unlike the 
blood vasculature, the lymphatic vasculature does not have the benefit of a centralized 
pump, like the heart, to propel fluid; because of this, lymph is transported through the 
collecting lymphatics via a combination of intrinsic and extrinsic factors (162, 172). 
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Intrinsic factors describe the active lymphatic pump, in which discrete pumping segments, 
known as lymphangions, contract to generate pressure that propels lymph flow (146, 172, 
233). Lymphangions are separated by one-way bi-leaflet valves to prevent backflow and 
their contractile activity is highly sensitive to mechanical and molecular stimuli (110, 251). 
Extrinsic factors are composed of other mechanisms that assist to propel lymphatic flow in 
addition to the intrinsic lymphatic contractions. These include lymph formation, pulsations 
in the circulatory system, respiration, and muscle pumps during musculoskeletal movement 
(38, 71). A combination of both intrinsic and extrinsic factors are essential to propel lymph 
against both an adverse pressure gradient from the interstitium and unfavorable hydrostatic 
pressure gradients caused by gravity  (75, 251). 
 The contractile activity of the collecting lymphatic vessels is enabled by the LMCs 
embedded within the vessel walls that govern both the tonic and phasic contractions of the 
vessels. Interestingly, these cells exhibit an array of contractile proteins that parallel the 
phenotypic characteristics of both vascular smooth muscle cells and cardiac myocytes 
(146). This enables the collecting lymphatic vessels to alter their tone to change their 
inherent resistance to flow, thus, becoming better fluid conduits in response to favorable 
upstream pressure gradients; however, when pressure gradients are unfavorable, the LMCs 
can rapidly contract the vessels by up 75% of their diameter, ejecting fluid from one 
lymphangion to the next. This pump-conduit behavior of the lymphatics stems from the 
ability of the vessels to sense their unique mechanical environments to maintain fluid 
transport (72, 171, 172). For example, isolated lymphatic vessels have been shown to react 
to increases in transmural pressure  (vessel stretch) and elevated outflow pressure by 
increasing their contractile activity (60, 217, 252). In addition to regulation of lymphatic 
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contractility via smooth muscle stretch, the lymphatic endothelium serves as a 
complementary and potent regulator of the lymphatic contractile response to flow (31, 73, 
110). Flow imposed on the lymphatic vessel induces contractile inhibition, relaxed vessel 
tone, and results in passive conduit behavior via endothelial nitric oxide synthase (eNOS) 
(171, 172, 193). 
 Because the lymphatics play an essential role in draining immune cells, lipid, 
proteins, and detritus from tissues, loss of lymphatic function has been implicated and 
demonstrated in many highly prevalent diseases such as obesity (84, 89, 153, 239), 
congestive heart failure (242), atherosclerosis (113, 230), diabetes (143), and cancer (127); 
however, the condition most directly linked to loss of lymphatic function is lymphedema. 
1.2 Introduction to Lymphedema 
Lymphedema is a debilitating incurable disease that is characterized by excessive 
regional fluid accumulation, tissue fibrosis, and adipose deposition (173). The disease is 
separated into primary and secondary forms that are delineated by how the condition is 
acquired. Primary lymphedema is the congenital or hereditary form of the disease and is 
rare, affecting roughly 1.15 in 100,000 children and adolescents (184, 202). Secondary 
lymphedema is the acquired form of the disease and is relatively common, with incidence 
rates estimated at 1.33 to 1.44 in 1,000 individuals (184, 202); however, lymphedema 
incidence rates are difficult to quantify due to lymphedema being under and mis-diagnosed 
(141, 184).   
Globally, the most common cause of lymphedema is due to a parasitic nematode 
infection called lymphatic filariasis. The filarial worms are thought to infect nearly 120 
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million individuals in 83 countries located primarily in tropical regions (30, 216). The 
infection is transmitted via a mosquito vector that deposits filarial larva on the skin of the 
host while seeking a blood meal. The larvae then penetrate the skin at the site of the 
mosquito bite and migrate to the lymphatic vessels and nodes where they dwell and 
subsequently reproduce for 5 - 8 years (103, 216). Our knowledge of the mechanism that 
triggers lymphedema pathogenesis following infection is incomplete (13, 40); however, 
studies have implicated a chronic inflammatory response mediated by CD4+ T-cells that 
may impair lymphatic function and subsequently induce lymphatic remodelling (6, 12). 
Interestingly, similar mechanisms have been linked to the development of non-filarial 
lymphedema.  
In more developed countries, the population most at risk for development of 
lymphedema is post-procedural cancer patients. This is because common cancer therapies 
such as radiotherapy and lymph node resection seek to target lymph nodes and lymphatic 
vessels to prevent metastasis of cancer (173, 232); however, any surgical intervention that 
inadvertently damages the lymphatic system can result in lymphedema. There is even 
evidence present that secondary lymphedema can occur without surgical disruption (84). 
Breast-cancer patients are the most at risk for developing lymphedema with incidence rates 
estimated 15% to 40% but prostate cancer, melanoma, and endometriosis also have 
moderately high incidence rates likely greater than 15% percent (7, 52). Cancer-related 
lymphedema typically localizes to the extremities that are drained by the damaged lymph 
nodes and vessels. In the case of breast cancer, lymphedema typically affects the arms 
while pelvic cancers are associated with leg lymphedema.  The onset of lymphedema can 
occur months to years following cancer therapies, with the majority of patients presenting 
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clinical lymphedema within 1 year of lymph node dissection or biopsy (154). Overall, 80% 
to 90% of individuals who will develop lymphedema do so within 3 years post-treatment 
(196); however, the remaining 10% to 20% will develop lymphedema at a rate of roughly 
1% per year (155, 164). It is believed that the delayed onset of lymphedema contributes to 
under and misdiagnosis of the disease due to the decreased likelihood that patients will 
continue clinical follow-ups to detect lymphedema after oncology follow-up visits have 
ceased (132). 
Treatments for lymphedema have traditionally utilized mechanical methods to 
remove fluid and prevent fluid build-up in the affected limb (88, 183). Manual lymphatic 
drainage therapy (MLD), is a specialized massage technique designed to rhythmically 
move fluid from the distal portions of the limb to the trunk of the body (5). Compression 
therapy relies on wrapping the limbs with bandages to achieve desired compressive 
pressures and to subsequently prevent fluid accumulation (14). Typically, a combination 
of these techniques, coupled with skin care and exercise, represents the standard of care for 
patients with lymphedema (111). Long-term management of lymphedema is achieved with 
the use of elastic compression garments (sleeves and stockings) (78, 99, 106). While these 
treatments can be effective even in progressed lymphedema, early detection is an integral 
part of preventing the drastic tissue changes associated with the disease (53, 207, 208); 
however, clinical detection methods often rely on measurements of tissue swelling as 
opposed to measuring the underlying lymphatic dysfunction that causes the disease. This 
is due in no small part to the dearth of technologies and techniques available to quantify 
dysfunction (235). Further, this has historically hindered research that aims to investigate 
the interplay between lymphatic dysfunction and the pathogenesis of lymphedema. 
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1.3 Pathogenesis and Pathophysiology of Lymphedema 
Lymphedema is a progressive disease that begins with a primary insult to the 
lymphatic vasculature. In the context of cancer-related lymphedema this insult is typically 
surgical and/or radiation induced disruption to the lymph nodes and vessels (144, 173, 
182). It is important to note that the time between primary insult and the onset of swelling, 
when the disease is clinically diagnosed, may be many years (7); however, the mechanisms 
involved in development of lymphatic transport insufficiency following initial insult are 
largely unknown. Despite this, the resulting stasis of lymph in the interstitium induces 
profound changes in tissue composition including cutaneous thickening, fibrosis, and 
adipose deposition that progressively worsens during lymphedema. It is this gross, 
progressive, tissue remodelling that is the hallmark of lymphedema. 
Given that the lymphatic system acts as the nexus between cardiovascular and 
immune systems it is unsurprising that the progressive tissue remodelling observed in 
lymphedema has been linked to inflammation; a complex biological response to harmful 
stimuli such as pathogens, cell damage, or other irritants. Although acute inflammation is 
a healthy physiological response associated with normal healing processes, chronic 
inflammation is implicated in a wide range of degenerative health disorders (64, 86, 101, 
167). Lymphatic vessels are directly involved in the inflammatory process by draining 
extravasated fluid and leukocytes from inflamed tissue space to the lymph nodes (231). 
Studies have shown that inflammatory mediators such as cytokines (3), prostanoids (245), 
histamine (66), and nitric oxide (NO) (32, 139, 149, 235) modulate lymphatic contractile 
activity and drainage. Others have demonstrated that the administration of pro-
inflammatory factors exacerbates lymphedema phenotypes in mouse models (147, 250). 
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Conversely, administration of non-steroidal anti-inflammatory drugs (NSAIDs) has been 
shown to ameliorate lymphedema phenotypes in mouse models (147).  
The biological mechanisms that govern inflammation’s role in lymphedema 
development have been widely studied in recent years and have produced exciting insights 
into the processes that drive lymphedema. CD4+ T-cells are an important mediator of the 
inflammatory response. Antigen presenting cells, such as dendritic cells, present antigen 
peptide via major histocompatibility complex II (MHC II) to activate naïve CD4+ T-cells; 
however, CD4+ T-cells can be activated by other cell types expressing MHC II such as 
adipocytes (61, 246). These cells subsequently differentiate into different T-helper (Th) 
subtypes, proliferate, and secrete their own cytokines to facilitate an immune response 
(108, 150, 203). Clinical and animal biopsies collected from lymphedematous tissue have 
demonstrated positive correlations between tissue fibrosis and the number of infiltrating 
CD4+ T-cells (11). Mice deficient in CD4+ T-cells have been shown to develop less 
swelling and tissue fibrosis in lymphedema models (11). Further, preventing T-cell 
differentiation, via topical treatment with the calcineurin inhibitor tacrolimus (156), has 
shown promising results in treating lymphedema in mouse models (70).  
Previously, decreasing inflammation via the cyclooxygenase (COX) and 
arachidonate 5-lipoxygenase (5-LO) inhibiting NSAID ketoprofen, has been shown to treat 
lymphedema in mice (147); however, ketoprofen treatment had undesirable off-target 
effects including gastrointestinal, cardiac, nervous system, renal, and hepatic toxicities, 
that limited clinical use for treating the disease. Therefore, a recent study sought to 
systematically identify the more targeted downstream mechanism of action that ketoprofen 
utilized to ameliorate lymphedema (219). The study identified that the effects of ketoprofen 
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on treating lymphedema can primarily be attributed to inhibition of leukotriene B4 (LTB-
4) synthesis, an inflammatory mediator produced by leukocytes. Further, LTB-4 
antagonism via pharmacological treatment with bestatin proved to effectively treat 
lymphedema. The results demonstrate that LTB-4 levels rise during lymphedema 
pathogenesis in the mouse tail. By inhibiting LTB-4 with bestatin 3 days after initial 
induction of lymphedema, the researchers demonstrated significant reductions in tail 
volume, tissue fibrosis, and increases in lymphatic function. Given that both LTB-4 and 
CD4+ T-cells seem to play integral roles in regulating lymphedema pathogenesis, it is 
unclear if the two pathways act independent of each other or if they act in concert. CD4+ 
T-cells are known to possess the LTB-4 receptor BLT-1, which is involved in chemotaxis, 
it seems reasonable to believe that the latter hypothesis is more likely (212).  
Currently, it is unclear why inflammation goes unresolved during lymphedema; 
however, impairment of lymphatic transport is hypothesized to play a role. The lymphatic 
system acts to mediate the inflammatory response by draining macrophages, dendritic cells, 
T-cells, antigen, and cytokines from the periphery to the lymph nodes and subsequently 
the blood stream (122, 174). This plays an important role in resolving acute inflammation; 
however, the prolonged presence of inflammatory cytokines and mediators can increase 
synthesis of compounds that are known to downregulate lymphatic contractile activity such 
as NO via iNOS (121, 193, 199, 222). Therefore, it is possible that inflammation goes 
unresolved during lymphedema due to negative feedback between the leukocytes 
producing pro-inflammatory factors that subsequently result in decreased lymphatic 
transport necessary to drain said leukocytes. This is supported by studies that have shown 
improvements in tissue swelling, fibrosis, and CD4+ T-cell infiltration upon surgical 
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lympho-venous bypass (223). In effect, this technique breaks the negative feedback cycle, 
increases lymph drainage from the tissue, and subsequently ameliorates inflammation. In 
addition to having direct effects on lymphatic function, inflammation has also been shown 
to induce lymphatic growth and remodeling that may be functionally mal-adaptive (82, 
105). Mechanistically, lymphangiogenesis is mediated by inflammation. This process is a 
result of  macrophage production VEGF-C that in turn induces proliferation and growth of 
new lymphatic vessels (19, 104, 130, 186); however, the majority of the newly formed 
vessels are immature, leaky, and their ability to properly facilitate lymph drainage from the 
tissue is unclear (82, 159). Additionally, recent studies have demonstrated hyperplasia of 
the lymphatic vessels coupled with progressive lymphatic dysfunction associated with 
increased inflammatory cell types during lymphedema (83). 
Multiple comorbidities that exacerbate inflammation are believed to negatively 
influence lymphedema development (39, 69, 128, 134, 229); however, obesity is the most 
widely demonstrated (48, 91). Obesity has been shown to cause chronic inflammation due 
to interactions between adipose tissue and immune cells (85, 93, 151, 247). This is believed 
to be initiated by T-cell inflammatory reactions that induce macrophage chemotaxis to 
adipose tissue. These macrophages then phagocytize necrotic adipocytes leading to release 
of inflammatory cytokines, recruiting other inflammatory cells, and progressive 
inflammation (151). Recent studies have also demonstrated that adipocytes express MHC 
II and can independently activate T-cells and thus aggravate inflammation (61, 246). 
Clinically, post-operative weight gain is recognized as a major risk factor for developing 
lymphedema (91). In fact, a recent clinical study has shown that obesity alone can cause 
lymphedema with no surgical intervention (84). Investigations using animal models have 
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demonstrated that obese mice possess impaired lymphatic function due to T-cell mediated 
inflammation (27, 192, 222). Specifically, collecting lymphatic contractile function is 
significantly decreased (27, 152, 192). Interestingly, this decrease in contractile activity 
does not appear to be a result of lymphatic remodeling because function is restored through 
weight loss (152). Upon induction of lymphedema via surgical insult obese mice have a 
more severe tail lymphedema phenotype, with increased adipose deposition, fibrosis, and 
CD4+ T-cell infiltration (192).  
Given that baseline lymphatic function is impaired during obesity, it seems 
reasonable to believe that this could play a role in the pathogenesis of the disease. For 
example, although obesity impairs baseline lymphatic function, this is still sufficient to 
mediate the chronic low-grade inflammation and to maintain tissue fluid homeostasis. 
Upon surgical insult that impairs lymph transport, inflammation can no longer be mediated 
by lymphatic drainage, thus increasing the number of leukocytes in the tissue, further 
impairing lymphatic transport, and further inducing tissue remodeling. It is therefore one 
of the goals of this thesis to investigate the influence of obesity on collecting lymphatic 
pump function during lymphedema.   
1.4 Collecting Lymphatic Pump Failure in Lymphedema 
The recent advancements discussed in the previous section have provided remarkable 
insights into the biological mechanisms and risk factors that regulate the profound tissue 
alterations associated with the development of lymphedema. The studies have 
demonstrated the unique interplay between immune mediated inflammation and the 
development of lymphedema that have led to emerging therapies that seek to cure the 
12 
 
disease. Unfortunately, there is still very little known about how lymphatic transport, or 
loss thereof, is altered during and/or influences the development of lymphedema. This is 
particularly true with regards to the collecting lymphatic vessels that actively regulate their 
intrinsic function to facilitate the transport of lymph. This section will discuss the 
observations that have motivated the study of the collecting lymphatic’s role in 
lymphedema progression, the technical challenges associated with this, and explore the 
current research in the field.  
Histological analysis conducted in lymphedema patients have demonstrated 
correlations between collecting lymphatic failure and lymphedema progression. Mihara et. 
al. sampled collecting lymphatic vessels from the legs of patients with gynecological 
cancers with varying stages of lymphedema, ranging from stage 0 (pre-clinical) to stage III 
(severely progressed) (137). Their findings demonstrate that alterations to the structure of 
the lymphatic vessels correspond to the severity of lymphedema in the limbs. This occurs 
in a progressive manner beginning with dilation of the vessels followed by subsequent 
contraction and vessel thickening ultimately resulting in stenosis of the lumen. They 
hypothesized that increases in the intralumenal pressure of the collecting vessels, due to 
the increased fluid load associated with lymphedema, subsequently induced a 
compensatory remodelling response that ends in an inability for the vessels to pump and 
transport fluid. This has been supported by more recent work from Ogata et al. 
demonstrating that the progressive thickening of the vessel walls is driven by the 
proliferation of smooth muscle cells (158). More specifically, they discovered an increase 
in smooth muscle cells exhibiting synthetic phenotypes with decreases in the contractile 
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markers SM1 and SM2. These cell types are associated with increased fibrosis of the vessel 
wall and decreased contractility.  
 It has been proposed that individuals who develop lymphedema have a 
constitutional predisposition to the disease (15, 46, 205, 206). These studies have 
demonstrated that patients who have higher rates of lymphatic drainage before axial lymph 
node dissection are at greater risk for developing lymphedema after surgery. Although this 
seems paradoxical, the authors hypothesize that these patients have higher lymphatic 
drainage because they have elevated lymph load that could potentially overload the 
functional capacity of the lymphatic vessels upon injury. This has been supported by recent 
work that demonstrates elevated pre-surgical lymphatic pumping pressure in women who 
later develop lymphedema (46). Further, it has been shown that patients with progressed 
chronic lymphedema have decreased lymphatic pumping pressure (140, 226). Taken 
together, these studies suggest that elevated lymph load corresponds to an increase in the 
functional capacity of the collecting lymphatic vessels; however, these vessels are likely 
operating at maximal capacity. Upon injury, the functional demands on the lymphatic 
vessels increase further, subsequently leading to overwork, muscle fatigue, and vessel 
remodelling. Ultimately, this results in hypertrophy of the vessels (137, 158) and an 
inability to pump (140, 226). This is, in a sense, analogous to cardiovascular hypertension 
that results in hypertrophy of the heart and subsequent heart failure. 
 Given that collecting lymphatic pump dysfunction appears to play a role in the 
development of lymphedema, several studies have been conducted in mouse lymphedema 
models that seek to quantify this contribution. Gousopoulos et. al. induced lymphedema in 
the mouse tail by ligating the collecting lymphatic vessels and dermal layer initial 
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lymphatics (83). They discovered that the collecting lymphatic vessels responded to the 
induction of lymphedema by slightly lowering their contraction frequency and amplitude. 
This decreased the average pumping score of the vessels, which is analogous to ejection 
fraction. This decrease in collecting lymphatic function corresponded with increases in 
interstitial fluid, tissue swelling, and infiltration of macrophages and CD4+ T-cells. 
Interestingly, in the early stages of lymphedema, they observed significant hyperplasia of 
the lymphatic vessels and profound remodeling of the lymphatic vasculature. Given that 
the increased infiltration of immune cells in the tissue corresponded with the declines in 
lymphatic function, it seems plausible that the collecting lymphatics play an active role in 
mediating the development of lymphedema.  
Mouse lymphedema models have traditionally relied on ligating all of the lymphatic 
vessels or nodes draining a distal tissue space (80, 147, 186, 214); however, in a clinical 
setting, lymphedema can develop even though there are remaining intact and functional 
collecting vessels (124, 189, 204, 253). Yet, it appears those intact vessels are unable to 
compensate for the increased fluid load caused by the initial surgical insult (15, 46, 205, 
206). Recent work has sought to determine the involvement of these intact collecting 
lymphatic vessels in the development of lymphedema. This was accomplished using a 
novel mouse tail lymphedema model that involved cauterization of one of two collecting 
lymphatics, along with the dermal initial lymphatics, while leaving the remaining 
collecting vessel intact for longitudinal functional imaging (236). Results from this study 
indicate that 2-4 days following the single-vessel ligation, the intact collecting lymphatic 
vessels exhibit relatively normal contractile activity and transport. Declines in the 
contractile activity of the vessel were delayed and observed 7-14 days after surgery, 
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resulting in decreased intrinsically driven transport. This result was observed even 3 
months after surgery, when tissue swelling had subsided. At the same time point, lymphatic 
pumping pressure was significantly decreased from baseline. This is in agreement with 
clinical studies that have demonstrated that patients with chronic lymphedema have lower 
lymphatic pumping pressure (140, 226). Interestingly, tail swelling was found to have 
correlated with loss of intrinsically driven transport at the early time points before peak 
swelling; however, after peaking, tail swelling no longer correlated with intrinsic transport. 
This indicates a co-dependence between collecting lymphatic contractile function and the 
degree of tissue swelling observed in the early stages of lymphedema. As a whole, these 
results are impactful from a clinical standpoint because they demonstrate that injury to the 
lymphatic vasculature can adversely affect the otherwise normally functioning collecting 
lymphatic vessel that are spared during surgery. It is possible that this is driven by a 
combination of mechanical and inflammatory factors, such as those discussed in the 
previous sections. 
1.5 Quantification of Collecting Lymphatic Function In Vivo 
A major hurdle to the study of collecting lymphatic pump function in the context of 
lymphedema is the paucity of non-invasive in vivo imaging methods that are capable of 
quantifying the effectiveness of intrinsically driven lymphatic transport (176). While 
numerous techniques have been used to visualize bulk lymphatic drainage including 
lymphoscintigraphy and MRI they lack the appropriate spatial and temporal resolution to 
assess lymphatic pump function (20, 136, 138, 197). Lymphoscintigraphy in particular has 
served as the “gold-standard” method in clinical diagnosis of fluid stasis caused by 
lymphatic dysfunction (142, 183, 220, 237). Near-infrared (NIR) imaging emerged as one 
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of the more promising imaging modalities due to its ideal combination of spatial and 
temporal resolution, allowing for dynamic imaging of initial and collecting lymphatics in 
real time (197, 225). NIR imaging provides excellent spatial resolution for superficial 
lymphatics because NIR excitation light resides in wavelength ranges ( >750 nm) that are 
minimally scattered and absorbed by biological tissues (17, 67). When these resolution 
capabilities are combined with the video frame-rates available with EM-CCDs, the 
technique is optimal for dynamic imaging of collecting lymphatic function (235). Using 
these techniques, a concentration of NIR fluorophore (typically bound to large molecular 
weight polyethylene glycol or albumin) is injected intradermally where it is taken up by 
the lymphatics (170, 235). It is then excited at NIR wavelengths and imaged using a CCD 
or EM-CCD camera with appropriate optics and filters (235). By utilizing these modalities, 
various quantitative metrics have been developed to characterize lymphatic function, 
including packet velocity, packet frequency, and transport time that correspond to the 
intrinsic contractile activity of the collecting lymphatic vessels (115, 116, 170, 176, 197, 
225–228, 235, 236).  
Novel NIR imaging approaches have been used to assess the structural and functional 
alterations of the collecting lymphatics associated with lymphedema in humans. A study 
by Unno and colleagues used NIR lymphatic imaging in patients to identify qualitative 
characteristics associated with lymphedema. These included dermal backflow, fluorophore 
retention at the injection site, dilated collecting lymphatics, and fluorescence diffusion due 
to leaky vessels (225). Similar qualitative assessments have confirmed these results (131, 
136, 175). More recent work by Liu et. al. has demonstrated that patients with breast cancer 
related lymphedema have significantly more tortuous lymphatic vessel morphology in the 
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affected arms; however, these vessels were also found to be functional, highlighting the 
necessity to quantify lymphatic function (124). Subsequent studies have developed 
quantitative techniques to non-invasively assess lymphatic contractile function. A method 
to measure lymphatic pumping pressure was pioneered by Modi and colleagues (140). This 
technique utilized lymphoscintigraphy to visualize lymph flow, coupled with a pressure 
cuff to apply an occlusive force. They subsequently utilized this technique to demonstrate, 
for the first time in-vivo, that patients with arm lymphedema had lower lymphatic pumping 
pressure. Unno et. al. expanded upon these techniques using NIR imaging methods as 
opposed to lymphoscintigraphy, to demonstrate that patients with leg lymphedema also 
had significantly lower lymphatic pumping pressure. The frequency and velocity of 
fluorescence packets has also been used to demonstrate declines in lymphatic contractile 
activity during lymphedema and increased functional response of these vessels to MLD 
therapy (215). 
Although NIR lymphatic imaging methods were pioneered in humans, they were 
quickly adapted for use in common animal research models (115, 197). These methods 
focused on tracking the frequency and velocity of fluorescent packets caused by the 
intrinsic contractile function of the lymphatics. Work by our group explored the sensitivity 
of these metrics to quantify the effects of known modulators of lymphatic function in the 
rodent tail (235). Subsequent studies developed a framework to characterize collecting 
vessel function in tissues that have a plurality of draining collecting lymphatics (234). More 
recent work has demonstrated that the amplitude of fluorescent packets correlates with the 
contraction amplitude of the vessels (45, 236). This has enabled non-invasive measurement 
of proxy metrics that quantify lymph transport driven by intrinsic contraction. As discussed 
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in detail within the previous section, these NIR imaging techniques have provided 
significant insight into collecting lymphatic function in both health and disease. 
Unfortunately, these methods have primarily focused on tracking and characterizing 
fluorescent packets or other singular metrics of collecting lymphatic performance. Thus, 
their use in determining collecting lymphatic dysfunction is limited. For example, there are 
numerous other factors that affect the overall lymph flow rate such as of contractile 
strength, valve performance, and vessel leakiness. Therefore, this thesis will explore the 
ability to non-invasively phenotype and longitudinally track a multiplicity of lymphatic 
failure modes in-vivo.  
1.6 Specific Aims 
Despite being an integral driver of lymphatic transport, relatively little is known 
about how lymphatic pump function and remodeling is affected following injury that 
results in a loss of lymphatic drainage pathways. In some cases, this loss ultimately results 
in chronic lymphedema whereas others do not. It is possible that predisposing factors that 
impact baseline lymphatic pump function become exacerbated by increased fluid loads due 
to surgical insult, ultimately manifesting in lymphedema. For example, in the context of 
obesity, impaired baseline lymphatic pump function could lead to a decline in the drainage 
and clearance of cells that mediate inflammation following injury. This could instigate a 
negative feedback loop where inflammatory cells induce adverse functional and 
remodeling responses from the lymphatic vessels, decreasing lymph clearance and 
drainage of said cells, ultimately resulting in continued lymph stasis and tissue remodeling. 
Alternatively, in scenarios where lymphedema does not immediately develop, it is unclear 
how collecting lymphatic vessels are able to alter their structure and function to compensate 
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for losses in lymphatic drainage pathways. Given that lymphedema often takes years to 
manifest, it is reasonable to believe that in many cases, despite initial functional 
compensation following surgery, the lymphatic pump becomes more susceptible to later 
insult or fatigue that finally induces lymphatic insufficiency. It is my central hypothesis 
that the collecting lymphatic vessels alter their functional and remodeling response to 
injury that disrupts lymphatic drainage pathways. Specifically; (1) known risk factors for 
lymphedema, such as obesity, will result in a greater degree of contractile dysfunction 
during lymphedema (Figure 1) and; (2) when lymphedema does not develop, the collecting 
lymphatic vessels will exhibit compensatory functional and remodeling responses (Figure 
2).  
 
Figure 1: Flow chart summary for our working understanding of the interplay 
between collecting lymphatic function, inflammation, and lymphedema development 
 
 
Figure 2: Flow chart summary for our working understanding of compensatory 




It is therefore the goal of this thesis to longitudinally determine the phenotypes of 
lymphatic pump dysfunction following a loss of lymphatic drainage pathways across 
research models with varying predispositions to lymphedema. To this end, I have outlined 
three specific aims of this thesis that, when complete, will; (1) Enable non-invasive 
phenotyping of lymphatic pump failure modes during disease; (2) Determine the effects of 
diet-induced obesity on collecting lymphatic pump function during lymphedema; and (3) 
Determine how collecting lymphatic pump function and remodeling may compensate for 
loss of lymphatic drainage pathways when lymphedema does not develop.  
1.6.1 Specific Aim 1: Develop and validate near-infrared (NIR) imaging methodologies 
suitable for phenotyping collecting lymphatic pump function during disease 
I hypothesize that different lymphatic pathologies will express differential and 
unique phenotypes of lymphatic failure. By combining NIR lymphatic imaging with a 
feedback controlled occlusion cuff and image processing algorithms, I will quantify 
multiple metrics representative of lymphatic function. These methodologies will provide 
the ability to phenotype a spectrum of collecting lymphatic failure modalities, allowing us 
to characterize changes occurring during disease pathogenesis and resolution.  
1.6.2 Specific Aim 2: Determine how diet-induced obesity differentially impacts 
collecting lymphatic pump function and remodelling in a mouse lymphedema model 
I hypothesize that diet-induced obesity adversely influences the lymphatic pump 
function and remodeling phenotype during the progression and resolution of lymphedema 
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in mice. I will investigate this hypothesis by using the methods developed in Specific Aim 
1 to assess the changes in the functional phenotype of the intact collecting lymphatic vessel 
on the tail in response to ligation of the contralateral vessel in a mouse model of diet-
induced obesity.  
1.6.3 Specific Aim 3: Determine how collecting lymphatic pump function and 
remodelling compensates for loss of lymphatic drainage pathways in a sheep model 
that does not develop lymphedema 
 I hypothesize that surgical ligation of a collecting lymphatic vessel will induce a 
compensatory functional and remodeling response from an undamaged vessel draining the 
same tissue space when lymphedema does not develop. Unlike mouse lymphedema 
models, human lymphedema typically does not manifest immediately after surgery. 
Therefore, I believe that sheep, given their size similarities to humans, may provide a more 
clinically relevant model for assessing lymphatic pump function and remodeling response 
to lymphatic injury. I will utilize the techniques described in Aim 1 to non-invasively assess 
the functional response of the intact collecting lymphatic vessel. I will subsequently utilize 




CHAPTER 2. DEVELOPMENT OF NEAR-INFRARED IMAGING 
METHODOLOGIES FOR LYMPHATIC DISEASE 
PHENOTYPING (AIM 1) 
2.1 Introduction 
As discussed in the previous chapter NIR imaging methodologies have been used to 
show differences in lymphatic function and architecture in patients and animals with 
lymphedema, as well as evaluate acute response to manual lymphatic drainage. Despite 
this, most functional assessments of lymphatic health have focused on measuring the 
frequency of fluorescence packets, which has been correlated to the frequency of lymphatic 
contractions (236). Contractile frequency is only one factor that affects overall lymph 
transport, and thus its use in determining lymphatic dysfunction is limited. For example, 
there are numerous other factors that affect the overall lymphatic function such as of 
contractile strength, valve performance, and vessel leakiness. To fill this gap, we set out to 
develop and validate new methods to quantify other modalities that contribute to lymphatic 
transport. In doing so, we can utilize a plurality of metrics in tandem to distinguish between 
different underlying causes of lymphatic pump failure non-invasively. This provides a 
powerful toolset for diagnosing specific failure modes that may be involved in the 
development of lymphatic disease.  
 Considering the wealth of information about cardiovascular health that 
measurements of blood pressure provide, it is reasonable to assume that a measurement of 
lymphatic pumping pressure would provide similar levels of insight about the health of the 
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lymphatic system. While pumping pressure of lymphangions has been measured  in situ 
(21, 87), the ability to obtain a minimally invasive measurement of the pumping capacity 
of the lymphatic network in vivo would be an invaluable tool, especially for longitudinal 
studies on disease progression. Excitingly, two important developments had been made in 
this regard. By utilizing a manually operated pressure cuff to occlude lymphatic flow, 
deflating the cuff, and then measuring the pressure at which flow is restored by visualizing 
lymphatic transport with either lymphoscintigraphy (140) or NIR imaging (226, 228), 
researchers were able to approximate lymphatic pumping pressure; however, these 
techniques were developed in humans and are thus unsuitable for comprehensive study of 
the pathophysiological progression of lymphedema in a lab-based setting. Moreover, these 
previous studies had only measured the lymphatic pumping pressure at a single location on 
the limb without consideration to how pressure may vary along the longitudinal axis due 
to the intrinsic contraction of lymphangions in series.  
This initial portion of this chapter discusses the development of a novel research 
platform to determine the effective lymphatic pumping pressure (Peff), packet restoration 
pressure, and emptying rate in rodents with minimal invasiveness by incorporating a 
closed-loop feedback system to control the occlusion pressure applied to the lymphatic 
vessel while simultaneously recording lymph transport with NIR imaging. We established 
the technique with the rat tail model, which was chosen because of the symmetry and 
anatomical consistency of the two collecting lymphatic vessels that drain along the sides 
of the tail. Additionally, the rodent tail is one of the most widely used animal models in 
lymphatic research and has provided remarkable insight into basic lymphatic physiology 
(22, 118, 210, 235), lymphangiogenesis (29, 49, 80, 248) and lymphedema pathology (11, 
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186, 211, 250). In fact, the rodent tail is likely one of the more clinically relevant locations 
to assess collecting lymphatic function. This is because the tail is an anatomic location on 
the rodent with collecting lymphatics that are composed of relatively long chains of 
lymphangions in series in a manner similar to those found in human limbs. We 
hypothesized that these lymphangion chains have the physiologic function of increasing 
lymph outflow pressure to overcome the hydrostatic pressure gradients found in the body. 
Therefore, we measured Peff at multiple locations along the rodent tail to establish if a 
greater number of lymphangions in series produced greater values of Peff in the proximal 
portions of the vessels.  
To determine the role that a known collecting lymphatic contractile mediator plays 
in modulating pressure generating ability, we applied a dermal nitric oxide (NO) donor 
ointment to the rat tails. NO has been shown to be a regulator of lymphatic function in 
several pathophysiologic or inflammatory conditions (2, 98, 117, 123, 180). Additionally, 
NO has been implicated in the inhibition of the intrinsic contractile capabilities of isolated 
lymphatic vessels (73, 139) and the slowing of lymph transport and reduction of lymphatic 
contractile frequency in vivo (190, 235). Based on these studies we hypothesized that the 
application of dermal NO donor ointment would reduce the observed Peff values obtained 
using our system and thus, demonstrate that our method is sufficiently sensitive to detect 
alterations of lymphatic function in vivo in a minimally invasive fashion.  
After developing and validating these methods, we utilized the entirety of our NIR 
imaging “suite” to phenotype the unique lymphatic failure modes involved in varying 
lymphatic pathologies. To accomplish this, we utilized two models that were known to 
possess lymphatic abnormalities, but with unknown failure modes, and thus unknown 
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levels of the severity of dysfunction. These include a mouse knockout model lacking 
lymphatic endothelial epsins (LEC-DKO) and a mouse model of diet-induced obesity.  
Post developmental lymphangiogenesis is critical for the maintenance, remodeling, 
and regeneration of the initial and collecting lymphatic vessels. The VEGF-C/VEGFR3 
signaling axis is a crucial regulator of this process; however, whether alterations in this 
signaling axis significantly contribute to impaired collecting lymphatic function are not 
clearly understood. Recent studies have uncovered an important regulatory role for the 
ubiquitin-binding clathrin-mediated endocytic adaptor family of epsins in the 
downregulation of VEGF-C/VEGFR3 signaling (125). Loss of lymphatic endothelial 
epsins has been shown to result in aberrant lymphangiogenesis and delayed pre-natal and 
early post-natal collecting lymphatic valve development. Despite these early defects, LEC-
DKO mice matured into phenotypically normal adults. Although seemingly normal, LEC-
DKO mice exhibit more tail swelling and delayed resolution of swelling upon induction of 
lymphedema (unpublished data). Therefore, we hypothesized that LEC-DKO mice have 
impaired baseline collecting lymphatic function and subsequently sought to prove or 
disprove the validity of this hypothesis using our NIR lymphatic imaging techniques to 
phenotype collecting lymphatic pump function in adult LEC-DKO mice.  
As discussed in the previous chapter, obesity is strongly associated with lymphatic 
dysfunction and the subsequent development of lymphedema. The prevailing hypothesis 
for this association is that obesity impairs baseline function due to T-cell mediated 
inflammation, thus positively influencing the development of lymphedema upon injury to 
the lymphatic vasculature (27, 192, 222). Previous studies supported this hypothesis by 
demonstrating that obese mice had decreased collecting lymphatic contraction frequency 
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compared to normal body weight controls (27); however, no studies had characterized other 
metrics of lymphatic pump performance. Because of this, it was unclear if obesity 
negatively influenced collecting lymphatic function outside of its effects on contraction 
frequency. To this end, we utilized our NIR lymphatic functional imaging techniques to 
phenotype collecting lymphatic function in obese mice.  
2.2 Materials and Methods 
2.2.1 Pressure cuff controller 
A closed-loop pressure cuff system was designed utilizing a commercially available 
pressure cuff (Kent Scientific, Torrington, CT) (Figure 3). The pressure cuff was attached 
to a 5 mL BD luer-lock syringe via plastic tubing (1/16” ID, 1/8” OD) and to a pre-
calibrated pressure transducer (Honeywell Sensing and Control, Morristown, NJ) via a 
plastic barbed T-fitting and additional plastic tubing (1/8” ID, 1/4" OD). The pressure 
transducer was connected to a data acquisition (DAQ) device (National Instruments (NI), 
Austin, TX) and pressure values were read in LabView. The pressure transducer was 
factory calibrated, but calibration was confirmed via a water column. A customized 
LabView virtual instrument (VI) (NI, LabView 2012 32-bit) was used to control the serial 
command output to the syringe pump (Harvard Apparatus PHD 2000 Infusion/Withdraw 
70-2001). Pressure transducer readings were sampled at 10 Hz and passed through a 5 point 
simple moving average filter. The difference between the desired pressure and the sampled 
pressure was used to control the flow rates on the syringe pump to subsequently inflate or 
deflate the pressure cuff. This was accomplished using simple on-off control. If the 
absolute pressure difference between the desired and sampled pressures was greater than 7 
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mmHg then a “high” infuse or refill flow rate of 1.00 mL/min was sent to the syringe pump. 
If the absolute pressure difference was less than 7 mmHg then a “low” infuse or refill flow 
rate of 0.25 mL/min was sent to the syringe pump. This allowed for a quicker response 
when the difference between the desired and measured pressure was large and a slower, 
finer response when it was small which minimized overshoot. These prescribed flow rates 
were used to modulate displacement of the syringe, thereby altering the volume and 
pressure of air inside the closed-tube system, and thus the pressure applied through the 
occlusion cuff to the tail or forelimb.  
 
Figure 3: An automated, integrated, feedback-controlled, lymphatic pumping 
pressure and imaging system with user interfaces serves as a powerful toolset for 
assessing lymphatic physiology. A schematic of the pressure cuff system including 
labeled depictions of its various components is shown. (Top right) A sample near-
infrared image of a rat and mouse tail with an example ROI identified. The pressure 
cuff can be seen at the right of the image. While two lymphatic vessels are visualized 
along the sides of the tail, the excitation source was focused on the lower vessel, which 
was used for quantification. (Bottom right) Bright field image of the pressure cuff 




Aided by the real-time feedback of the pressure transducer, the closed-loop system 
allowed for steady-state tracking of the desired pressure with an overall root mean squared 
(RMS) steady state error of 0.48 mmHg excluding the initial ramp-up to 80mmHg (Figure 
4). Fluctuations at steady state were mostly due to noise in the pressure transducer 
measurements. The rise and fall times were fast enough for accomplishing the purposes of 
this experiment while avoiding significant undesirable overshoot. Overdamping of the 
system was acceptable since the slight increase in time to reach a desired pressure value 
would not significantly affect the total duration of the experiment. 
 
Figure 4: Feedback-controlled pressure curves are applied to the tail with sufficient 
precision and speed. The pressure curve used to apply pressure during each 
experiment is shown. The exploded image shows the close tracking of the filtered 
actual pressure to the desired pressure. Root mean squared error (RMSE) for the 
entire pressure curve (disregarding the initial ramp up to 80 mmHg) for this curve is 
1.821 mmHg. Steady RMSE during the 10 minutes at 80 mmHg is 0.477 mmHg. The 
actual pressure data was filtered throughout the experiment using a 5 rank mean 
filter. The reported mean squared errors are based on this filtered data. 
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2.2.2 Near-infrared imaging system 
The NIR imaging system was set-up as described previously (235). A diode driver 
and temperature control box powered a 1 W 808 nm laser diode (Thorlabs, Newton, NJ), 
which provided excitation light. To disperse the laser over a larger area of approximately 
75 cm2 with less than 1.9 mW/cm2, a 20 degree beam diffuser (Thorlabs, Newton, NJ) was 
fixed in front of the diode. An Infinity K2/SC video 2.15x magnification microscope lens 
(Edmund Optics, Barrington, NJ) and a bandpass filter (CW: 840 nm, FWHM: 15 nm, 
Omega Optical, Brattleboro, VT) were attached to a PIXIS 1024B back-illuminated CCD 
camera (Princeton Instruments, Trenton, NJ) to capture fluorescence emission centered at 
840 nm. These wavelengths were chosen based on previous work that showed that ICG 
undergoes a spectral shift when it binds to albumin (235). The camera was connected to 
the same computer as used for the pressure cuff system, where the images were acquired 
by an additional custom LabView VI. 
2.2.3 Measurement of effective lymphatic pumping pressure in-vivo 
A standardized procedure was carried out on 9 week old male Sprague Dawley 
(Charles River, Wilmington, MA) rats. In order to minimize light scattering, a depilatory 
lotion was used to remove hair in the region of interest on the tail or forelimb one day prior 
to experimentation. Rats were anesthetized with an intramuscular injection of diazepam 
(2.5 mg∕kg) followed by a cocktail of fentanyl (0.12 mg∕kg) and droperidol (6 mg∕kg). After 
waiting for approximately 10 minutes for the anesthetics to take effect, the rat was 
positioned under the camera. To determine the effects of NO on lymphatic pumping 
pressure, some animals received a topical application of 500 mg glyceryl trinitrate ointment 
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(GTNO, 0.2% wt∕wt, Rectogesic, Care Pharmaceuticals) applied to the entirety of the tail.. 
To confirm that GTNO ointment was not drastically altering lymph formation and dye 
uptake at the injection site on the tail, an additional group of treatment animals had GTNO 
ointment applied only to areas of the tail 3 cm downstream of the injection site. Control 
animals received no GTNO ointment.  
The pressure cuff was calibrated by removing and then reattaching the tubing 
connected to the syringe to ensure that the steady state pressure was zero. The proximal 
edge pressure cuff (0.7 cm ID) was placed 4 cm, 8 cm, and 12 cm from the tip of the tail at 
which point the inner diameter of the cuff was uniformly touching the tail without applying 
any pressure, as verified by transducer readings. For a subset of rats a larger pressure cuff 
(1 cm ID) was fitted on the outstretched forelimb, past the elbow joint, with the proximal 
edge of the cuff 4 cm from the phalanges. Also, the cuff was positioned on the tail or 
forelimb in the same rotational orientation for each rat to compensate for any non-
uniformity in pressure application by the elastic bladder during inflation. The rat was 
positioned so that the field of view was proximal to the cuff, including only the edge of the 
cuff. A mixture of 30 µL of ICG/albumin solution (150 g/mL ICG (Acros Organics, Geel, 
Belgium) and 60 g/mL bovine serum albumin (MP Biomedicals, Auckland, New Zealand) 
dissolved in deionized water was injected intradermally at the tip of the tail, as described 
previously (235), or in the footpad of the forelimb. 
Image acquisition began just prior to intradermal injection of the dye. Once steady 
state fluorescence was established, more than 3 minutes after injection, a predetermined 
sequence of pressure cuff applications was administered to the tail. Specifically, the 
pressure was increased to 80 mmHg over a period of approximately 65 seconds and held 
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at this value for 10 minutes to allow for the proximal vessel to complete empty its contents. 
This pressure was chosen for lymph flow occlusion because 80 mmHg is close to the 
diastolic blood pressure of a rat and well below the mean arterial pressure, so blood supply 
was not occluded during the experiment (34). After 10 minutes at 80 mmHg, the pressure 
was decreased to 55 mmHg over a period of approximately 25 seconds. The pressure was 
then decreased in decrements of 2.5 mmHg and held at each pressure step for 60 seconds 
until the pressure value was zero, where it remained for 3 minutes before the program was 
terminated. The pressure cuff controller took less than 15 seconds to reach each new 
pressure decrement. This standardized pressure curve was used for all experiments (Figure 
4). 
Images of the tail or forelimb were captured by the NIR imaging system throughout 
the experiment at a frame rate of 1 fps with a camera exposure time of 50 ms. This frame 
rate has been shown to provide sufficient temporal resolutions for dynamic imaging of 
lymphatics (235). After the first frame was captured, the system paused to allow the user 
to select a region of interest (ROI) which was positioned just proximal to the pressure cuff, 
over the fluorescent vessel. The ROI selected for use in the data analysis was always 
positioned over the left vessel of the tail (Figure 5) or a lymphatic vessel residing on the 
front of the left forelimb. This was done both for the sake of consistency and to optimize 
the optics for achieving the best signal on a single vessel. The intensity plots obtained were 
consistent in form between all experiments. While flow was occluded at 80 mmHg, a 
gradual emptying of florescence within the proximal vessel was observed. Florescence was 
not restored until the pressure applied to the cuff was lowered and was no longer sufficient 




Figure 5: (Top) A representative intensity plot. The intensity spike at around 500 
seconds is caused by the inflation of the pressure cuff to 80 mmHg pushing ICG dye 
into the region of interest (ROI). While the pressure is held at 80 mmHg the intensity 
within the ROI drops as the vessel is cleared of dye. As the pressure cuff is deflated 
using the control algorithm, the intensity within the ROI rises, indicating the 
beginning of flow restoration. Eventually, flow is completely restored within the vessel 
and intensity plots exhibit typical packet flow. (Bottom) Time lapse images at various 
time points (A-F) in an experiment showing dye emptying from the vessel during flow 
occlusion and dye filling the vessel as flow is restored. The pressure cuff can be seen 
on the right side of the time lapse images. The arrow in image A indicates the direction 





In order to confirm that GTNO did not have significant effects on the arterial blood 
pressure (ABP) we measured ABP in four animals pre and 20 minutes post GTNO 
application. ABP was measured using a Non-Invasive Blood Pressure Monitor NIBP-8 
(Columbus Instruments, Columbus, OH). All animal procedures were performed in 
accordance with the Georgia Institute of Technology Internal Animal Care and Use 
Committee and complied with National Institutes of Health Guide for Care and Use of 
Laboratory Animals. 
2.2.4 Image processing 
Three primary measurements were taken from each intensity plot and pressure curve 
combination using customized data analysis algorithms written in MATLAB. The first was 
Peff, which was calculated using two points: the minimum intensity value before flow 
restoration and the maximum intensity value after flow restoration. The average of these 
two values was the intensity threshold for flow restoration. The pressure at the time where 
the intensity rose to equal the intensity threshold was Peff (Figure 6). The second parameter 
determined was the “packet restoration pressure”. NIR imaging of lymphatic uptake 
produces discrete packets of fluorescence that travel through the vessel as a result of the 
intrinsic contractility of the lymphatic vessels working in coordination with lymphatic 
valves. The frequency of these packets has previously been reported as a measurement of 
lymphatic function (235). To determine the pressure at which packet flow was restored in 
the lymphatic vessel, a fast Fourier transform (FFT) was used to calculate the power 
spectral density (PSD) of the intensity signal in the frequency range of 0.06 – 2 Hz prior to 
flow occlusion (before 80 mmHg) and after complete flow restoration (at 0 mmHg). Since 
packet frequency can be somewhat variable even in non-occluded vessels, the PSD was 
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used to calculate the magnitude of the spectral content within this frequency range to 
provide a measure of contractile activity. The point at which this value recovered to 50% 
of its non-occluded value was indicative of the restoration of packet flow. The packet 
restoration metric was used to identify the pressure when packets were evident that rivaled 
those seen during uninhibited flow (Figure 6). The third parameter was the average 
“emptying rate” of the vessel during flow occlusion, the average rate of fluorescence 
intensity decrease as the proximal vessel emptied during the period when the pressure was 
raised and held at 80 mmHg (ER, Figure 6). To calculate the average emptying rate of the 
vessel two time points were used: the time of maximal fluorescence at the beginning of 
flow occlusion and the time at which the intensity fell within 5% of the minimal steady 
state value during flow occlusion. The average emptying rate was then calculated as the 
difference in intensity over the difference in time between the two points. The values for 
Peff, packet restoration pressure and emptying rate were averaged for the treatment and 





Figure 6: (Top) Overlaid pressure and intensity plots demonstrate the calculation of 
the effective pumping pressure (Peff) and the emptying rate (ER). Typical pack flow 
that is present before the beginning of flow occlusion (bottom left) is recovered after 
occlusion (bottom right). To quantify the point at which packet flow was restored, the 
time at which the magnitude of the power spectral density function (PSD) recovered 








2.2.5 Assessment of lymphatic function in disease models 
2.2.5.1 Lymphatic endothelial cell epsin knockout 
Lyve-1 EGFP-hCre mice were purchased from Jackson Laboratory (Bar Harbor, 
ME) (166). Epsin1fl/fl; epsin 2-/- ; Lyve-1-Cre (LEC-DKO) were generated by crossing 
epsin 1fl/fl; epsin 2-/- mice with Lyve-1-Cre mice as previously described (125). 8-10 week 
old LEC-DKO or WT animals underwent NIR functional imaging procedures as previously 
described (149, 234, 235). However, an additional functional metric, fluorescence area, 
was developed to quantify the relative amount of initial lymphatic recruitment in fluid 
transport. Fluorescence area was calculated by converting the 16-bit greyscale images that 
were captured during the 10 min imaging segment following fluorophore injection to 
binary images. The binary threshold was determined by cluster based thresholding using 
Otsu’s method over the entire imaging segment. The total area of pixels above this 
threshold was calculated and then normalized by the total area of the tail. This yielded the 
percentage of the tail positive for fluorescence as a function of time. The raw data was then 
passed through a set of smoothing filters to exclude frames captured during tail movement 
to limit motion artifact noise. Specifically, the percent fluorescence area signal was 
discretized into 100 bins of 6 frames. The highest 2 values within these bins was averaged 
to generate an upper envelope of the percent fluorescence area signal. This upper envelope 
of the time dependent signal was then fit with a 4-point locally weighted linear least squares 
regression. The resulting smoothed percent fluorescence area curve was used for 
expression of percent fluorescence area as a function of time. All experiments using the 
LEC-DKO model were conducted at the Oklahoma Medical Research Foundation (OMRF) 
and approved by the OMRF Institutional Animal Care and Use Committee (IACUC).  
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2.2.5.2 Diet-induced obesity 
Six week old male C57BL/6J (Jackson Laboratories, Bar Harbor, Maine) mice were 
fed either a high fat diet (60% kcal from fat; W.F Fisher & Son, Inc., NJ) or a normal chow 
diet ad libitum for 12 weeks (191). To facilitate easy access to food, the diet was placed in 
a dish within the cage as opposed to overhead. At the end of this period chow fed and diet-
induced obese animals underwent the NIR functional imaging procedures as previously 
described (149, 191, 234, 235). These procedures were approved by the Georgia Institute 
of Technology Institutional Animal Care and Use Committee (IACUC). 
2.3 Results 
2.3.1 Nitric oxide reduces lymphatic pumping pressure and emptying rate 
Nitric oxide, via application of the GTNO ointment, significantly reduced Peff of the 
lymphatics in vivo from 34.8 mmHg to 18.5 mmHg as determined by the functional NIR 
imaging system (p<0.05) (Figure 7). Additionally, GTNO significantly reduced the 
average packet restoration pressure from 40.3 mmHg to 18.4 mmHg (p<0.005). There was 
no statistical difference between the two different metrics of lymphatic pumping pressure 
(Peff and packet restoration pressure) for either control or GTNO-treated animals. GTNO 
application also caused a significant decrease in the emptying rate of fluorescence from the 
proximal vessel of the cuff after occlusion: from 6.15 IU/s to 2.19 IU/s (p<0.05) (Figure 
8). To determine the extent that the decreases in lymphatic pump function might have been 
caused by changes in lymph formation due to the effects of GTNO on blood pressure and/or 
capillary permeability, rather than due to the direct action of NO on lymphatics, GTNO 
application was restricted to areas 3 cm downstream of the injection site in a subset of rats. 
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No differences were observed in Peff, packet restoration pressure, or emptying rate 
between rats with GTNO applied to the whole tail and those with the altered application 
protocol (Figure 9). Since no statistical difference was observed between these two 
treatment groups, they were grouped together in the comparison between GTNO and 
control (Figure 7) and (Figure 8). In order to determine if dermal NO application may have 
altered arterial blood pressure in the tail, blood pressure in a subset of rats (n = 4) was 
measured before and 20 minutes after GTNO application. Mean tail blood pressure was 
found to be 80/48 ± 18/14 mmHg for the control group vs 97/56 ± 12/8 mmHg for the 
GTNO treated group. No statistical differences were observed in either systolic or diastolic  
arterial blood pressure in the tail as a result of GTNO application. 
 
Figure 7: Dermally applied nitric oxide significantly reduced both the Peff and packet 
restoration pressure of the lymphatics (p<0.05) and (p<0.005). The treatment group 
received 500 mg GTNO ointment applied to the tail (n=12). The control group 




Figure 8: Dermally applied nitric oxide significantly decreased the average rate of 
emptying of the lymphatic vessel (p<0.05). The treatment group received 500 mg 
GTNO ointment applied to the tail (n=12). The control group received no GTNO 
ointment (n=5). Error bars represent SEM. 
 
 
Figure 9: The location of GTNO ointment application did not significantly impact 
effective lymphatic pumping pressure or packet restoration pressure. 500 mg GTNO 
ointment was applied to the entire tail (GTNO- Whole Tail) (n= 12) or was restricted 
to a portion of the tail 3 cm distal to the injection site of fluorophore (GTNO- Partial) 
(n= 4). Error bars represent SEM. 
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2.3.2 Effective lymphatic pumping pressure is dependent on measurement location 
To demonstrate the feasibility of our method to be used on other anatomical 
locations more relevant to human pathologies we measured Peff, packet restoration 
pressure, and emptying rate on the forelimb of rats. Interestingly, when the cuff was placed 
on the left forelimb 4 cm from the phalanges the measured Peff and packet restoration 
pressure values of 14.9 mmHg and 14.7 mmHg were not significantly different from the 
values obtained from measurements taken 4 cm from the tip of the tail but were 2-3x less 
than the values collected at 12 cm on the tail (p<0.01) and (p<0.05) (Figure 10). The 
average emptying rate of vessels on the forelimb was found to be 2.08 IU/s.  
Because the average Peff on the forelimb was discovered to be significantly lower 
than the tail, we sought to determine the extent to which the location of the pressure 
measurement affected our metric. To investigate this, we positioned the proximal edge of 
the cuff and the imaging frame 4 cm from the tip of the tail. When functional measurements 
were taken at 4 cm, the Peff decreased to 15.2 mmHg from 34.8 mmHg (p<0.01) in the 
control animals which were measured at 12 cm from the tip of the tail (Figure 10). A similar 
trend was observed in the packet restoration pressure which decreased to 11.6 mmHg from 
40.3 mmHg (p<0.05) (Figure 10). The average emptying rate obtained 4 cm from the tip 





Figure 10: When measurements were taken at 4 cm (n=3) from the tip of the tail 
versus 12 cm (n=5) a significant decline in the Peff and packet restoration pressure 
was observed (p<0.01) and (p<0.05). Peff and packet restoration pressure values 
obtained on the forelimb (n=5), 4 cm from the phalanges, were not significantly 
different from those obtained 4 cm from the tip of the tail. Values of Peff and packet 
restoration pressure on the forelimb were significantly different from those obtained 
at 12 cm from the tip of the tail (p<0.005) and (p<0.05). Forelimb measurements 
exhibit very little difference in variability from measurements taken on the tail. Error 
bars represent SEM. 
 
2.3.3 Effective lymphatic pumping pressure is dependent on lymphangion chain length 
We hypothesized that the length of the collecting lymphatic vessel influenced the 
pressure measurement due to a relative increase in the number of lymphangions contracting 
in series. We subsequently investigated this by taking measurements of Peff at 4, 8, and 12 
cm from the distal tip of the tail. We discovered that Peff in the rat tail progressively 
increases along the length of the tail as one moves from the tip of the tail towards the base 
(Figure 11). Specifically, the average pumping pressure for each group of rats was 15.2 ± 
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5.17 mmHg (n=3), 21.3 ± 5.06 mmHg (n=4), and 34.8 ± 2.52 mmHg (n=5) at distances of 
4 cm, 8 cm, and 12 cm from the tip of the tail respectively (Figure 11).   
When GTNO was applied to the tails, the average pumping pressure for each group 
of rats was found to be 10.3 ± 4.02 mmHg (n=4), 12.43 ± 5.80 mmHg (n=3), 18.54 ± 3.4 
mmHg (n=12), and distances of 4cm, 8cm, and 12 cm from the tip of the tail, respectively. 
Comparing to control and GTNO data sets using the extra sum of squares F-test on the 
quadratic best-fit regressions of the data revealed that the two groups are statistically 
different (p<0.05) (Figure 11). Interestingly, the effect of GTNO treatment was much more 
pronounced when the measurement was taken at 12 cm, which is likely due to the increased 
contribution of the intrinsic lymphatic pump to generate pressure in the more proximal 




Figure 11: (Top Left) The effective lymphatic pumping pressure increases moving 
proximally along the tail. GTNO application attenuates this pressure increase (*- 
denotes significant difference between control and GTNO, p<0.05) (^- denotes 
significant difference between control at 4 cm and 12 cm, p<0.05). (Top Right and 
Bottom) Experimental set-up for measuring lymphatic pumping pressure. The 
pressure cuff is positioned at various locations measured from the tip of the tail. Flow 
restoration is imaged by capturing the return of fluorescence into the collecting vessel 
in a region proximal to cuff 
 
2.3.4 Lymphatic diseases produce unique functional phenotypes 
By combining the pressure cuff techniques described in the prior sections with 
previously developed methods designed to measure lymphatic contractile function, we 
enable a more comprehensive assessment of collecting lymphatic health and disease. The 
combination of these performance metrics is used to generate a unique phenotype of 
collecting lymphatic function in-vivo (Table 1). This is important for providing novel 
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insight into how lymphatic diseases differ across etiologies and at different stages of 
disease progression. The results of the LEC-DKO and diet-induced obesity studies 
highlight how these phenotyping techniques provide novel insight into the previously 
uncharacterized spectrum of lymphatic disease.  
 
Table 1 – Summary of the NIR imaging suite used for phenotyping collecting 
lymphatic dysfunction in the LEC-DKO and diet-induced obesity studies 
NIR Functional Metric 
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2.3.4.1 Loss of lymphatic endothelial epsins adversely affects collecting lymphatic 
function 
Collecting lymphatics in LEC-DKO mice exhibited no discernable anatomical 
differences in vessel morphology, as assessed by whole mount immunofluorescence 
staining (125), but appeared to present significant functional deficiencies when assessed 
using our NIR functional phenotyping techniques. The qualitative differences in 
fluorescence transport, between control and LEC-DKO mice, were striking. On the tail of 
control mice, ICG was quickly transported post-injection by the collecting lymphatic 
vessels, reaching steady state fluorescence within 5 min (Figure 12). On the tails of LEC-
DKO mice faint uptake of ICG was observed in collecting lymphatic vessels within 5 min, 
however at 10 min significant recruitment of the initial lymphatic network, not seen in 
control mice, was observed (Figure 12). More quantitatively, in control mice a spike in 
percent fluorescence area, corresponding to collecting vessel uptake of ICG, occurred 30 s 
post-injection, reaching steady state at 100 s. Uptake by the initial lymphatic network in 
control mice was not observed, and thus the average percent fluorescence area of the tail 
for the 10 minute period was 9.5%. In LEC-DKO mice a rise in percent fluorescence area, 
corresponding to collecting vessel uptake, did not occur until about 90 sec post-injection. 
Interestingly, a steady rise in percent fluorescence area, corresponding to transport of ICG 
by the initial lymphatics, was observed throughout the 10 minute period. Because the initial 
lymphatic network exhibits significant amounts of fluorescence, over large portions of the 
tail, the average percent fluorescence area of the tail for the 10 minute period was 20.6%. 
After 10 minutes mean percent fluorescence area of the tail for control and LEC-DKO was 
8.1% and 36.4% respectively.   
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 Loss of epsins adversely affected collecting lymphatic vessel function in the mouse 
tails as assessed by NIR functional lymphatic imaging. Fluorescence packet frequency of 
collecting lymphatics in the tails of control and LEC-DKO mice was 1.1 min-1 vs 0.0 min-
1 (p< 0.05) respectively (Figure 12). Upon lymphatic flow occlusion, with the pressure cuff 
at 80 mmHg, significant differences, between control and LEC-DKO mice, in vessel 
emptying rate were observed. The emptying rate of the collecting lymphatic vessels on the 
tail for control and LEC-DKO mice was found to be 1.02 IU/s vs -0.32 IU/s (p< 0.001) 
(Figure 12). Because the lymphatic vessels of LEC-DKO mice did not clear their contents 
during upstream occlusion, as assessed by the emptying rate metric, effective pumping 
pressure was unable to be measured. In control mice the effective pumping pressure of the 
lymphatics was found to be 16.8 mmHg on average (Figure 12). 
 
Figure 12: LEC-DKO mice exhibit significantly impaired lymphatic function. (A-B) 
LEC-DKO mice exhibit abnormal recruitment of the initial lymphatic network to 
transport fluid to compensate for deficiencies in collecting lymphatic function. This 
result is quantified in (E) (p<0.05). (D) LEC-DKO mice exhibit significantly lowered 
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packet frequency (p<0.05). (F) Due to the valve malformations in the lymphatics of 
LEC-DKO mice, the lymphatics are unable to prevent backflow, and thus results in 
a negative emptying rate (p<0.01). (G) LEC-DKO mice exhibit no detectable pumping 
pressure, indicating that the lymphatic contractile strength is impaired (p<0.05). 
Error bars represent SEM 
 
2.3.4.2 Obesity causes significant decreases in lymphatic contractile frequency 
C57BL6J mice placed high fat diet (60% kcal from fat) for 12 weeks exhibited 
significant increase in body weight compared to chow fed controls with values of 55 ± 1 g 
and 30 ± 2 g respectively (Figure 13). Functional NIR lymphatic imaging revealed 
functional alterations caused by obesity. Packet frequency was significantly decreased in 
obese animals compared to control with values of 2.6 ± 1.6 min-1 and 4.0 ± 1.7 min-1 
respectively (p<0.05) (Figure 13). However, fluorescence area, emptying rate, and 




Figure 13: NIR imaging was used to evaluate lymphatic function of obese mice. (A) 
C57BL/6 mice exhibit significant weight gain on a 60% fat diet compared to chow fed 
controls (p<0.0001). (B) Representative NIR images of a mouse tail showing the two 
parallel collecting lymphatic vessels. (C) Representative intensity tracking showing 
differences in the frequency of fluorescence pulsations between lean and obese mice. 
(D) Obesity causes significantly lower packet frequency (p<0.05). (E-G) No 
statistically significant differences were observed in fluorescence area, emptying rate, 
or pumping pressure. Error bars represent SEM. 
 
2.4 Discussion and Conclusions 
2.4.1 Lymphatic pumping pressure is a novel metric that enables greater insight into 
collecting lymphatic physiology and pathophysiology 
The ability to monitor pressure and hemodynamics in the blood circulation has been 
crucial for both assessing vascular health in a clinical setting and for probing the molecular 
mechanisms that regulate vascular biology in a laboratory setting. Development of 
technologies that enable similar measurements in the lymphatic vasculature in a non-
49 
 
invasive or minimally invasive fashion, such as those reported here, have the potential to 
make a substantial impact on the future of lymphatic research and patient care. While the 
general approach of using an occlusion cuff to stop lymphatic flow as a means of 
determining the pumping pressure was pioneered previously in humans (140, 226, 228), 
there are some substantial differences in the presented approach that improve the accuracy 
of the technique as a laboratory research tool. First, by utilizing an automated, computer-
controlled, closed-loop feedback system to generate the desired pressure curves, greater 
precision and sensitivity were achieved than with previous manually controlled, open-loop 
feed-forward systems (140, 226, 228). Additionally, by combining this system with our 
previously optimized experimental functional lymphatic imaging platform (235), improved 
spatial and temporal resolutions were achieved over lymphoscintigraphy (20, 136, 140, 
197). 
Applying these techniques to the study of rodent lymphatic vessels has opened the 
door for in vivo, non-invasive, studies on the regulation of lymphatic pumping and pump 
regeneration. The simple geometry and anatomy of the lymphatic vessels in the rodent tail 
make this is an ideal location to measure Peff. Also, the rodent tail is one of the most 
developed animal models of lymphedema (11, 147, 186, 211, 250), where the addition of 
this toolset could provide remarkable insight into lymphedema progression and pathology. 
By artificially elevating the external pressure applied to the exterior of the vessel using the 
pressure cuff, we can determine the maximal occlusive pressure the lymphatic vessel is 
able to overcome, Peff. This pressure is much higher than previous measurements of systolic 
pressures in rats (21, 87) and is higher than the maximum pressure that can be overcome 
in isolated collecting lymphatic vessels that are exposed to an elevated output pressure 
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(60). However, the measurements are made almost exclusively in single lymphangions, not 
chains of lymphangions as was done here. Additionally, in these previous experiments the 
pressure applied externally to the vessel is close to zero and thus the average of the applied 
pressures at the inlet and outlet of the vessel equals the transmural pressure. To our 
knowledge there are no measurements of systolic pumping pressure of an isolated 
lymphatic vessel that is under an elevated external pressure. Additionally, the injection 
itself, while only 30 µL, could also elevate the contribution of the extrinsic factors to our 
pressure measurement.  
Although the rodent tail does appear to have many advantages as a research tool 
there exists some concern that the low amount of variability we observed in our 
measurements is not due to the implemented feedback control of the pressure application, 
but rather is dependent on the unique anatomy of the tail and would not be as effective at 
other anatomical locations. This is of particular concern when evaluating the potential for 
this methodology to be used as a clinical tool. We used the forelimb to investigate other 
regions on the rat that could be used as a suitable measurement location. The animal-to-
animal variability of Peff values obtained on the forelimb was not significantly different 
from those obtained on the tail. This demonstrates that our methodology could be easily 
adapted for use in other animal models in which functional pump measurements are of 
interest. Interestingly, it appears that the measure of Peff is far more dependent on the length 
of the lymphatic vessel chain being measured as opposed to the anatomical location of 
measurement, whereas the emptying rate metric appears to vary with anatomical location. 
Peff values taken on the forelimb, 4 cm from the phalanges, were not significantly different 
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from those obtained 4 cm from the tip of the tail. This result further demonstrates the 
importance of vessel chain length in the transport of lymph.  
2.4.2 Lymphangion chain length and contractile strength are primary contributors to 
lymphatic pumping pressure 
To examine the effects of lymphangion chain length on Peff, we varied the location 
of the cuff in relation to the tip of the tail. Peff measurements taken 4 cm from the tip of the 
tail were 2-3x less than those obtained at 12 cm, and progressively increased along the 
length of tail. These increases in Peff with varying measurement locations are consistent 
with our understanding of the measurement. Peff captures the effects of the lymphatics distal 
to the pressure cuff to overcome occlusive force. It stands to reason that as the number of 
lymphangions along a lymphatic vessel increase then the overall ability of the vessel to 
overcome an externally applied pressure gradient will also increase.  
In collaboration with other researchers, my experimental data was incorporated into 
a computational model of a chain of pumping lymphatics to provide insight into the nature 
of the pressure-length relationship that exists when measuring Peff  (177). This 
microstructurally motivated model of a chain of lymphangions was informed from biaxial 
testing of isolated lymphatic vessels from the rat tail. Simulations from this model suggest 
that maximal pressure generation of the lymphatic chain is primarily a function of the 
contractile force of the smooth muscle cells surrounding the lymphangions and the number 
of lymphangions in the chain. This result indicates that Peff is a proxy measurement for the 
contractile force of the lymphatics in-vivo. However, this conclusion can only be drawn so 
long as the number of lymphangions in the chain and subsequently the measurement 
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location remains roughly consistent across different animals. This ability for the smooth 
muscle cells to contract and generate high outflow pressure is of great importance when 
considering that lymphatic must overcome large hydrostatic pressure gradients to return 
lymph from the interstitial space to venous circulation. However, the pressure generating 
abilities of the lymphatics is likely dependent on operating within a physiologically optimal 
range. It is possible that extra-physiological elevations in outflow pressure could induce 
pump overwork and subsequent lymphatic incompetency (15, 46, 59, 65, 194). 
In human lymphatic vessels, long chains of lymphangions and valves must contract 
to drain fluid from the distal portions of the limb. Although the rodent tail has no human 
analogue, we believe that it provides an excellent research model for investigations relating 
functional metrics of lymph transport to vessel chain length. Thus, in some sense, when 
utilizing rodent animal models of lymphatic physiology, the tail is one of the more 
“physiologic” locations to capture certain aspects of lymphatic physiology, since it is the 
only appendage in which lymph must be transported a considerable distance.  
2.4.3 Nitric oxide decreases lymphatic pumping pressure via downregulation of intrinsic 
contraction 
GTNO was used to uncover the role of nitric oxide on Peff and emptying rate 
measurements because of its known inhibitory effects on lymphatic contractility.  NO has 
been shown to decrease the intrinsic contraction of collecting vessels ex vivo (76, 139) as 
well as decrease lymphatic transport in vivo (190, 235). In fact, it is becoming apparent that 
NO is a primary mechanism utilized by lymphatics to regulate flow. Specifically, immune-
cells have been shown to release NO as a mechanism for manipulating lymphatic flow as 
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part of a local immune modulatory response to inflammation (32, 77, 120, 127). Also, 
transient changes in wall shear stress (WSS) on lymphatics lead to NO release as a means 
of either promoting vasodilation and reducing vascular resistance to flow during sustained 
WSS or possibly transiently increasing the vessel diameter as a regulatory mechanism for 
lymphatic pumping (31, 32, 76, 110). Based on the plethora of previous works that have 
demonstrated the effects of NO on lymphatic vessels, the use of a dermally applied NO 
donor provides an excellent pharmacological tool for modulating lymphatic function non-
invasively to determine the effect of excess NO on lymphangion chain pressure generation. 
In this study, we have demonstrated that our measurements of Peff and emptying 
rate are sensitive to perturbations in lymphatic function caused by NO. Specifically, we 
showed that the Peff was cut in half when GTNO was applied to the surface of the tails. This 
decrease in Peff shows that the lymphatics are less able to overcome flow occlusion with 
increased levels of NO and are thus less effective at moving fluid up the externally applied 
adverse pressure gradients. It is important to note that we do not propose that Peff is the 
actual systolic pressure of the lymphangions in the collecting vessel, but rather is a measure 
of the maximal externally applied pressure that can be overcome by the contributions of 
intrinsic and extrinsic factors which drive lymph flow. Since NO could have effects on 
extrinsic factors, it was important to determine if the decline in Peff and emptying rate was 
primarily due to the loss in lymphatic contraction or a secondary result due to changes in 
the local Starling forces caused by lymph formation. NO could be affecting vascular 
permeability and thus lymph formation in two different ways. The first is that NO could 
increase vascular permeability and fluid extraversion into the interstitium (68, 213), 
increasing lymph formation and subsequently driving lymph flow. The second is that given 
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the potential of NO to lower capillary blood pressure, it is possible that GTNO could also 
decrease lymph formation and thus there would be less of a driving force of fluid upstream 
(112, 185). This appears unlikely because applying the occlusion cuff for 10 minutes at 80 
mmHg likely blocks venous return. This would increase venous pressure and cause an 
increase in interstitial fluid buildup regardless of NO’s effects on capillary permeability. 
In both scenarios, the conditions for lymph formation are high and thus should in-turn 
correspond to increases in the extrinsic mechanisms responsible for lymph flow. However, 
we showed that Peff and packet restoration pressure was halved in the presence of GTNO. 
Also, application of GTNO away from the injection site, but still on the tail surface above 
the vessels at the measurement location, had the same effect on our metrics of lymphatic 
pump function as when applied to the entire tail. Therefore, the most likely explanation is 
that the decreases in Peff, packet restoration pressure, and emptying rate are due to the NO-
induced loss of intrinsic lymphatic contractility, not a secondary result due to changes in 
lymph formation upstream. Our more recent collaborative study utilized a computational 
model to simulate output pressure of a chain of lymphangions in series (177).  The results 
of this study indicate that the reduction in effective pumping pressure with GTNO 
application can be best replicated by lowering the active muscle tension of the 
lymphangions and not the contraction frequency or interstitial fluid pressure. However, 
because active muscle tension includes both the combined effects of tonic constrictions 
and phasic contractions, it is not clear in this study whether nitric oxide effects on tone (and 
indirectly valve function) or contraction amplitude are primarily responsible for the 
reduction in effective pumping pressure observed in-vivo. 
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We calculated the emptying rate to quantify the average rate of dye removal, a 
metric that is reflective of lymph flow (assuming that the solute flux follows the convection 
of the fluid). By occluding lymph flow distal to the imaging site, we were able to isolate 
the effects of intrinsic pumping from the effects of upstream lymph formation. It is 
reasonable to assume that the emptying rate captures an overall metric of lymphatic 
transport driven by intrinsic pumping effects of the downstream lymphatic chain (and 
perhaps the effects of nearby arterial pulsations). Since vessel filling is being occluded 
upstream of the imaging location by the pressure cuff, fluorescent dye must be transported 
out of the imaging location by intrinsic contractility of the lymphatic vessels. This metric 
thus decouples the effects of lymph formation upstream as a driver for lymphatic transport. 
In effect, emptying rate characterizes the downstream (proximal to the cuff) lymphatics 
ability to transport fluid, whereas Peff characterizes the upstream (distal to the cuff) 
lymphatics. Utilizing these two metrics, we are able to characterize the effects of two 
separate segments of a single lymphatic vessel in the transport of fluid. GTNO significantly 
lowered the average emptying rate of the collecting vessels on the tail by nearly three-fold. 
This result follows a similar pattern to two previous studies which showed that lymph 
transport is substantially decreased in the presence of GTNO (190, 235). When the two 
metrics used in this study (Peff and average emptying rate) are examined in conjunction 
with these two previous studies, it becomes clear that the pumping pressure measurement 
system provides a complementary platform for quantifying lymphatic function; providing 
additional insight into the mechanisms regulating lymphatic dysfunction during disease.  
Throughout the experimental process, consistency was maintained for as many 
variables as possible. However, there are some limitations of the technique that are worth 
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mentioning. First, the physiological effects of anesthesia on the measured Peff are unknown. 
This could be problematic in studies where it is suspected that the anesthesia itself might 
mask hypothesized losses in lymphatic pumping. Second, the application of the occlusion 
cuff at 80 mmHg for 10 minutes likely causes a buildup of interstitial fluid by blocking 
venous return. This would tend to give elevated measures of Peff over baseline values. 
However, the technique itself, while not providing a direct measurement of baseline 
systolic lymphatic pressure, is indicative of lymphatic pump function and provides, in our 
opinion, one of the most quantitative non-invasive measures of total lymphatic pumping 
capacity available. Third, we and others have reported effects of ICG on lymphatic pump 
function (74, 234). However, the negative effects of ICG appear primarily upon repeat 
injections and are reversible if enough time occurs between each injection (around 4 
weeks). Since multiple injections were not given in this study, this does not appear to be 
problematic. Future work, discussed in Chapters 3 and 4, will utilize NIR tracers that do 
not influence lymphatic function, thus making these methods suitable for use in time course 
studies.  
2.4.4 Combinations of NIR functional imaging techniques can be used to phenotype and 
provide novel insight to lymphatic disease 
 The studies described in the previous sections have demonstrated the development 
and validation of novel NIR imaging techniques to quantify collecting lymphatic pumping 
pressure and emptying rate in vivo. However, by combining these new techniques with 
previously established packet performance metrics (115, 116, 235), we enable the unique 
ability to non-invasively phenotype the modalities of collecting lymphatic failure in the 
context of disease. To demonstrate this, we utilized two models that are known to possess 
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deficiencies in lymphatic transport, but the involvement of the collecting vessel pump in 
these deficiencies was unknown, and thus its appropriateness as a therapeutic target has 
remained elusive. These include a genetic mouse model of delayed lymphatic valve 
development and a mouse model of diet-induced obesity. These two models were chosen 
to capture the clinical breath of lymphatic dysfunction, including a model with an 
underlying genetic deficiency (as occurs in primary lymphedema), as well as a model of 
acquired dysfunction (as in secondary lymphedema).  
2.4.4.1 Genetic deletion of lymphatic endothelial epsins profoundly impairs collecting 
lymphatic function 
Lymphatic valve malformations have been suggested to be one of the most common 
causes of hereditary lymphedema and have also been suggested to be involved in the 
progression of secondary lymphedema (125, 165). These malformations result in an 
inability for the lymphatics to prevent back flow, and subsequently lead to fluid leaking 
from the vessels back into the initial lymphatics and the interstitium. However, the 
functional response of the collecting lymphatic vessels has not been described in the 
context of lymphatic valve malformations caused by genetic aberrations. Therefore, it was 
imperative to utilize our functional phenotyping methods to provide novel insight into how 
dysregulation of lymphatic valves impact collecting vessel performance. To achieve this, 
we utilized a genetically modified mouse model with a modest valve dysfunction. This was 
important as mouse models in which lymphatic valves fail to form, such as the FoxC2 -/- 
mouse, are embryonic lethal (165). In fact, continual FoxC2 expression is necessary 
postnatal maintenance of lymphatic valves, as induced FoxC2 knockout results chylous 
ascites and death  (188). 
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Epsins are a family of highly conserved multivalent endocytic adaptor proteins that 
mediate clathrin-dependent endocytosis of a subset of ubiquitinated cell surface proteins. 
Epsins 1 and 2 are ubiquitously expressed in most tissues where they perform overlapping 
functions (35, 42, 43). In lymphatic endothelial cells, epsins facilitate the internalization 
and downregulation VEGFR3. A lymphatic endothelial cell epsin knockout (LEC-DKO) 
mouse has been developed that results in altered VEGF-C/VEGFR3 signaling and 
subsequent malformation of lymphatic valves (44, 125, 163). Research has shown that 
these mice developed more severe lymphedema after a surgical insult (unpublished), and 
it is believed that this was due to abnormal lymphatic repair, due to the inability of 
VEGFR3 to be recycled, and that there was no underlying defect prior to surgery. However, 
with our highly sensitive phenotyping approaches, we could detect several abnormalities 
in the function of the lymphatic network that was present at baseline even with histological 
appearance of “normal” valves. Specifically, LEC-DKO mice exhibited enhanced reliance 
on the initial lymphatic network for fluid clearance as reflected in the representative images 
and quantification of total fluorescence area. LEC-DKO mice exhibited significant declines 
in lymphatic packet frequency. Upon upstream lymphatic flow occlusion, significant 
differences between the vessel emptying rates of control and LEC-DKO mice were 
observed. In fact, KO mice exhibited a negative emptying rate, suggesting the collecting 
vessels experienced back flow due to incompetent valves once the influence of the 
upstream injection pressure was blocked off with the occlusion cuff. Because the lymphatic 
vessels of LEC-DKO mice did not clear their contents during occlusion, the lymphatics 
exhibited no detectable lymphatic pumping pressure above the resolution limit of the 
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system (2.5 mm Hg), while controls showed normal values of effective pumping pressure 
(16.8 mmHg). 
The results of this study have raised a novel line of questioning regarding the role 
of lymphatic endothelial epsins in the regulation of lymphatic physiology and the 
development of lymphedema. Epsins clearly play a role in lymphatic development and 
subsequently function; however, it is unclear if epsins have direct regulatory effects on 
collecting lymphatic pump function post-developmentally. Additionally, in the context of 
surgically induced lymphedema, it is unclear to what extent lymphatic endothelial epsins 
serve in the repair and remodeling response of the collecting vessels. To this end, the work 
presented in this thesis has motivated the use of an inducible lymphatic endothelial epsin 
knockout model coupled with the disease phenotyping techniques described here that 
enables investigation into the post-developmental role of epsins in regulating lymphatic 
function and remodeling.  
2.4.4.2 Diet-induced obesity impairs collecting lymphatic contractile frequency but not 
other metrics of lymphatic performance 
Obesity has previously been shown to adversely affect lymphatic packet frequency 
in mice, as assessed with NIR imaging (27). However, these studies only assessed one 
potential collecting lymphatic failure mode, contraction frequency, when there is a 
multiplicity of other potential lymphatic failure modes. To this end, we have used our NIR 
imaging suite to assess the failure modes of collecting lymphatics on both the hind limbs 
and tails of obese mice. Our published study demonstrates that even though the frequency 
of lymphatic contractions are reduced (which has previously been shown to be linked to 
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inflammation), the capacity of the lymphatics to generate the pressure needed to move fluid 
against an adverse pressure gradient is normal (191). This suggests that the lymphatic’s 
maximum pumping capacity is not damaged, that the collecting vessels have not adversely 
remodeled, and thus deficits in transport could potentially be improved pharmacologically. 
This is in contrast with the functional data from the LEC-DKO model, which had no 
detectable pumping pressure and very low contraction frequency, indicating a deficiency 
in the either the valve competency and/or contractile strength of the lymphatic muscle cells 
in addition to declines in peacemaking frequency. In fact, this highlights the primary 
benefit of our functional phenotyping techniques. If we had only assessed lymphatic 
contraction frequency as the sole metric of collecting lymphatic function in these two 
disease models, we would not be able to elucidate the stark differences pumping pressure 
that suggest a more profound impairment in lymphatic function.  
These results are interesting because they indicate that obesity alone causes down 
regulation of lymphatic contraction frequency. However, obese mice exhibit no 
development of lymphedema without surgical insult, suggesting that compensatory 
mechanisms are occurring during obesity that results in lymphatic transport sufficient to 
maintain tissue fluid balance. Despite these compensatory mechanisms, obesity is known 
to significantly increase risk for developing lymphedema (91). Therefore, it seems likely 
that declines in lymphatic contraction frequency, because of obesity, induce a “tipping 
point” during lymphatic injury in which lymphatic transport declines further and 
lymphedema pathogenesis occurs. It was my goal for Specific Aim 2 to determine the 
specific lymphatic failure modes involved in lymphedema pathogenesis during chronic 
inflammation due to obesity. This is examined in detail within chapter 3.  
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CHAPTER 3. THE EFFECTS OF DIET-INDUCED OBESITY ON 
COLLECTING LYMPHATIC PUMP FUNCTION AND 
REMODELING DURING LYMPHEDEMA (AIM 2) 
3.1 Introduction  
 One of the strongest associations with the onset of lymphatic dysfunction and 
subsequent lymphedema is obesity. As early as 1957 it was observed that larger individuals 
had greater incidence of developing lymphedema after breast cancer treatment (224). More 
recent clinical studies have made it abundantly clear that pre-surgical BMI strongly 
correlates with post-operative development of lymphedema in breast cancer patients (91, 
133, 241). Conversely, reductions in BMI via dietary alterations and exercise appears to be 
one of the only effective non-compressive or massage based treatments for lymphedema 
(114, 198). The cause of this correlation is currently unknown; however, the preponderance 
of evidence in the clinical literature strongly suggests that adipose accumulation during 
obesity has a direct role in impairing lymphatic tissue drainage, ultimately resulting in 
prolonged lymph stasis and subsequently lymphedema. Studies supporting this hypothesis 
have demonstrated that obese individuals have impaired lymphatic clearance as assessed 
by lymphoscintigraphy and tissue scintillation-counting techniques (8, 84). In fact, it has 
been demonstrated that obesity alone, without surgical insult, can cause lymphedema (84). 
 Although it is clear that obesity and lymphedema are related, the mechanisms that 
regulate this interplay are incompletely understood. Perhaps surprisingly, studies have 
suggested a reciprocal relationship between obesity and lymphedema in which obesity can 
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cause lymphatic dysfunction but lymphatic dysfunction can also cause obesity. 
Histological analysis of mouse tissues have shown that adipose deposits associated with 
lymphedema appear similar in morphology to those observed in obese animals (249). 
Additionally, both obese and lymphedematous tissues are chronically inflamed and are 
infiltrated by macrophages and lymphocytes. These lymphedematous tissues have an 
upregulation in genes associated with adipocyte differentiation and increased expression 
of adipokines (9). These findings suggest that when lymphatic function is surgically 
impaired, the distal tissues become “regionally obese” even in the absence of excessive 
caloric intake. Further evidence linking lymphatic dysfunction to the development of 
obesity comes from transgenic mouse models possessing lymphatic specific mutations. In 
a model of Milroy disease, mice lacking VEGFR3 have abnormal lymphatic vessel 
development and subsequently exhibit chylous ascites abnormal fat deposition (102). 
Similarly, mice with heterozygous mutation of the prospero homeobox protein 1 (PROX 
1), a gene essential for lymphatic endothelial cell differentiation, exhibit adult-onset 
obesity in contrast their non-mutated normal body weight litter mates (90). Taken together 
these findings demonstrate that loss of lymphatic transport may result in adipose excessive 
deposition that is phenotypically similar to diet-induced obesity at a tissue level. 
Additionally, these tissues exhibit the excessive lymphocyte and macrophage infiltrations 
associated with the chronic inflammation observed during diet-induced obesity.   
 Recent work has sought to investigate the cellular mechanisms that link obesity to 
the development of lymphedema. Evidence in the literature strongly suggests that this is 
due to influences of adipose tissue on the inflammatory response and subsequently on 
lymphatic drainage. Obesity has been shown to cause chronic systemic inflammation due 
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to interactions between adipose tissue, lymphocytes, and macrophages (85, 93, 151, 247). 
This is believed to be initiated by a T-cell inflammatory response within the adipose tissue 
that results macrophage chemotaxis. It is currently unclear how naive T-cells become 
activated to initiate macrophage recruitment to adipose tissues; however, recent work has 
provided compelling evidence that CD4+ T-cells may be activated directly by adipocytes 
as opposed to typical antigen presenting cell types. Xiao et. al. found that large, 
hypertrophic, adipocytes express MHCII and can function as an antigen presenting cell to 
activate CD4+ T-cells (246). It is possible that these T-cells may differentiate into the Th1 
subtype and subsequently initiate macrophage homing and activation via release of IFN-γ 
(107).  These newly recruited adipose tissue macrophages are then thought to phagocytize 
necrotic adipocytes, leading to the release of inflammatory cytokines, recruiting other 
leukocytes, and progressing inflammation (4, 95, 107, 151, 244, 247, 249). Studies have 
shown that obese adipose tissues have a greater proportion of classically activated 
macrophages (M1), which are characterized by expression of CD11c in addition to CD11b, 
as opposed to adipose tissues in lean animals that have more alternatively activated 
macrophages (M2). This is important because the M2 subtype is known to secrete a higher 
proportion anti-inflammatory cytokines including IL-10 and IL-1, in contrast to the pro-
inflammatory cytokines secreted by M1 macrophages such as TNF-α and IL-6 (126, 145). 
It is the infiltration of macrophages and T-lymphocytes in obese adipose tissue that are 
believed to modulate lymphatic function and increase susceptibility to later development 
of lymphedema. 
Inflammatory mediators such as cytokines (3), prostanoids (245), histamine (66), 
and nitric oxide (NO) (32, 139, 149, 235) are known to be potent modulators of lymphatic 
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contractile activity and drainage. Given that obesity often results in chronic inflammation 
it is perhaps unsurprising that obesity has been widely shown to adversely influence 
collecting lymphatic function. Obese mice have been shown to have impaired lymphatic 
drainage as assessed by lymphoscintigraphy. Additionally, as discussed in Chapter 2, we 
and others have demonstrated via NIR imaging that this impaired drainage corresponds 
with  decreased lymphatic contractile frequency compared to their lean counterparts (27, 
192, 222). Treatment of obese mice with a selective iNOS inhibitor has been shown to 
improve lymphatic drainage, decrease immune cell infiltration, and decrease expression of 
inflammatory cytokines in the tissue (222). However, inhibition of local T-cell 
differentiation, using topical treatment with a calcineurin inhibitor called tacrolimus, was 
more effective at decreasing tissue inflammation while also producing similar 
improvements in lymphatic drainage and contractile function. Taken together, these results 
suggest that T-cells play a prominent role in mediating the inflammation induced declines 
in lymphatic function observed during obesity. This is, perhaps, expected given that it is 
hypothesized that T-cell activation initiates the inflammatory cascade during obesity. 
Interestingly, weight loss in obese mice via caloric restriction has been shown to decrease 
infiltration of pro-inflammatory immune cells and produces a corresponding increase in 
lymphatic contractile frequency and drainage (152).  
Given that baseline lymphatic function is impaired by chronic inflammation during 
obesity, it seems likely that this plays a role in increasing susceptibility to lymphedema 
development upon surgical insult to the lymphatic vasculature. Thus far, research using 
mouse lymphedema models have supported this hypothesis. Upon induction of 
lymphedema via surgical insult obese mice have a more severe tail lymphedema 
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phenotype, with increased adipose deposition, fibrosis, macrophage and CD4+ T-cell 
infiltration (192). This increase in lymphedema severity corresponds with declines 
transport of tracer via the lymphatics to the lymph nodes. It is important to note that this 
aggravation of lymphedema observed during obesity does not appear to be a result of high 
fat diet, but rather increased adiposity and its associated hyper-inflammatory response (81). 
Although it is clear that obesity impairs overall lymphatic drainage both pre- and post-
surgically, corresponding to increased severity of lymphedema, the degree of contribution 
from dysfunction of the collecting lymphatic vessels is, as of yet, unclear. That is, does 
obesity influence the performance of the collecting lymphatic pump during the 
pathogenesis of lymphedema and to what degree? It is possible that although obesity 
impairs baseline collecting lymphatic function, this is still sufficient to mediate the chronic 
low-grade inflammation and to maintain tissue fluid homeostasis. Whereas Upon surgical 
insult that impairs lymph transport, inflammation can no longer be mediated by lymphatic 
drainage, thus increasing the number of leukocytes in the tissue and further impairing 
lymphatic transport. This could ultimately result in a feedback loop in which fibrosis and 
adipose deposition in the tissue elicits dysregulation of collecting lymphatic function and 
remodeling response.  
It is therefore the goal of this study to investigate the influence of obesity on 
collecting lymphatic pump function and remodeling during lymphedema.  We hypothesize 
that diet-induced obesity adversely influences the lymphatic pump function and 
remodeling phenotype during the progression and resolution of lymphedema. We 
investigated this hypothesis by using the methods developed in Chapter 2, along with a 
recently developed single-vessel ligation model of mouse tail lymphedema (236), to assess 
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the functional changes of an intact collecting lymphatic vessel on the tail in  response to 
ligation of the contralateral vessel in a mouse model of diet-induced obesity. At the end of 
the study, we surgically isolated the intact lymphatic vessels to determine if there are any 
differential alterations to the structure of the vessel because of obesity. To investigate the 
role of T-cells in mediating the functional dysregulation of the collecting lymphatic vessels 
observed during obesity, we pharmacologically inhibited T-cell differentiation by applying 
topical tacrolimus ointment to the lymphedematous tails of a subset of obese mice. 
3.2 Materials and Methods 
3.2.1 Study overview 
In order to determine the effects of obesity on collecting lymphatic function and 
remodelling, we utilized a common C57BL6J model of diet induced obesity (152, 192, 
222, 239). Mice were allowed to gain weight for a 20-week period before beginning the 
study. On Day 0, obese or chow-fed control animals underwent baseline NIR lymphatic 
functional imaging to characterize their baseline collecting lymphatic function. The 
“dominant” lymphatic vessel on the tail was identified as the vessel in which NIR tracer 
appears first after injection (234). Following baseline imaging, the dominant lymphatic 
vessel was ablated along with the dermal lymphatics. The function of the remaining intact 
lymphatic vessel on the tail was periodically characterized via NIR imaging at 7, 14, 28, 
42, 56, and 70 days post-surgery. In order to elucidate the effects of T-cell differentiation 
and activation on any functional differences observed between the obese and chow fed 
control groups, an additional subset of obese mice were treated twice daily with tacrolimus 
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ointment beginning at the 14 day time point. After the 70-day study period, mice were 
euthanized for tissue collection and isolation of the intact lymphatic vessel.  
 
Figure 14: Graphical representation of the study design. 
 
3.2.2 Animal models 
 All animal procedures were approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee (IACUC). 8-Week-old male C57BL6J mice 
were placed on a high fat diet (n=11) (60% kcal fat, TestDiet 58Y1, W.F. Fisher & Son, 
Sommerville, NJ) or chow diet (n=8) (13% kcal fat, Purina PicoLab Rodent Diet 20, W.F. 
Fisher & Son, Sommerville, NJ) for 20 weeks. Mouse bodyweight was measured using a 
digital scale. Mice were housed one per cage in a temperature and humidity controlled (21 
± 1C) vivarium on a 12-hr light, 12-hr dark cycle. Food and water were available ad 
libitum. 
3.2.3 NIR lymphatic Tracer 
 The NIR lymphatic tracer used for the imaging procedures consisted of a NIR 
fluorophore IRDye 800 CW NHS Ester (929-70020, LI-COR Biotechnology, Lincoln, NE) 
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bound to 20kDa methoxypolyethylene glycol (mPEG) (JenKem Technology USA, Plano, 
TX) in a manner similar to a previously described method (28, 169). During all following 
steps, aluminum foil was used to shield the fluorophore to ambient light exposure. 
Equimolar ratios of IRDye 800CW NHS Ester (75 nmol) and mPEG (75 nmol) were bound 
room temperature in 0.5mL anhydrous dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. 
Louis, MO) for 24hrs. After binding, the mixture was transferred into a dialysis cassette 
with a 7 kDa molecular weight cutoff (66370, Thermo Fisher Scientific, Waltham, MA). 
The cassette was submerged in a 4L beaker of de-ionized water and was dialyzed for 24hrs. 
The dialyzed solution was removed from the cassette, separated into 100 uL aliquots in 0.6 
mL microcentrifuge tubes and lyophilized for 24hrs. The lyophilized tracer was stored prior 
to use in -20 C freezer. Before use, the aliquots were re-constituted in 35µL sterile saline 
0.9% NaCl (Baxter Healthcare Corp., Deerfield, IL) 
3.2.4 NIR imaging system and imaging procedure 
Images were taken with a customized imaging system consisting of a Sutter 
Instruments Lambda LS Xenon arc lamp (Sutter Instruments, Novato, CA), an Olympus 
MVX-ZB10 microscope (Olympus, Tokyo, Japan), a 769 nm bandpass excitation filter (49 
nm full-width half maximum, FWHM), an 832 nm bandpass emission filter (45 nm 
FWHM), and an 801.5 nm longpass dichroic mirror (Brightline Filters, Semrock, Lake 
Forrest, IL). Images were acquired with a Photometrics Evolve Delta 512 EM-CCD 
(Photometrics, Tucson, AZ) using Micromanager software (Vale Lab, University of 
California San Francisco).  
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NIR lymphatic imaging was performed in accordance with previously published 
methods and those described in Chapter 2 (149, 234, 235).  Briefly, mice were anesthetized 
with 5% isoflurane and maintained on a steady plane of anesthesia at 1.8-2.2% isoflurane 
(SomnoSuite, Kent Scientific, Torrington, CT). Mice were placed on a small animal 
heating pad to maintain body temperature of 37 °C (K&H Pet Products, Colorado Springs, 
CO). To assess tail size, bright field images of the tails were taken next to a ruler before 
the NIR tracer was injected. The animals were placed in a prone position, the tails were 
sanitized with a 70% isopropyl alcohol swab and 10 μL IRPEG 20 was injected 
intradermally into the tip of the tail using a 0.3 mL insulin syringe with 5/16” long 32 G 
ultra-fine needle (BD, Franklin Lakes, NJ).  Care was taken to position the injection as 
close to the midline of the tail as possible to avoid favoring one collecting vessel over the 
other.   
The imaging system’s field of view was centered on the mouse’s tail 7 cm 
downstream (towards the base of the tail) from the injection site at the tip of tail.  The 
animals were imaged continuously from the time of injection at until roughly 8-minutes 
post-injection at 1.25x zoom with a 50 ms exposure time and a frame rate of 10 fps. After 
this period, animals were positioned on their right sides to image the left lymphatic vessel 
and images were captured for 5-minutes. Animals were subsequently positioned on their 
left sides to image the right lymphatic vessel and images were captured for 5-minutes. 
Analysis of NIR functional metrics was performed on the image segments from the 5-
minute periods on the respective sides. After this imaging session a pressure cuff was fitted 
to the tail, and mice underwent the lymphatic pumping pressure measurement technique 
that has been previously described (149). During the pumping pressure measurement 
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images were captured at 1 fps with a 50 ms exposure time with the field of view centered 
at the proximal edge of the pressure cuff (OCC-XS, Kent Scientific, Torrington, CT). The 
cuff was inflated and held at 80 mmHg for 5-minutes. After the 5-minute hold the cuff was 
deflated to 55 mmHg and subsequently lowered by 2.5 mmHg every 30 seconds.  
3.2.5 Quantification of NIR functional metrics 
In order to quantify the efficacy of lymphatic uptake and subsequent transport by 
the collecting lymphatic vessels, we assessed the fluorescence arrival time of tracer from 
the upstream injection to the downstream site of imaging. Arrival time was assessed by 
computing the time difference between tracer injection and the arrival of fluorophore in the 
intact lymphatic vessel at the wound site during the roughly 8-minute (5000 frame at 10 
fps) imaging session immediately post injection. In order to assess collecting lymphatic 
pump function three distinct metrics were evaluated in accordance with our previously our 
previously developed methods discussed in Chapter 2 (149, 235, 236). Packet frequency 
was evaluated by tracking the average time between peak fluorescence pulsations within 
regions of interest (ROIs) traced over lymphatic vessels during our initial imaging sets. 
Packet frequency has been correlated with the frequency of intrinsic lymphatic contractions 
in vivo. Florescence transport was not discussed in Chapter 2, but has been recently 
developed and described within our research group (236). This metric was calculated by 
summing the integral of the packet signal with respect to time and dividing by the total 
amount of time over which it was assessed. It is the absolute amount of fluorescence 
transported by intrinsic contraction through a region of interest over time and can be 
roughly correlated to fractional pump flow. Fluorescence transport is a function of 
lymphatic contraction frequency, contraction amplitude, and packet velocity. 3) Effective 
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lymphatic pumping pressure was calculated by determining the occlusion pressure at which 
the fluorescence within the vessel proximal to the cuff returns to half of its pre-occlusion 
value. It is a measure of the collecting lymphatic vessel chain’s ability to generate the 
pressures needed to overcome an occlusive force.  
Significant differences between control and obese was tested via student’s t-test for 
each time point with p < 0.05 denoting significance. In order to compare later time points 
to their respective pre-surgical baseline (Day 0) we used 1-way ANOVA with post-hoc 
Dunnett’s correction for multiple comparisons with p < 0.05 indicating statistical 
significance. In scenarios where the tacrolimus treated group was compared to both the 
obese and control groups, 2-way ANOVA with post-hoc Tukey correction for multiple 
comparisons was used with p < 0.05 indicating statistical significance. All statistical 
analysis was done using Prism 6 software (Graphpad Software, La Jolla, CA).  
3.2.6 Lymphedema induction via single vessel ligation surgery 
Immediately after the baseline NIR imaging session mice from the experimental 
groups underwent a lymphatic vessel ligation surgery to the tail. Mice were kept 
anesthetized with 1.8-2.2% isoflurane (SomnoSuite, Kent Scientific). Mice were kept on 
the heating pad during the surgery. The location of the dominant lymphatic vessel was 
confirmed via NIR imaging. The tails of the mice were sterilized with alternating scrubs of 
an iodophor and 70% isopropyl alcohol. Lymphatic vessel ablation was located 1.5 cm 
from the base of the tail using a fine tipped tissue cauterizer (Small Vessel Cauterizer, Fine 
Science Tools, Forest City, CA) to create a 1-2 mm deep wound 70-80% of the 
circumference of the tail. NIR imaging was used throughout the procedure to confirm the 
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location of the intact lymphatic vessel so that it is not accidentally ablated. After surgery, 
mice were given a 1 mg/kg subcutaneous injection of  sustained release buprenorphine as 
an analgesic. Anti-bacterial ointment (Neosporin, Johnson & Johnson, New Brunswick, 
NJ) was applied to the wound site immediately after the surgery. Animals were monitored 
for signs of necrosis in the tissues distal to the wound site, indicating accidental ligation of 
blood supply/return. If necrosis or abnormal darkening of the tails occurred, the animals 
were removed from the study and euthanized.  
3.2.7 Topical tacrolimus treatment 
0.1% (wt/wt) tacrolimus ointment was made using tacrolimus powder and a base. 
10 mg of tacrolimus powder (FK-506, Fisher Scientific, Pittsburgh, PA) was levigated in 
1 mL of anhydrous glycerine (Sigma Aldrich, St. Louis, MO) with a glass stir rod. Roughly 
100 g of Aquaphor (Beiersdorf Inc., Wilton, CT) was melted at 40°C until liquified. The 
tacrolimus and glycerine mixture was geometrically diluted in this liquified Aquaphor base 
to a final weight of 100 g, stirring thoroughly in between dilutions to ensure even 
distribution of tacrolimus in the suspension. The ointment was then sealed in an air tight 
plastic jar and stored at room temperature in a dark place until use. Topical tacrolimus 
treatment of a subset of obese mice (n=5) began 14 days after the induction of lymphedema 
via the ligation surgery, immediately after the 14-day NIR imaging time point. Roughly 
100 mg of tacrolimus ointment was applied in an even coat to the entirety of the tails twice 
daily until the end of the 70-day study.  
3.2.8 Vessel isolation and tissue collection 
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Lymphatic vessels were isolated and tested from mice in a manner similar to our 
previously described methods in rats (109, 110). Within 1-5 days after the final NIR 
imaging session at the 10-week time point mice were euthanize via asphyxiation with CO2. 
After euthanasia, the skin was removed from the tails to expose the collecting lymphatic 
vessels. Sterile saline was periodically perfused onto the tissue to ensure that it did not dry. 
The intact lymphatic vessel distal to the wound site on the tail was located and an 
approximately 3 mm segment was isolated from the surrounding adipose and fascia. The 
segment was removed and immediately placed in a bath containing DMEM/F12 (GE 
Healthcare Life Sciences, Logan, UT) with added antibiotic mixture (Invitrogen Corp., 
Carlsbad, CA) to achieve a concentration of 100 units of Penicillin and 100 μg of 
streptomycin per ml of DMEM/F12. The segment was subsequently cannulated onto micro 
pipettes in a single vessel cannulation chamber (Living Systems Instrumentation, St. 
Albans, VT).  
 Cannulated vessel segments from control (n=2) and obese (n=2) groups underwent 
2nd harmonic generation imaging of collagen in a manner previously described (37). Vessel 
segments were pressurized at a transmural pressure of 2 cmH2O were placed under a LSM 
710 META inverted confocal microscope (Zeiss) to visualize the microstructure across the 
entire wall of unfixed lymphatic vessels. The vessels were imaged using a 40×/1.3NA 
immersion objective (Zeiss). The META module was set to a bandpass filter of 380–420 
nm and excited at 800 nm in order to detect backward-scattering second harmonic 
generation signal from collagen. Collagen waviness was assessed using a method adapted 
from Rezakhaniha et. al. that measured the absolute length of collagen fibers compared to 
their end-to-end length (179). Briefly, 3D image stacks from the 2nd harmonic imaging 
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were opened in ImageJ software (195). A 2D image was obtained from each vessel for 
analysis from 10 µm within the vessel wall. The ImageJ curve tool was used to trace four 
lines over collagen fibers for each vessel image. After tracing, the lines were measured 
using the ImageJ measurement tool to find the absolute length, L, and the end-to-end 
length, Lo (Figure 20). Collagen waviness was computed by dividing L by Lo for each 
tracing. 
3.3 Results 
3.3.1 Obese animals do not differentially swell following induction of lymphedema 
Mice placed on high fat diet for a 20-week period exhibit significant weight gain 
compared to chow fed controls (p < 0.0001). On Day 0 of the study the average body weight 
of high fat fed mice 57 ± 4 g (n=6) compared to 31 ± 1 g (n=8) for chow fed controls 
(Figure 15). Upon induction of lymphedema via the single vessel ligation model both obese 
and control mice exhibit swelling of the tails distal to the wound site, which was assessed 
by measuring the tail diameter. The swelling peaks at the 7 and 14-day time points, but 
progressively declines to the 70-day value of roughly 6% for both control and obese (Figure 




Figure 15: (A) High fat diet induces significant weight gain in male C57BL6J mice (p 
< 0.0001). (B) Following lymphedema induction via ablation of a collecting lymphatic 
vessel and the dermal lymphatics the distal tissues exhibit progressive swelling that 
subsequently subsides. The tails of control and obese mice were not found to 
differentially swell. Error bars represent SEM. (*, denotes significant difference 
between control and obese, p < 0.05) 
 
3.3.2 Obesity delays fluorophore transit via the intact collecting lymphatic vasculature 
The lymphatic anatomy of the mouse tail is characterized by two lateral collecting 
lymphatic vessels that drain the distal tissue space. Upon disruption of one vessel via 
surgical ablation, the remaining intact lymphatic vessel serves as the primary outflow 
pathway to bypass fluid around the wound site. Using NIR imaging we observed that obese 
animals had delayed fluorophore transport by the intact collecting lymphatic vessel after 
initial tracer injection at pre-surgical baseline and at the 7-day time point. However, by 70 
days post-surgery the intact lymphatic vessel exhibited fluorophore uptake and transit past 




Figure 16: Representative NIR images taken at the wound site 5-minutes after tracer 
injection at the distal tip of the tail. Pre-surgery images depict the two collecting 
lymphatic vessels located on the lateral aspects of the tail. 1 week after ligation chow 
fed control animals exhibit uptake of fluorophore in the intact lymphatic vessel that 
subsequently transits the wound site. This was delayed in obese animals. However, 
this difference is attenuated by the 10-week time point.  
 
 
Figure 17: Obesity causes delayed fluorophore uptake and transport through the 
intact collecting lymphatic vessel to the wound site as assessed by arrival time.  
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Significant differences in arrival time between control and obese animals we observed 
pre-surgery in addition to 7 and 56 days post-surgery. Induction of lymphedema via 
single vessel ligation surgery resulted in significant delays in arrival time compared 
to pre-surgical baseline for both the control and obese groups. Error bars represent 
SEM. (n=8, control) (n=6, obese) (*, denotes significant difference between control 
and obese; †, denotes significant difference between control value and the baseline 
pre-surgical control value; ‡, denotes significant difference between obese value and 
the baseline pre-surgical obese value, p < 0.05). 
 
3.3.3 Surgically ablated collecting lymphatic vessels do not regain intrinsic pump 
function  
At pre-surgical baseline, both primary collecting lymphatic vessels located on the 
tail exhibited intrinsic contractility; however, following surgery, the ablated vessel was 
found to lose its intrinsic contractile function. 8-minutes after injection of NIR tracer, 
animals were placed on either their right or left sides to image either the intact or wounded 
vessel for 5-minute periods respectively. Upon imaging the wounded vessel we discovered 
that drainage of NIR tracer was obstructed at the wound site (Figure 18). Specifically, 7 
days post-surgery, we observed significant accumulation of tracer distal to the wound. This 
tracer appears to be accumulating in the interstitial space as opposed to the collecting or 
initial lymphatic vessels. In fact, the collecting lymphatic vessels are wholly obscured by 
the fluorescence emitted from this extravasal tracer. At later time points, after tissue 
swelling has subsided, the wounded collecting lymphatic vessels are observable but remain 
obstructed at the wound site. Near this obstruction, we observed rerouting of tracer by the 
initial lymphatic network. These initial lymphatics connect collaterally with the intact 
lymphatic vessels, which serves as the primary lymphatic drainage pathway. Interestingly, 
upon follow-up assessment of lymphatic pump function post-surgery, we were not able to 
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detect any dynamic fluorescent packets in the wounded lymphatic vessel in either control 
or obese mice (Figure 18). These results suggest that the damage caused to the vessel from 
the surgical ablation inhibits the intrinsic contractile response and that the initial lymphatic 
network serves as a collateral drainage pathway to facilitate lymph removal from the tissue.  
 
Figure 18: Representative NIR images of the ligated lymphatic vessels following the 
single-vessel ligation surgery. After surgery, the ablated collecting lymphatic vessels 
no longer exhibit intrinsic contractile behavior. (A) Pre-surgical NIR images depict 
tracer uptake by the collecting lymphatic vessels running laterally along the mouse 
tail. One week after ligation of these vessels, swelling of the tissues distal to the wound 
site was observed in conjunction with non-specific build-up of tracer that obscures 
the collecting lymphatic vessels. Ten weeks post-surgery, after swelling has subsided, 
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the wounded collecting lymphatic vessels were observable; however, they remained 
obstructed by the wound. Tracer was observed extravasating from the collecting 
lymphatic vessels into the “honeycomb” network of initial lymphatic vessels. (B) 
Representative intensity tracking from the control imaging segments depicts the 
presence of discrete fluorescent packets pre-surgically with a subsequent absence at 
later time points.  
 
3.3.4 Obesity adversely influences lymphatic pump function following lymphedema 
induction and resolution 
We utilized our previously described NIR imaging techniques to non-invasively 
assess the functional response of the intact lymphatic vessel during lymphedema 
progression and resolution (149, 235). Functional measurements indicate that obesity 
adversely impacts the functional response of the intact lymphatic vessel following surgery. 
Packet frequency, indicative of contractile frequency, was found to be significantly 
decreased at multiple time points in obese animals compared to control. Pre-surgical values 
for packet frequency were significantly different between control and obese at 6.7 ± 0.7 
min-1 vs 3.9 ± 0.3 min-1. Following surgery, the average packet frequency of the intact 
lymphatic vessel acutely declines at day 7 by roughly 80% of the pre-surgical value for 
both control and obese animals. Interestingly, control animals have greater decreases in 
packet frequency over time compared to their pre-surgical baseline values and continued 
to exhibit these declines 70 days after surgery. However, obese animals have significantly 
lower absolute packet frequency compared to controls at days 0, 28, and 56 (Figure 19). 
Similar trends are observed in packet transport, a metric indicative of transport driven by 
intrinsic contractility.  Control animals had greater impairment of lymphatic packet 
transport caused by the surgery when compared to pre-surgical baseline values that 
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subsequently persisted throughout the course of the study. However, obese animals 
exhibited significantly lower absolute values for packet transport compared to controls at 
the 28 and 56-day time points (Figure 19). Lymphatic pumping pressure, a metric 
indicative of contractile force (149, 177),  was found to present striking differences. 
Despite pre-surgical pumping pressure values being relatively similar between control and 
obese, obese animals displayed profound decreases following the surgery. Specifically, at 
the 28-day time point, obese animals exhibited no detectable pumping pressure compared 
to control with values of 0.0 ± 0.0 mmHg vs 23.4 ± 5.2 mmHg respectively. A similar 
difference was observed at the 42-day time point. Interestingly, at the end of the study, 70 
days after the initial surgery, obese animals still exhibited significant latent defects in 
lymphatic pumping compared to controls that were not otherwise evident pre-surgery 
(Figure 19). Taken together these results indicate that obesity adversely alters the function 
of the intact lymphatic vessel following surgery. Interestingly, obesity does not seem to 
increase risk for functional impairment of the collecting vessel when compared to pre-
surgical baseline values. However, when looking at the absolute differences between the 
control and obese groups, it becomes apparent that obesity results in lowered contractile 
frequency, actively driven transport, and pumping pressure of the collecting lymphatics at 
multiple time points. The most profound differences were observed in the persistently 
lowered lymphatic pumping pressure, suggesting impairments to the force generating 




Figure 19: Functional measurements, obtained via NIR imaging, indicate that obesity 
adversely impacts the functional response of the intact lymphatic vessel following 
surgery. (A) Packet frequency, the frequency of fluorescent pulsations within the 
vessel, exhibited significant differences between control and obese groups. (B) Packet 
transport, the integral of the packet frequency signal over time, was used to evaluate 
fluorescence transport driven by intrinsic lymphatic contractions. (C) Effective 
pumping pressure was used to evaluate the maximal pressure generated by the 
collecting vessel to overcome occlusion. Error bars represent SEM. (n=8, control) 
(n=6, obese) (*, denotes significant difference between control and obese; †, denotes 
significant difference between control value and the baseline pre-surgical control 
value; ‡, denotes significant difference between obese value and the baseline pre-
surgical obese value, p < 0.05). 
 
3.3.5 Obese animals have increased waviness of the collagen microstructure in the intact 
collecting lymphatic vessels following lymphedema 
 To determine if the latent differences in collecting lymphatic function corresponded 
with differences in structure, we surgically isolated the intact collecting lymphatic vessels 
distal to the wound site in control and obese mice. First, to observe the collagen 
microstructure of the vessel wall, we utilized 2nd harmonic microscopy coupled with 
confocal Z-stack. Quantititative analysis of these images indicate that vessels collected 
from the obese animals have a modest difference in the morphology of collagen. 
Specifically, the collagen microstructure of isolated collecting vessels from obese mice 
was found to exhibit significantly increased waviness of collagen fibers (Figure 20). This 
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increased waviness suggests that the lymphatic vessels could withstand increased 
transmural pressurization before straightening and subsequently mechanically engaging 
the collagen .  
 
Figure 20: (A) Representative 3D 2nd harmonic generation images of collecting 
lymphatic collagen microstructure from control and obese mice. (B) Collagen fibers 
were found to be significantly wavier in obese mice compared to control. (C) 
Representative image depicting the calculation of the collagen waviness ratio 
computed from the total length of the collagen fiber and the end-to-end length. (*, 




 Given that we observed profound declines in the lymphatic pumping pressure of 
obese mice via NIR imaging methods, we investigated how smooth muscle cell coverage 
may be altered. Collecting lymphatic vessels were briefly fixed and immunofluorescently 
stained for alpha smooth muscle actin (α-SMA) and prospero homeobox protein-1 (Prox-
1). Fluorescent images with confocal Z-stack depict no striking differences between 
smooth muscle coverage or lymphatic endothelial cells.  
 
Figure 21: Representative immunofluorescent images of collecting lymphatic vessels 
labeled for α-SMA (red) and Prox-1 (blue). Confocal images of isolated collecting 
lymphatic vessels were used to produce 3D Z-stack renderings of the α-SMA/Prox-1 
structure. 
 
3.3.6 Inhibition of T-cell differentiation with tacrolimus protects against the functional 
declines caused by obesity during lymphedema 
To determine the extent that T-cells are mediating the differences in lymphatic 
function caused by obesity during lymphedema, we pharmacologically prevented local T-
cell activation and differentiation by treatment with a calcineurin inhibitor called 
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tacrolimus. A subset of obese animals (n=5) were treated via topical application of 
tacrolimus ointment twice daily beginning immediately after the 14-day functional imaging 
session. Results from these experiments show that tacrolimus does not appear to 
differentially impact tail swelling following treatment; however, this could be because the 
obese + tacro treated experimental group swelled, on average, more than the obese group, 
despite undergoing identical experimental protocols before day 14 (Figure 22). Upon 
functional assessment with NIR imaging, tacrolimus treatment was not found to 
statistically improve the fluorescence arrival time compared to untreated obese animals. 
Despite this, a trend towards decreased arrival time in the treated group was observed at 
day-42 (Figure 23).  
 
Figure 22: Topical tacrolimus ointment was used to treat a subset of obese mice (n=5) 
beginning at day 14 post-surgery. (A) Treatment with tacrolimus ointment did not 
differentially impact absolute tail swelling; however, this is likely caused by the 
tacrolimus treated group exhibiting significantly greater swelling prior to the start of 
treatment. (B) Treatment with tacrolimus ointment resulted in a significant reduction 
in tail swelling when compared to start of treatment values at day 14. Red arrows 
indicate the beginning of tacrolimus treatment at the 14-day time point. Error bars 
represent SEM. (n=8, control) (n=6, obese) (n=5, obese + tacro) (¢, denotes significant 
difference between obese + tacro and control; ¥, denotes significant difference 




Figure 23: Treatment with tacrolimus ointment did not differentially impact the 
fluorescence arrival time to the wound site following injection of fluorophore. Red 
arrows indicate the beginning of tacrolimus treatment at the 14-day time point. Error 
bars represent SEM. (n=8, control) (n=6, obese) (n=5, obese + tacro) (¢, denotes 
significant difference between obese + tacro and control; ¥, denotes significant 
difference between obese + tacro and obese, p < 0.05). 
 
 Our NIR functional imaging techniques were used to assess the response of the 
intact collecting lymphatic vessel to tacrolimus treatment. Tacrolimus was found to 
positively impact the packet frequency of the intact lymphatic vessel in a differential 
manner from the untreated group. Specifically, tacrolimus treatment appeared to aid the 
recovery of packet frequency, significantly increasing to 4.3 ± 1.1 min-1 vs 0.0 ± 0.0 min-1 
in the untreated obese animals. In fact, the tacrolimus treated animals achieved day 70 
values of packet frequency comparable to chow fed controls, despite having significantly 
lower baseline values than controls (Figure 24). Similar trends were observed with regards 
to packet transport; however, these trends were not statistically different. One of the more 
striking alterations caused by tacrolimus treatment was the recovery observed in lymphatic 
pumping pressure. Specifically, the tacrolimus treatment improved lymphatic pumping 























untreated obese animals had no detectable effective pumping pressure at days 28 and 42, 
tacrolimus appears to facilitate a striking improvement in the pressure generating 
capabilities of the lymphatics (Figure 24). Taken together, these results suggest that 
pharmacological treatment with tacrolimus is able to attenuate the declines in the active 
contractile response of the intact lymphatic vessel associated with obesity during 
lymphedema.   
 
Figure 24: Tacrolimus ointment protects against the declines in collecting lymphatic 
function caused by obesity after induction of lymphedema as assessed by NIR 
imaging. (A) Tacrolimus treatment for a subset of obese mice increased lymphatic 
packet frequency to levels similar to control with significant differences between the 
obese group manifesting at 56-days post-surgery. (B) Tacrolimus treatment was not 
found to significantly improve lymphatic packet transport. (C) Tacrolimus treatment 
protected against the declines in pumping pressure caused by obesity with significant 
differences from the untreated group being observed at days 28 and 42. Red arrows 
indicate the beginning of tacrolimus treatment at the 14-day time point. Error bars 
represent SEM. (n=8, control) (n=6, obese) (n=5, obese + tacro) (¢, denotes significant 
difference between obese + tacro and control; ¥, denotes significant difference 
between obese + tacro and obese; Ø, denotes significant difference between obese + 
tacro and baseline day 0 value, p < 0.05) 
 
3.4 Discussion and Conclusions 
Obesity has long been demonstrated to be a primary clinical risk factor in the 
development of lymphedema. Motivated by this, a number of studies have demonstrated 
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robust characterizations of the pathophysiology and the biological mechanisms that drive 
the pathogenesis of the disease during obesity. However, despite their essential role in the 
active transport of lymph, the effects of obesity on the collecting lymphatic vessels have 
not been fully characterized during lymphedema. Specifically, no study has assessed 
collecting lymphatic pump performance over the course of lymphedema induction and 
resolution.  It was therefore the goal of this work to determine if and how obesity alters 
collecting lymphatic function during lymphedema development and resolution. By using 
functional NIR lymphatic imaging approaches we have demonstrated that obesity 
adversely impacts lymphatic contractile activity and that this continues even after 
lymphedema is resolved. Further, we have demonstrated that pharmacological calcineurin 
inhibition, via tacrolimus, can protect against these functional declines. 
A lack of clinically relevant animal research models for lymphedema has historically 
limited the study of the collecting lymphatic vessels in the disease. The most commonly 
described model is the rodent tail, which traditionally involves ablation of all the initial and 
collecting lymphatic vessels on the tail to induce lymphedema (49, 147, 186, 201). 
However, since all the collecting lymphatics have been ligated, this limits the use of 
imaging techniques with the ability to quantify collecting lymphatic functional response. 
Recently, our lab has produced the rodent tail model shown here that leaves a collecting 
vessel intact while still inducing the swelling a tissue remodeling associated with 
lymphedema (236). By coupling this model with our novel NIR functional lymphatic 
imaging approaches discussed in Chapter 2 (149, 235), we are able to longitudinally assess 
how increased fluid load due to the loss of lymphatic drainage pathways influences the 
intact collecting lymphatic vessel. This is particularly relevant in the context of obesity 
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where we and others hypothesize that collecting vessel dysfunction plays a role in 
lymphedema development. 
We and others have previously shown that obesity has direct negative effects on the 
intrinsic contractile activity of the lymphatics (27, 152, 153, 192, 222). The results of this 
study have further confirmed that obese animals have decreased pre-surgical baseline 
packet frequency corresponding to decreased contractile frequency. It has become apparent 
that this impairment is tied to increased CD4+ T-cell mediated inflammation during 
obesity, which increases release of known contractile mediators such as nitric oxide (27, 
152, 153, 192, 222). Interestingly, no other metrics of lymphatic pump function are 
significantly impaired by obesity pre-surgically. This suggests that obesity alone may not 
cause adverse remodeling that reduces the pressure generating capacity of the lymphangion 
chain. This hypothesis is supported by studies that demonstrate increases in contractile 
frequency upon inhibiting inflammation within a 2-week period (222); however, this 
warrants further investigation.  It was less clear, until this point, how the contractile 
response was altered following the induction of lymphedema.  
Surgical disruption of the lymphatic vasculature via our single-vessel ligation 
induced a swelling cascade similar other rodent tail models of lymphedema and obesity 
that involve all the collecting and dermal lymphatic vessels (192). However, given that 
there remains an intact lymphatic vessel draining the tail, it is unsurprising we observed 
substantially less peak swelling of the tail in comparison to traditional tail lymphedema 
models (roughly 30%). This implies that the collecting lymphatic vessels play a role in 
mediating the tissue swelling associated with lymphedema (236). Interestingly, despite 
using a unique experimental model, our results correspond to previous studies in mice 
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showing that obesity does not increase absolute amounts of tissue swelling following 
lymphedema induction in mice (192).  
Although a collecting lymphatic vessel remained structurally intact throughout the 
study, the ligation of its counterpart along with the dermal lymphatics induced significant 
declines in function for both control and obese mice within the 14 days following surgery. 
It is during this period that tissue inflammation and swelling is heightened in response to 
tissue damage (147, 192, 249, 250). During this time frame, obese animals exhibited 
delayed fluorophore transit through the intact collecting lymphatic vessel in comparison to 
lean controls. This is supported by work demonstrating that obesity delays nodal uptake of 
tracer as assessed by lymphoscintigraphy (192). Despite having an apparent functional 
deficit, packet frequency, packet transport, and pumping pressure were not significantly 
different compared to lean controls. Taken together, this suggests that obesity may 
adversely impact the rate of fluorophore uptake into the collecting lymphatics during this 
time period as opposed to having direct differential effects on the collecting lymphatic 
vessels themselves. This could be caused by the decreased interstitial fluid flow observed 
during obesity that decreases convection of fluorophore to the draining initial lymphatics 
and subsequently intact collecting lymphatic vessels (239).  
28 days post-surgery, after swelling has substantially declined, obese animals begin 
to manifest a differential functional phenotype compared to controls. Specifically, obese 
animals exhibit decreased packet frequency, packet transport, and pumping pressure. 
Given that obesity is known to negatively influence lymphatic contraction frequency (27, 
152, 153, 192, 222), it is relatively unsurprising that this trend continues throughout the 
resolution of lymphedema. However, pumping pressure was not shown to be affected by 
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obesity at pre-surgical, and declines compared to control only appear manifest after 
lymphedema is induced. Further, this difference in pumping pressure persists even at the 
70-day time point when nearly all swelling has subsided. In a recent publication, discussed 
in Chapter 2, we demonstrated that lymphatic pumping pressure is primarily governed by 
the number of lymphangions in the vessel chain, their contractile force, and the frequency 
of lymphatic contractions (177). Given that we observed a simultaneous decline in packet 
frequency, it seems reasonable to infer that this decline may be caused in part by a decrease 
in the intrinsic contractile frequency of the collecting vessel. It is also possible that the 
etiology is multi-factorial and that obesity alters the contractile strength of lymphatic 
muscle cells at later time points following induction of lymphedema. In fact, this is 
supported by studies demonstrating that rats with metabolic syndrome possess collecting 
lymphatic vessels that generate significantly less contractile force (252).  
Because obese animals possess latent functional declines that may be linked to 
alterations in intrinsic contractile forces, we investigated if remodeling of collagen 
microstructure or LMC coverage could explain the significant loss in lymphatic pressure 
generation (137, 214, 252). We found that the collagen microstructure of the intact 
lymphatic vessels in obese animals exhibited an increase in the waviness of the fiber 
bundles. This increase in waviness likely influences the passive mechanical behavior of the 
vessel. For example, other properties being equal, wavy collagen fibers will result in 
decreased collagen engagement upon pressurization of the vessel and a subsequent increase 
in the compliance of the vessel (37, 179). However, this is only true for tensile loading of 
the collagen fibers. Given that contractions of LMCs produce compressive forces on the 
fibers, it is unclear how the increase in waviness would ultimately influence pressure 
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generation. Further, qualitative assessments of smooth muscle coverage did not appear to 
provide any insight into the differences in pumping pressure between obese and control. 
To better assess the etiology of the pumping pressure differences, it would be beneficial 
for further studies to use a combination of isolated vessel functional testing in addition to 
a thorough investigation of the mechanical properties of the vessels. 
The latent collecting lymphatic dysfunction that we observed here could have 
clinical relevance. In the case of surgically-related lymphedema, the patients that later 
develop the disease still possess patent collecting lymphatic vessels (47) and often do not 
present with symptoms of lymphedema until 1 or more years after surgery (7). It is possible 
that latent collecting lymphatic dysfunction increases susceptibility of patients to 
developing lymphedema following a secondary insult that challenges the lymphatic 
system’s ability to properly drain fluid. This has been supported by research that has 
demonstrated that outward recovery from lymph node dissection in the rat foreleg masks 
an ensuing chronic and latent lymphatic insufficiency, which reduces the ability of the 
foreleg lymphatic system to prevent edema during an acute inflammatory process (135). 
However, further studies are necessary to determine what role the collecting lymphatic 
vessels play in the later susceptibility to lymphedema development. 
Although studies have demonstrated that CD4+ T-cells are an essential mediator of 
the tissue changes associated with lymphedema development during obesity, it is less clear 
how these cell types may directly or indirectly influence collecting lymphatic function 
during the disease (192). Recent studies have demonstrated that pharmacological 
prevention of T-cell activation and differentiation via a calcineurin inhibitor called 
tacrolimus shows promise for decreasing the chronic tissue inflammation associated with 
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obesity and improve collecting lymphatic contraction frequency (222). Further 
investigation has demonstrated that tacrolimus produces promising results for treating and 
preventing lymphedema (70). We subsequently utilized these methods to investigate the 
role of T-cells in mediating the functional dysregulation of the collecting lymphatic vessels 
observed during obesity. Tacrolimus ointment was applied to the tails of obese mice 
beginning 14 days after surgical induction of lymphedema in our single vessel ligation 
model. In contrast to the previous studies we did not observe any significant declines in 
tail swelling compared to baseline (70); however, this could be due to the fact that our 
tacrolimus treated experimental group exhibited significantly greater swelling before the 
start of treatment. Upon examination of the post start of treatment reduction in tail swelling, 
it became apparent that tacrolimus had in fact provided modest improvements. It is 
important to note that these discrepancies could be due to differences in disease 
pathogenesis between our single vessel ligation model and the total vessel ligation model. 
For example, perhaps the swelling observed in the total vessel ligation model is primarily 
mediated by the accumulation of pro-inflammatory T-cells to a greater extent than our 
model. This would explain why inhibition of T-cell activation and differentiation would 
produce a greater decrease in swelling; however, this remains speculative and should be 
more thoroughly investigated.  
Despite observing only modest decreases in the tail swelling of obese animals we 
discovered, for the first time, that tacrolimus protects against the functional declines 
associated with the collecting lymphatics during obesity and lymphedema. The primary 
effects of tacrolimus on collecting lymphatic function where observed at the 28 days post 
induction of lymphedema. At this time point treatment with tacrolimus caused an increase 
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in lymphatic pumping pressure in comparison to untreated obese animals. This effect 
persisted throughout the 70-day time course. Interestingly, this rise in pumping pressure 
corresponds with an increase in packet frequency. The combination of these results lends 
credence to the hypothesis that the declines in pumping pressure seen in the untreated obese 
animals is caused by declines in packet frequency, corresponding to decreases in the 
intrinsic contractile frequency of the vessels. Given that inflammatory mediators such as 
cytokines (3), prostanoids (245), histamine (66), and nitric oxide (NO) (32, 139, 149, 235) 
are known to be potent modulators of lymphatic contractile activity, it seems reasonable to 
infer that tacrolimus may have downstream effects on these mediators via inhibition of T-
cell activation. This is supported by work demonstrating that tacrolimus decreases iNOS 
expression (222). Tacrolimus could also have direct effects on collecting lymphatic 
contractile response. Unpublished preliminary data from our research group has indicated 
that tacrolimus may increase the contractile frequency of rat collecting lymphatic vessels. 
However, this work is preliminary and warrants more in-depth investigation. Further, it is 
unclear from this study if tacrolimus influences collecting lymphatic remodeling during 
lymphedema. For example, would treatment with tacrolimus differentially influence the 





CHAPTER 4. LYMPHATIC FUNCTION AND REMODELING 
RESPONSE COMPENSATE FOR A LOSS OF FLUID RETURN 
PATHWAYS IN SHEEP (AIM 3) 
4.1 Introduction 
Research on lymphatic growth and remodeling following injury have primarily 
utilized mouse lymphedema models, with the mouse tail model being the most widely used 
(10, 82, 83, 187). This model involves circumferential ligation of the dermal level initial 
lymphatics and collecting lymphatics on the mouse tail. Following the surgery, the tissues 
distal to the wound exhibit significant swelling. Although these models have provided 
valuable information about molecular factors that affect lymphatic growth and remodeling 
of the initial lymphatics following injury, the relevance to human lymphatic physiology, 
where the vessels must overcome large gravitational loads, is lacking. This is highlighted 
by the fact that most mouse models of lymphedema typically resolve if given enough time, 
which isn’t surprising since the vessels only need to transport fluid up a few centimeters of 
a hydrostatic pressure gradient (251).  
In this study, we present an adaptation of methodologies used in rodent models for 
use in sheep, and utilize these to longitudinally evaluate the functional and molecular 
changes of an uninjured collecting lymphatic vessel as it compensates for a compromised 
lymphatic network. We then utilized MRI to evaluate structural changes in the lymphatic 
network as well as near-infrared (NIR) lymphatic imaging approaches to quantify changes 
in collecting lymphatic function of the vessels over a 42-day period of remodeling. After 
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this, we harvested the collecting lymphatic vessels and utilized ex-vivo vessel perfusion 
techniques to examine changes in the lymphatic vessel’s intrinsic contractile response to 
transmural pressure and flow. Proteomics and subsequent pathway analysis was used to 
elucidate pathways impacting structure and function of the lymphatic muscle cells that 
were altered by the lymphatic remodeling. Finally, isolated vessels were mechanically 
tested and the mechanical properties of the vessels were used to inform a computational 
model to simulate how the differences in these properties affect lymphatic function. 
4.2 Materials and Methods 
4.2.1 Study Overview 
All animal procedures described in this study were approved by the University of Georgia 
Institutional Animal Care and Use Committee.  A graphical depiction of the study design 
is shown in (Figure 25). A total of 5, 3 to 5-year old randomly bred female Suffolk sheep 
were used in this study; Before the study, 3 of the sheep underwent Gadolinium-Enhanced 
MR imaging (GE MRI) to structurally map the lymphatic anatomy of the hind limbs. One 
day after the MRI the sheep underwent the initial NIR functional lymphatic imaging 
procedure on both hind limbs. After imaging, the collecting lymphatic ligation surgery was 
conducted on one of the hind limbs, with the contralateral limb remaining intact to act as 
an internal control. The sheep were recovered from anesthesia following the completion 
imaging procedure and surgery. Follow-up NIR functional lymphatic imaging was 
conducted 7, 14, 28, and 42 days after the procedure. One day before the final NIR imaging 
session, the 3 sheep that underwent the MR lymphatic imaging underwent a second MR 
imaging session. On day 42, following the NIR imaging procedure, the sheep were not 
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recovered and were euthanized via pentobarbital overdose for tissue collection. Collecting 
lymphatic vessels from the control and wounded legs were isolated and excised for ex-vivo 
functional testing of the vessels. The datasets generated during and/or analyzed during the 
current study are available from the corresponding author on reasonable request. 
Additionally, any custom software or code used in this study are available on request. 
 
Figure 25: (A) Graphical depiction of the study design. On day -1, pre-surgery MRI 
was used to map the lymphatic anatomy of the hind limbs in sheep. On day 0 pre-
surgical NIR imaging was used to evaluate baseline lymphatic function. Immediately 
after imaging, the caudal lymphatic vessel on one of the hind limbs was ligated in 
order to create a lymphatic injury, while the contra-lateral limb was left intact. 
Follow-up NIR imaging was used to evaluate changes in lymphatic function of the 
vessels on the intact and wounded limbs at days 7, 14, 28, and 42. (B) Evans blue was 
injected intradermally and uptake by the lymphatic vessels was visualized with the 
skin removed. Two primary collecting lymphatic vessels (cranial and caudal) run 
along the lateral aspect of the hind limb and serve to drain fluid from the distal 
portions of the limb. During surgery on Day 0, the caudal vessel was ligated whereas 
the cranial vessel was left intact. (C) NIR imaging was used to guide and confirm 
ligation of the caudal lymphatic vessel. Pre-ligation images exhibit fluorophore 
uptake by the vessel. After ligation, and excision of a 2 cm segment of vessel, NIR 
imaging confirmed the absence of fluorescence transport by the vessel. (D) 
Circumferential measurements taken at the mid tarsus on the hind limb was used to 
97 
 
identify the presence or absence of swelling due to the injury. No significant swelling 
of the tissue was observed. Error bars represent SEM. 
4.2.2 Surgical procedure 
Sheep were anesthetized with midazolam 0.25 mg/kg and ketamine 5 mg/kg, 
intubated and maintained under anesthesia at 1-3% sevoflurane in oxygen. The animals 
were placed on either their right or left sides. Vitals, including heart rate, body temperature, 
blood pressure, and partial oxygen pressure were monitored throughout the imaging 
procedure. The hind limbs of the animals were shaved with electric sheers, and sterilized 
with three alternating scrubs of 2% chlorhexadine and 70% isopropyl alcohol. A 4 cm 
incision was made on the lateral aspect of the hind limb proximal to the tarsus, exposing a 
collecting lymphatic vessel running in parallel to the saphenous vein. A 2 cm portion of 
the vessel along with the vein was ligated with sutures and resected. 3 animals had the 
surgical procedure done on the right hind limb while the remaining 2 animals had the 
procedure done on the left hind limb. The contralateral limb was left intact to serve as an 
internal control. 
4.2.3 Near-infrared imaging system 
The NIR imaging system was set-up in a manner similar to our previously described 
system (149, 234, 235). A diode driver and temperature control box powered a 300 mW 
785 nm laser diode (Thorlabs, Newton, NJ), which provided excitation light. To disperse 
the laser over a larger area of approximately 75 cm2 with less than 1.9 mW/cm2, a 20 
degree beam diffuser (Thorlabs, Newton, NJ) was fixed in front of the diode. A 25 mm 
fixed focal length lens (MVL25M43, Thorlabs, Newton, NJ) and a bandpass filter (CW: 
835, FWHM: 45) were attached to a Pixis 1024B back-illuminated CCD camera (Princeton 
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Instruments, Trenton, NJ) to capture fluorescence emission. The camera was connected to 
a computer where images were acquired by a custom LabView VI. The camera and light 
source were mounted to a 1.8 m camera crane jib, which enabled positioning of the camera 
with 3 degrees of freedom (ADC-306, Advanced Digital Inc.).  
To measure the effective lymphatic pumping pressure, a custom feedback-
controlled pressure cuff was developed. Inflation of a veterinary blood pressure cuff (UP-
0925, Technicuff, Leesburg, FL) was controlled using an air pump (VMP1625MX-06-50-
CH, Virtual Industries Inc., Colorado Springs, CO) and generic solenoid valve. Commands 
to control the relays powering the pump and solenoid were sent via 5v output on an NI-
DAQ 6008 (National Instruments, Austin, TX). Pressure output from a pressure transducer 
(SSCDRRN005PDAA5, Honeywell, Morristown, NJ) attached to the cuff was fed back 
into the DAQ and used by a custom LabView VI to make the logic decisions for inflation 
and deflation of the cuff (available on request).  
4.2.4 Near-infrared imaging procedure 
The NIR lymphatic tracer used for the imaging procedures consisted of a NIR 
fluorophore IRDye 800 CW NHS Ester (929-70020, LI-COR Biotechnology, Lincoln, NE) 
bound to 40kDa methoxypolyethylene glycol (mPEG) (JenKem Technology USA, Plano, 
TX) in a manner similar to a previously described method (28, 169). Equimolar ratios of 
IRDye 800CW NHS Ester (75 nmol) and mPEG (75 nmol) were bound room temperature 
in 0.5mL anhydrous dimethyl sulfoxide (DMSO) for 24hrs. After binding, the mixture was 
transferred into a dialysis cassette with a 7 kDa molecular weight cutoff (66370, Thermo 
Fisher Scientific, Waltham, MA). The cassette was submerged in a 4L beaker of de-ionized 
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water and was dialyzed for 24hrs. The dialyzed solution was removed from the cassette 
and lyophilized for 24hrs in 1.5mL conical centrifuge tubes. The lyophilized tracer was 
stored prior to use in -20C freezer. A day before use the dry tracer was re-constituted in 0.5 
mL sterile saline and filtered into a sterile rubber topped vial using a 0.2 um syringe filter 
(IRPEG40).   
The camera and excitation light source were positioned over the lateral aspect of 
the mid hind limb centered 10 cm proximal to the hock. 0.5 mL of IRPEG40 was injected 
intradermally into the fatty part of the hoof cleft on the frontal aspect of the hind limb with 
a sterile 21g needle. A second injection of 0.5 mL IRPEG40 was given in the dorsal aspect 
of the hind limb 5 cm distal to the hock. NIR images of dynamic fluorescence transport 
were captured at a rate of 1 fps with a 50 ms exposure time for a total of 20 min. The 
pressure cuff was then fitted to the hind limb with the proximal edge touching the apex of 
the hock. The pressure in the cuff was controlled to produce the following sequence. The 
pressure was increased to 80 mmHg over a period of 65 s and held at this value for 10 min 
to allow for the proximal vessel to completely empty its contents. This pressure was chosen 
for lymph flow occlusion because 80 mmHg is close to the diastolic blood pressure of a rat 
and well below the mean arterial pressure, so blood supply was not occluded during the 
experiment. After 10 min at 80 mmHg, the pressure was decreased to 55 mmHg over a 
period of 25 s. The pressure was then decreased in decrements of 2.5 mmHg and held at 
each pressure step for 60 s, until the pressure value was zero, where it remained for 3 min 
before the program was terminated. The pressure cuff controller took less than 15 s to reach 
each new pressure decrement. The pressure at which flow was restored as observed by 
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fluorescence return proximal to the cuff was determined as the lymphatic pumping 
pressure. 
4.2.5 Near-infrared imaging analysis 
Three distinct metrics of lymphatic function were evaluated using previously our 
previously developed methods (149, 235). 1) Packet frequency was evaluated by tracking 
the average time between peak fluorescence pulsations within regions of interest (ROIs) 
traced over lymphatic vessels during our initial imaging sets. Packet frequency has been 
correlated with the frequency of intrinsic lymphatic contractions in vivo. 2) Florescence 
transport was calculated by evaluating the average integral of packets with respect to time. 
It is the absolute amount of fluorescence transported through a region of interest over time. 
Fluorescence transport is a function of lymphatic contraction frequency, contraction 
amplitude, and packet velocity. 3) Effective lymphatic pumping pressure was calculated 
by determining the occlusion pressure at which the fluorescence within the vessel proximal 
to the cuff returns to half of its pre-occlusion value. It is a measure of the collecting 
lymphatic vessel chain’s ability to generate the pressures needed to overcome an occlusive 
force.  
Significant differences between control and wounded groups was determined via 
unpaired t-test for each time point with p < 0.05 indicating statistical significance. 
Significant difference between pre-surgical baseline (Day 0) and later time points was 
evaluated using 1-way ANOVA with post-hoc Dunnett’s test for multiple comparisons 
with p < 0.05 indicating statistical significance. All statistical analyses were done using 




4.2.6 Functional testing of isolated collecting lymphatic vessels 
Lymphatic vessels were isolated and tested from sheep in a manner similar to our 
previously described methods in rats (109, 110). After the final NIR imaging session, sheep 
were euthanized via barbiturate overdose. After euthanasia, the skin was removed from the 
hind limb to expose the collecting lymphatic vessels. Sterile saline was periodically 
perfused onto the tissue to ensure that it did not dry. The intact cranial lymphatic vessel on 
either the control or wounded leg was located and 1 cm segments were isolated from the 
surrounding adipose and a fascia. The segments were removed and immediately placed in 
a bath containing DMEM/F12 (GE Healthcare Life Sciences, Logan, UT) with added 
antibiotic mixture (Invitrogen Corp., Carlsbad, CA) to achieve a concentration of 100 units 
of Penicillin and 100 μg of streptomycin per ml of DMEM/F12.  
Individual segments were subsequently cannulated onto micro pipettes in a single 
vessel cannulation chamber (Living Systems Instrumentation, St. Albans, VT) and placed 
under a microscope with a 2X objective (VWR, Radnor, PA) and a GuppyPRO (Allied 
Vision, Exton, PA) camera to capture dynamic video of contractile behavior. The vessel 
chamber inlet and outlets were connected via silicon tubing to inlet and outlet water 
columns, which were used to vary transmural pressure and transaxial pressure gradient. 
The chamber bath was constantly perfused with fresh media and was held at a 38°C 
throughout the experiment by a flexible Kapton heater and CN740 temperature controller 
(Omega Engineering, Norwalk, CT). 
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The experimental protocol began with 45-50 min equilibration at 6 cmH2O 
transmural pressure to ensure the presence of spontaneous vessel contractions. After the 
equilibration, vessel segments were exposed to increasing transmural pressures via water 
column with values of 1.5, 3, 5, 7, 9, 11, 12, 15, 17, and 19 cmH2O for 5-10 min at each 
pressure. The functional response of the lymphatics to axial pressure gradient was 
evaluated by maintaining an average transmural pressure of 6 cmH2O while increasing the 
inlet water column to achieve axial pressure gradients of 0, 1, 3, and 5 cmH2O for 5-10 min 
at each axial pressure.  
Isolated vessel functional metrics were calculated from the diameter tracings in a 
manner similar to our previously described methods in rats (109, 110). The data shown in 
this manuscript represent individual segments collected from individual animals (ie. there 
were no replicates from animals and each data point shown represents an individual 
segment from a different animal). Significant difference between control and wounded 
groups was evaluated at their respective transmural or axial pressure gradient using 2-way 
ANOVA with post-hoc Sidak correction for multiple comparisons.  In addition to this, 1-
way ANOVA with post-hoc Dunnett’s correction for multiple comparisons was used to 
determine significant differences between baseline transmural or transaxial pressure and 
the applied transmural or transaxial pressure for control or wounded groups respectively. 
All statistical analyses were done using Prism software (GraphPad Software, La Jolla CA) 
with p < 0.05 indicating statistical significance.  
Wire myography was done on vessel segments from a single animal (n=4 control, and n=4 
wounded) similar to a method previously described by (41). 2 mm segments of vessel were 
cut from the 1 cm segments that had been collected and were mounted individually to a 
103 
 
small vessel wire myograph (Model 500A, Danish Myo Technology, Denmark). Segments 
were allowed to equilibrate for 1 hr in a bath containing DMEM/F12 at 38°C. After the 1 
hr equilibration period force transducer readings from the wire myograph were recorded at 
a rate of 1 Hz and spontaneous vessel contractions were confirmed. Peak contractile 
tensions from the force transducer readings were averaged over a 30 min period for each 
segment. Statistical significance between control and wounded segment groups was 
determined using an unpaired t-test with p < 0.05 indicating a significant difference 
between groups. 
4.2.7 Proteomic analysis of lymphatic muscle cells 
A primary lymphatic muscle cell (LMC) line was formed from collecting lymphatic 
vessels isolated from sheep hind limbs. The collecting vessel were rinsed in a physiological 
saline before being transferred to a tissue culture dish where it was attached by gently 
pressing the ends to the surface with forceps. Vessels were cultured in Dulbecco’s 
Modified Eagle’s Medium (Thermo 11965-092), high glucose, with 10% Fetal Bovine 
Serum, along with Antibiotic-Antmycotic (Thermo 15240062). Media was exchanged 
every 2-3 days. Muscle cells began to migrate and proliferate from the vessel around day 
3. Vessel were gently discarded after a week, leaving only the newly migrated cells. Cells 
were split using Trypsin, 0.25% EDTA, and frozen in liquid nitrogen at passage 3. 
Experiments were conducted on LMCs between passage 5-7. 
LMCs were solubilized in 8M Urea/2%SDS/100 mM Ammonium Bicarbonate and 
sonicated for 10 min on ice. Samples were then centrifuged at 14,000g for 5 min and the 
supernatant remove.  Proteins in the supernatant were reduced, alkylated and trypsin 
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digested, as previously reported (50). Peptides were separated on a C18 column and 
analyzed with a Q Exactive Plus mass spectrometer. Each sample was run in technical 
triplicate. Raw files from each technical and biological replicate were filtered, de novo 
sequenced and assigned with protein ID using Peaks 8.0 software (Bioinformatics 
Solutions, Waterloo, Canada), by searching against the sheep (Ovis Aries) Swiss-Prot 
database (April 2017; 781 entries). Peptide identifications were accepted if they could be 
established at greater than 95.0% probability by the Peptide Prophet algorithm with 
Scaffold delta-mass correction. Protein identifications were accepted if they could be 
established at greater than 95.0% probability and contained at least 1 identified peptide. 
Protein probabilities were assigned by the Protein Prophet algorithm. Proteins that 
contained similar peptides and could not be differentiated based on MS/MS analysis alone 
were grouped to satisfy the principles of parsimony as originally described (51). 
Label-free quantitative (LFQ) methods directly used the raw spectral data from 
parallel MS runs to determine relative protein abundances.  We used both “MS/MS (MS2) 
spectral counting” and “precursor MS1 area” methods for label free quantitation and 
further contrasting the differentially expressed proteomic profiles across the control and 
wounded lymph muscle samples.  The relative protein abundance was displayed as heat 
maps including representative proteins of each protein group after normalization of the 
corresponding weighted spectral counts using the built-in algorithm from “perSPECtives”.  
Only proteins which passed a selected significance statistical threshold (ANOVA, p < 0.05 
and FDR < 1% for protein and peptide expression) and had been identified with at least 
two-fold differential expression across all samples are shown in the representative heat 
map.  Networks, functional analyses, biochemical and cellular pathways were generated 
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by employing the ingenuity pathway analysis (IPA; Ingenuity Systems, Redwood City, 
CA, USA) on the list of differentially abundant proteins extracted from LFQ analyses 
(based on both the precursor ion areas and spectral counts) and presented categorized in 
(Table 2) found in Appendix C. 
4.2.8 Quantification of the biomechanical properties of isolated lymphatic vessels 
Using a previously developed biaxial testing device in a temperature-controlled 
incubator at 370C, which is capable to measure and control transmural pressure, diameter, 
and axial force (or stretch), we performed intermittent biaxial (pressure–diameter and axial 
force–stretch) tests as described previously (79). In brief, two segment of lymphatic vessels 
(one from control leg and one from ligated leg) were mounted on two opposing cannulae 
in a vessel chamber with a bath of Ca+2-free PSS solution. Vessels were visualized under 
different transmural pressures and axial stretches using an inverted microscope (2.5x 
magnification) and digital camera (Allied Vision Technologies, Marlin F-033B). A custom 
program in LabVIEW controls inlet, outlet, and transmural pressures (Honeywell FPG 060-
E418-11) as well as axial length and axial force using linear actuators (Newport Precision 
LTAseries) and a load cell (Delta Metrics), respectively. Once preconditioned, vessels 
were subjected to three loading cycles of ramping the transmural pressure from 3 to 40 
cmH2O at axial stretch values of 1, 1.1, 1.2, and 1.3.  
4.2.9 Computational modeling of lymphatic flow and intraluminal lymphatic valves  
The pumping function of a lymphangion was modeled based on a previously 
developed computational framework for a single lymphangion (36). In brief, this 
framework consists of a structure-function relationship for wall mechanics, a model for 
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active force generation of lymphatic smooth muscle cells, and a model for intraluminal 
valve function. A Matlab script was used to solve respective models along with mass and 
momentum conservation equations to obtain lymphatic flow and pressure during 
lymphangion contraction. Upon incorporation of ex-vivo experimental data from control 
and ligated vessels into computational framework, we simulated different loading 
scenarios for a single lymphangion. Specifically, inflow pressure was set at 6 mmHg while 
outflow was altered until lymphatic flow ceased. Next, pressure-flow and pressure-volume 
curves were obtained for both control and ligated lymphatic vessels. Simulations were also 
conducted using the average in-vivo contraction frequencies (packet frequency) assessed 
via NIR imaging at day 42. For these simulations, inflow pressure was also set at 6 mmHg 
while outflow pressure was altered until lymphatic flow ceased. 
Lymphatic  flow rate was calculated using Hagen-Poiseuille equation for 
collapsible vessels which has been shown a good approximation for flow rate in lymphatic 






(𝑃𝑖𝑛 − 𝑃𝑜𝑢𝑡) 
where 𝑄𝑖𝑛  and 𝑄𝑜𝑢𝑡 are inlet and outlet flow rates, respectively; D and L are diameter and 
length of lymphangion, respectively; 𝜇 denotes lymph viscosity; 𝑃𝑖𝑛 and 𝑃𝑜𝑢𝑡 are inflow 
and outflow pressures, respectively. In addition, temporal change in lumen dimeter is 








Intraluminal valves were modeled based on computational-experimental 
framework developed  by Bertram et al (23–26, 96) to simulate the function of one-way 
valve in mesenteric lymphatic vessels. Briefly, this model simulates the function of 
intraluminal valve through imposing variable resistance to lymphatic flow based on the 
transaxial pressure gradient across the valve. The minimum and maximum valve 
resistances are associated with valve opening and closure, respectively, while an empirical 
parameter (s) dictates transition rate from minimum to maximum resistance, namely: 
𝑅𝑣𝑎𝑙𝑣𝑒=𝑅𝑣,𝑜𝑝𝑒𝑛 +
𝑅𝑣,𝑐𝑙𝑜𝑠𝑒𝑑 − 𝑅𝑣,𝑜𝑝𝑒𝑛
2 (1 + exp (𝑠 ∗ (𝑃𝑝𝑟𝑜𝑥𝑖𝑚𝑎𝑙 − 𝑃𝑑𝑖𝑠𝑡𝑎𝑙)))
 
where  𝑅𝑣,𝑜𝑝𝑒𝑛  and 𝑅𝑣,𝑐𝑙𝑜𝑠𝑒𝑑  are resistance to flow when valve is open and close 
respectively; 𝑃𝑝𝑟𝑜𝑥𝑖𝑚𝑎𝑙 and 𝑃𝑑𝑖𝑠𝑡𝑎𝑙  are pressure proximal and distal to intraluminal valve; 
s is a constant parameter that dictates translon rate from valve opening to valve closure. 
We used a previously developed computational framework to model pumping 
function of a single lymphangion. In brief, this model utilize a constitutive framework 
based on hyper-elasticity framework to model passive mechanical behavior of lymphatic 
vessels (e.g., distension) in response to mechanical stimuli (e.g, transmural pressure. The 
biaxial data were used to calculate model parameters that dictate the relationship between 
biomechanical force (e.g., lymphatic pressure and axial force) and wall mechanics (e.g., 
wall diameter and thickness). This relationship employs a 4-fiber family strain energy 
density function that models contribution of amorphous matrix and collagen fibers as 
follows (92):                  
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𝑘 denote material properties, 𝐼𝐶𝑒  is first invariant deformation gradient and 
𝜆𝑘 is stretch of kth family of collagen fibers. 
This computational framework model phasic (spontaneous contractions) and tonic 
contractions (basal contractions) of lymphatic smooth muscle cells based on a length 
















where 𝑇𝜃𝜃,𝑎𝑐𝑡  is circumferential contractile stress; 𝑇  models amplitude of active-
contractile tension in systole, which was estimated from myography data on lymphatic 
vessel, H denotes vessel thickness, b is a constant parameter that defines basal force 
generation in diastole based on ex-vivo experiments, 𝜆𝜃 indicates elastic circumferential 
stretch; 𝜆𝑚, 𝜆0  are stretches at which contractile tension is maximum and minimum, 
respectively; f is frequency of spontaneous contractions that follows frequency-pressure 
curves. 
4.3 Results 




MRI imaging of the lymphatic anatomy of the hind limbs was conducted one day 
pre-surgery and 42 days after surgery (5 sheep total). Pre-surgical MRI shows the two 
primary collecting lymphatic vessels that drain the hind limbs (Figure 26). These two 
vessels run in parallel and both drain to the popliteal lymph node. At day 42 post-surgery 
MRI images show the absence of contrast agent transport by the caudal collecting 
lymphatic vessel due to the ligation surgery. However, the cranial lymphatic vessel remains 
intact. Quantification of vessel diameters in the MR images shows a significant decrease 
in the apparent lumen diameter of the intact vessel on the wounded leg 42 days post-
surgery. However, vessels from the control leg exhibited an observed increase in diameter 




Figure 26: (A) MRI imaging of the lymphatic anatomy of the hind limbs was 
conducted one day pre-surgery and 42 days after surgery. Pre-surgical MRI shows 
the two primary collecting lymphatic vessels that drain the hind limbs. These two 
vessels run in parallel and both drain to the popliteal lymph node. At 42 days post-
surgery the caudal vessel is absent from the MR images on the wounded leg. (B) NIR 
imaging allowed visualization of network remodeling due to the lymphatic ligation. 
Pre-surgical images show both the cranial and caudal collecting lymphatics intact. 
Immediately after ligation of the caudal collecting lymphatic, an absence of 
fluorophore transport confirmed successful ligation and excision of the vessel. (C) The 
diameter of the cranial vessel on the control and wounded leg was measured distal to 
the wound site using the MR images before and 42 days after surgery. Values were 
normalized by the pre-surgical average diameter of the respective vessel. (****, p < 
0.0001). 
 
NIR imaging allowed longitudinal visualization of local lymphatic vascular 
remodeling caused by the lymphatic ligation (Figure 26). Representative pre-surgical 
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images show both the cranial and caudal collecting lymphatics intact. Immediately after 
ligation of the caudal collecting lymphatic, an absence of fluorophore transport confirmed 
successful ligation and excision of the vessel. Day 7 after surgery the cranial lymphatic 
vessel was intact and functioning but the ligated caudal vessel was not visualized. By day 
14 after the surgery, fluorophore was observed in tortuous initial lymphatics at the site of 
the wound. However, there was no regrowth of a patent caudal collecting lymphatic vessel. 
Day 28 after surgery there is regrowth of a caudal lymphatic vessel bypassing the wound 
site. At day 42 after surgery initial lymphatic uptake of fluorophore was absent at the 
wound site and, in one case (1/5), a collateral lymphatic vessel exhibited packets at the 
wound site. However, it is unclear if this vessel was newly formed or existed previously. 
4.3.2 Lymphatic function of the intact vessel slowly declines following damage to the 
parallel vessel but subsequently recovers 
NIR lymphatic imaging was used to non-invasively evaluate lymphatic functional 
changes in response to the lymphatic injury. Packet frequency, corresponding to the 
frequency of lymphatic contractions, was evaluated for the intact cranial vessel on the 
control leg and the wounded leg (Figure 27). Significant differences in packet frequency 
between the control and wounded legs are not observed until day 28 corresponding to 
averages of 4.5 ± 1.2 min-1 and 0.9 ± 0.7 min-1 respectively; However, this difference is 
attenuated by 42 days after surgery. Interestingly the difference is attributed primarily to 
an increase in the packet frequency of the lymphatic from the contralateral control leg. To 
better visualize alterations in packet frequency over the experimental time course, the 
percent difference between the control and wounded leg was used to visualize a persistent 
decline caused by the wound (Figure 27). Packet transport, a metric indicative of 
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fluorescence transport propagated by intrinsic contraction, was calculated for the vessels 
on control and wounded legs. At day 28 post-surgery, total packet transport on the wounded 
leg was significantly lower than the control, corresponding to averages of 3481 ± 2409 
RFU and 22590 ± 5172 RFU respectively (Figure 27). Effective pumping pressure was 
measured to determine the effects of the surgery on lymphatic contractile force.  Significant 
differences in the effective pumping pressure were not observed until 28 days after surgery, 
corresponding to values of 36.3 ± 7.0 mmHg and 13.6 ± 6.7 mmHg respectively (Figure 
27). Collectively, these results suggest that the functional response of the intact vessel is 
compromised 28 days after the surgery; However, the functional declines appear to be 




Figure 27: NIR lymphatic imaging was used to non-invasively evaluate lymphatic 
functional changes in response to the lymphatic injury. NIR imaging data was 
collected from the intact vessels on both the control (n=5) and wounded (n=5) legs. 
(A) Packet frequency, the frequency of fluorescent pulsations within the vessel, 
exhibited significant differences between intact vessels on the control and wounded 
legs at day 28 post-surgery. (B) The percent difference between the packet frequencies 
of the control and wounded leg depict a decline due to the surgery. (C) Effective 
pumping pressure (Peff), was used to evaluate the maximal pressure generated by the 
collecting vessel to overcome occlusion. Significant differences in Peff were observed 
at day 28. (D) Packet transport, the integral of the packet frequency signal over time, 
was used to evaluate fluorescence transport driven by intrinsic lymphatic 
contractions. Significant differences in packet transport were observed at day 28. 
Error bars represent SEM. (*, significant difference between control and wounded, p 





4.3.3 Isolated lymphatic vessels from the wounded and control legs differentially respond 
to alterations in transmural pressure 
 Following sacrifice, the intact lymphatic vessels on the control and wounded legs 
were isolated and excised. A subset of these segments (n=4) underwent wire myography. 
Results from the wire myograph suggest that vessel segments from the control and 
wounded exhibit significantly different peak tensions during spontaneous contraction with 
values of 2.92 ± 0.002 mN/mm and 3.02 ± 0.013 mN/mm respectively (Figure 28). Other 
segments of isolated vessel were cannulated in our previously described lymphatic vessel 
perfusion system (109, 110). This system was used to prescribe various transmural 
pressures to the vessel segment while simultaneously recording contractile response via 
video. Vessel segments from the wounded leg exhibited increased contractile frequency 
compared to control at all transmural pressures tested (Figure 28). The average contraction 
frequencies at 5 cmH2O were 8.7 ± 1.3 min
-1 and 12.9 ± 0.3 min-1 for control and wounded 
respectively. Contraction amplitude as a function of transmural pressure was increased in 
vessel segments from the wounded leg, which is in agreement with myograph data (Figure 
28). Peak contraction amplitudes were observed at 5 cmH2O for segments from the control 
leg and 7 cmH2O for segments from the wounded leg, corresponding to normalized 
contraction amplitudes of 31.6 ± 6.9% and 43.5 ± 3.9% respectively. Lymphatic tone index 
was calculated from the ratio of diastolic diameter to diastolic diameter in calcium free 
media (detailed in methods). The metric is a measure of the lymphatic smooth muscle’s 
contribution to the tonic diameter of the vessel. Lymphatic tone was found to be decreased 
in vessel segments from the wounded leg compared to control (Figure 28), while the 
passive lymphatic diameter was not different (Figure 29). Ejection fraction and fractional 
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pump flow were calculated from the frequency and amplitude data. The ejection fraction 
and fractional pump flow for the wounded leg was elevated over control due to increased 
contraction amplitude and frequency (Figure 31). 
 
Figure 28: Intact lymphatic vessels were isolated from the control and wounded legs 
to evaluate changes in the stretch response due to the surgery. Vessel segments were 
cannulated and exposed to a range of transmural pressures. (A) Wire myography was 
used to evaluate the contractile force of isolated lymphatic vessels (non-pressurized) 
and exhibited significant increases in the contractile force of vessels from the 
wounded leg (n=4 control, n=4 wounded). (B) Vessel segments from the wounded leg 
exhibited higher contraction frequencies than control segments (n=4 control, n=4 
wounded). (C) The amplitude of lymphatic contractions did not significantly differ 
between the control and wounded groups (n=4 control, n=4 wounded). (D) Lymphatic 
tone was not significantly different in vessel segments collected from the wounded leg 
(n=4 control, n=4 wounded). Error bars represent SEM and open circles represent 
individual data points (*, significant difference between control and wounded, p < 
0.05; †, significant difference between control and control baseline at 1.5 cmH2O 
transmural pressure, p < 0.05; ‡, significant difference between wounded and 




Figure 29: Diameters of vessels from the control and wounded leg were measured 
during the isolated vessel procedures at 5 cmH2O transmural pressure and 0 cmH2O 
axial pressure gradient. There was no observed statistically significant difference in 
the outer diameters of the vessels between the control or wounded leg. Error bars 
represent SEM. 
 
4.3.4 Isolated lymphatic vessels from the wounded and control legs differentially respond 
to imposed flow and inhibition of eNOS 
 Isolated lymphatic vessel segments were subjected to varying imposed axial 
pressure gradients, while maintaining a constant transmural pressure of 6 cmH2O, by using 
our previously described lymphatic vessel perfusion system (109, 110). To determine the 
role of eNOS in the response to imposed flow, vessel segments received treatment with the 
eNOS inhibitor L-NAME. Flow inhibited contractile response occurred at an axial pressure 
gradient of 3 cmH2O for control segments whereas no such inhibition was observed in 
segments from the wounded leg (Figure 30). Contraction frequency of the wounded vessels 
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with values of 11.7 ± 2.6 vs 3.1 ± 1.7 and 8.92 ± 1.1 vs 0.3 ± 0.3 respectively. Upon 
inhibition of eNOS with L-NAME, vessels from the control segment experienced no shear 
inhibited contractile response above axial pressure gradients of 3 cmH2O whereas wounded 
segments exhibited little response to the loss in eNOS (Figure 30). The amplitude of 
contractions was relatively similar between control and wounded segments at axial 
pressure gradients of 0 and 1 cmH2O. However, at 3 cmH2O and 5 cmH2O control segments 
did not contract and thus had no contraction amplitude (Figure 30). Upon treatment with 
L-NAME at 0 and 1 cmH2O axial pressure gradient, contraction amplitude for control 
segments was halved, whereas wounded segments exhibit little alteration in amplitude 
(Figure 30). The tone index of both control and wounded segments was not significantly 
different (Figure 30). Treatment with L-NAME elicited a strong increase in the tone of 
control segments. Conversely, wounded segments exhibited no change in tone compared 
to untreated conditions with increasing axial pressure gradients (Figure 30). In a subset of 
vessel segments, shear sensitivity was evaluated by linearly increasing axial pressure 
gradient while maintaining constant transmural pressure. Segments from the wounded leg 
were less shear sensitive; exhibiting contractile inhibition at higher shear stress values than 
control segments (Figure 30). Ejection fraction was significantly decreased for vessels 
from the control leg in the presence of L-NAME, however wounded leg vessels were non-
responsive to L-NAME (Figure 30). Fractional pump flow for control vessels increased in 
the presence of L-NAME, but not for wounded leg vessels (Figure 31). As a whole, these 
results suggest that vessels from the wounded leg have impaired eNOS-dependent flow 




Figure 30: Intact lymphatic vessels were isolated from the control and wounded legs 
to evaluate changes in the flow response to the surgery. Vessel segments were 
cannulated and exposed to a range of transaxial pressure gradients. 100uM LNAME 
was used to inhibit endothelial nitric oxide synthase (eNOS). (A) The frequency of 
lymphatic contraction was slightly increased for isolated vessels collected from the 
wounded leg when compared to control. The addition of LNAME inhibits intrinsic 
contraction of vessels from the wounded leg. However, control vessels exhibit a 
differential response; increasing contractile frequency in response to LNAME (n=3 
control, n=5 wounded). (B) Lymphatic contraction amplitude was decreased in 
response to imposed flow. Vessels from the wounded limb exhibited lesser degree 
amplitude loss with the addition of L-NAME (n=3 control, n=5 wounded) (C) 
Lymphatic muscle tone of vessels from the wounded leg was decreased compared to 
control. Isolated lymphatic vessels from the wounded leg exhibit a little response to 
application of LNAME compared to control vessels (n=3 control, n=5 wounded). (D) 
The vessel from the wounded leg exhibited less of a contractile response to shear stress 
than vessels from the control leg (n=1 control, n=1 wounded). Error bars represent 
SEM and open circles represent individual data points (*, significant difference 
between control and wounded, p < 0.05; †, significant difference between control and 
control baseline at 0 cmH2O axial pressure gradient, p < 0.05; ‡, significant difference 






Figure 31: Fractional pump flow and ejection fraction were derived from isolated 
vessel diameter tracings. (A) Fractional pump flow of vessels from the wounded leg 
and control leg as a function of transmural pressure. (B) Ejection fraction as a 
function of transmural pressure. (C) Fractional pump flow at varying axial pressure 
gradients with an average transmural pressure of 6 cmH2O with and without the 
addition of L-NAME. (D) Ejection fraction at varying axial pressure gradients with 
an average transmural pressure of 6 cmH2O with and without the addition of L-
NAME. (*, significant difference between control and wounded, p < 0.05; †, 
significant difference between control and control baseline at 1.5 cmH2O transmural 
pressure, p < 0.05; ‡, significant difference between wounded and wounded baseline 





4.3.5 Lymphatic muscle cells from wounded vessels exhibit differential protein 
expression profiles 
 As a next step to further understand the biomolecular underpinnings correlated with 
the observed changes in lymphatic function we performed a label free comparative 
proteomic analysis between muscle cells harvested from control and wounded lymphatics.  
A distinct protein signature could be observed between the control and wounded muscle 
cell proteome (Figure 32).  Comparative analysis of the cellular proteome, using the 
Ingenuity Pathway Analysis determined that several metabolic, signaling and apoptotic 
pathways were up-regulated in the wounded muscle cells, as compared to healthy controls 
(Figure 32). Fold change data is detailed in (Table 2) which can be found in Appendix C. 
Notably, oxidative phosphorylation and markers of oxidative stress including cellular 
amount of reactive oxygen species and their metabolites were significantly up-regulated in 
the injured muscle cells (Figure 32 and Figure 33). Likewise, inflammatory signaling and 
markers of cellular apoptosis were significantly more expressed in the injured muscle cells 
(Figure 32 and Figure 33) On the other hand functions related to tissue growth and 
development, and muscle contraction were downregulated in the injured muscle cells 




Figure 32: Comparative protein expression profiling of control vs wounded lymphatic 
muscle cells together with the molecular and cellular pathways predicted by IPA.  (A) 
Un-biased, non-clustered heat map generated in “perSPECtives” using the 
normalized weighted spectral counts highlights the change in the protein expression 
profiles in the “wounded” relative to the “control” lymph muscle cells.  (B) The main 
canonical pathways affected by the top 105 genes with higher than twofold expression 
level in the “wounded” vs “control” samples, subjected to the analysis by IPA 
algorithm.  The % of total molecules up- (red color) or downregulated (green color) 
in each pathway together with the corresponding log (-p value) are displayed.  (C) 
Protein networks significantly regulated (p< 0.05) in the “wounded” relative to the 
“control” lymph muscle cells are displayed as IPA predicted diseases and cellular 
functions using the z score (down-regulated corresponding to z<-1.5 and blue color; 
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up-regulated, corresponding to z>+1.5 and orange color). The size of each rectangle 
is proportional with the value of the z score associated to a specific pathway.  
Increased organismal injury, cell death, small molecules and lipids metabolism and 




Figure 33: Protein networks significantly regulated (p < 0.05) in the wounded relative 
to the control lymph muscle cells.  The proteins with at least two-fold changed in the 
expression profiles were analyzed by Ingenuity Pathways Analysis (IPA, Ingenuity 
Systems) to determine the cellular pathways impacted by the wounded conditions 
relative to the control in the lymph muscle cells. (A) The functional networks with the 
highest scores were predicted by IPA to be related to the increased cellular movement 
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of fibroblasts, smooth muscle cells and leukocytes in the wounded cells as compared 
with control.  The wounded conditions are prone to experience a significant in the 
networks associated with the fibrosis, reactive oxygen species (B) and cell 
proliferation (C).  The proteins in red and green had a significantly up- or down-
regulated expression (p < 0.05), respectively.  The shape of symbols denotes the 
molecular class of the proteins. A solid line indicates a direct molecular interaction, 
whereas a dashed line indicates an indirect molecular interaction. 
 
4.3.6 Isolated lymphatic vessel segments from the wounded leg are structurally and 
mechanically altered compared to control 
 Isolated lymphatic vessel segments exhibited alterations in the morphology of 
lymphatic valves. Vessels from the wounded leg had valve leaflets that appeared prolapsed 
compared to control when pressurized (Figure 34). Isolated vessel segments were frozen 
and later underwent staining with hematoxylin and eosin. Wounded vessel sections 
exhibited an increase in matrix surrounding the lumen of the vessel when compared to 
control. Additionally, wounded segments showed atrophy of the intima that was not 
observed in control segments (Figure 34). Biaxial testing of isolated vessel segments was 
used to evaluate changes in the mechanical properties of the vessels in response to the 
ligation surgery and then fit to a previously developed microstructural based constitutive 
model of the lymphatic vessel. Vessels from the wounded leg displayed an increase in 
stiffness compared to control. Interestingly, wounded segments have a less pronounced toe 
region of the pressure-diameter curves compared to control, indicating alterations in elastin 




Figure 34: Vessels from the wounded leg displayed structural and mechanical 
changes caused by the ligation surgery. (A) The lymphatic valves of vessel segments 
from the wounded leg were prolapsed upon pressurization. (B) Vessel cross sections 
from the wounded leg (left column- transverse, right column- axial) exhibited atrophy 
of the musculature surrounding the vessel compared to control. Additionally, vessel 
segments from the wounded leg appear to have an increase in matrix surrounding the 
vessel. (C) Biaxial testing was conducted on isolated vessel segments at various axial 
stretches and transmural pressures. Wounded vessels exhibited increases in vessel 
compliance compared to control. The biaxial data was fit to a constitutive model to 





4.3.7 Computational modeling of the lymphatic chain predicts that wounded vessels 
functionally compensate for changes in the mechanical properties of the vessel 
Data from isolated vessels, wire myography, and biaxial mechanical testing were 
used to inform a computational model of a lymphatic vessel chain. This model was used to 
evaluate the predicted flow and contractile response of the lymphatic vessel under a 
confronting pressure gradient given the changes caused by the remodeling. Our 
computational model suggests that the remodeled vessel would have a lower flow rate than 
the control given equal contraction frequency. However, this difference in flow rate can be 
attenuated by an increase in the contraction frequency. Interestingly, upon incorporating 
the average contraction frequencies from the isolated vessel data, we found that the flow 
rate for the lymphatic chain from the wounded leg may exceed control (Figure 35). Our 
computational model suggests that this increase in flow rate occurs despite the decrease in 
the average predicted stroke volume of the lymphangions due to a combination of increased 




Figure 35: Isolated vessel function and mechanical properties were utilized to inform 
a computational model, which was used to elucidate how the structural and functional 
changes caused by the surgery would affect intrinsically driven flow. (A) Biaxial 
testing data was used to inform a computational model that predicts active and 
passive wall stress as a function of circumferential stretch. Testing data suggests an 
increase in the passive and active compliance of the vessels from the wounded leg. (B) 
(Left) Mechanical parameters coupled with ex-vivo isolated vessel frequencies were 
used to simulate predicted lymph flow rates as a function of pressure generation. Our 
computational model suggests that vessel segments from the wounded leg may exceed 
the flow rate of control by increasing contraction frequency and contractile force. 
(Right) Pressure-volume curves for these simulations. (C) (Left) Mechanical 
parameters coupled with in-vivo contraction frequencies assessed via NIR imaging at 
day 42. Our computational model suggests that, in an in-vivo context, vessel segments 
from the wounded leg may have decreased intrinsically driven lymph flow rates. 
(Right) Pressure-volume curves for these simulations. 
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4.4 Discussion and Conclusions 
Injury to the lymphatic vasculature is quite common in surgery, whether 
unintentionally as in the case of chyle leak, or intentionally when metastatic lymph nodes 
must be removed in the context of cancer surgery. Despite its occurrence, and the vast 
importance of lymphatics in maintaining fluid balance, lipid transport, and immune cell 
trafficking, very little is known regarding how lymphatics adapt and remodel after injury 
and the resulting implications of this remodeling on lymphatic pump function. Here we 
utilize an interdisciplinary approach involving large animal lymphatic imaging, functional 
isolated vessel pumping and biomechanics tests, proteomics, and computational modeling 
to provide unique insight into the functional and molecular adaptions of lymphatics due to 
alterations in the collecting vessel network. Following surgical damage to lymphatic 
vessels, the intact collecting vessels draining the tissue space alter their functional response 
and subsequently remodel to compensate for the increased fluid loads caused by the injury. 
Similar to observations made in vascular diseases such as hypertension and atherosclerosis, 
abnormal mechanical loading on the vessel leads to stiffening, endothelial dysfunction, and 
a shift in pathways involved in mitochondrial metabolism. 
A number of animal models have been developed for the purpose of studying 
lymphatic healing and edema development following a wound (94, 161, 201, 221). These 
models suffer from two primary limitations when extrapolating results to the context of 
common clinical lymphatic injuries in humans: 1) small rodent models lack the hydrostatic 
pressure gradients that serve as the primary mechanical load which the collecting vessels 
must work overcome; 2) the models are created through extensive damage of the lymphatic 
vasculature in which there is usually no intact lymphatic pathways in the limb with which 
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fluid may be returned. Thus, these models are unable to recapitulate the gradual adaptation 
of the intact lymphatic vasculature following a surgical insult. This study is the first of its 
kind to probe the effects of collecting lymphatic ligation alone on the functional response 
of the surrounding intact lymphatic network. This has relevance from a clinical standpoint 
because in the case of secondary lymphedema, patients that later develop the disease still 
possess intact and functional collecting lymphatic vessels (47) and often do not present 
with symptoms of lymphedema until 2 years or more after surgery (7). In fact, in our model, 
we detected no observable swelling of the limbs. This approach also afforded us the ability 
to longitudinally track lymphatic function over the course of adaption using NIR imaging.  
The enhanced intrinsic contractile frequency of the isolated remodeled vessel when 
compared to the same vessel from the contralateral control limb, is likely a compensatory 
mechanism to handle the elevated fluid loads placed on this vessel as it now seeks to do 
the work of two vessels. This is supported by the observed decrease in basal tone, which is 
known to lower fluid resistance of the vessels (57) as well as the return of the in vivo 
pumping pressure to normal levels at day 42. Because these alterations in the vessel’s 
response to stretch is governed by the smooth muscle surrounding the vessel, it stands to 
reason that these observed differences are caused by alterations to the structure or function 
of the lymphatic smooth muscle initiated by the wound to the lymphatic network (58). 
Proteomics of isolated lymphatic smooth muscle cells from the wounded leg revealed an 
upregulation of pathways associated with oxidative phosphorylation and mitochondrial 
dysfunction caused by oxidative stress (16). This complements the observed increase in the 
contractile frequency of isolated vessels, given that increased oxidative stress has been 
demonstrated as a result of increased contractile frequency of cardiomyocytes (54). It is 
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important to note a sustained elevated effort by LMCs could lead to muscle fatigue and 
thus decreased lymphatic contractility over time, and may have implications in the later 
development of lymphatic dysfunction (218), although currently this remains speculative 
and should be supported by future work. 
The lymphatic endothelium serves as a complementary and potent regulator of the 
lymphatic contractile response to flow. It is believed that this mechanism is a result of 
pump-conduit duality of the lymphatics, wherein flow imposed on the lymphatic vessel 
induces contractile inhibition and passive conduit behavior via endothelial nitric oxide 
synthase (eNOS) (31, 75, 172, 193). Lymphatic vessels from the wounded leg experienced 
less contractile inhibition in response to flow when compared to control. Upon inhibiting 
eNOS with L-NAME we determined that vessels from the wounded leg were less 
dependent on eNOS for regulating contraction than control and thus continued to contract 
at higher imposed transaxial pressures. These vessels also exhibited a lower sensitivity to 
flow induced wall shear stress. These results are consistent with those reported in a 
postnatal model of abnormal lymphatic developmental due to enhanced flow, in which the 
lymphatics exhibited enhanced contractility, impaired NO bioavailability, altered 
posttranslational regulation of eNOS, and enhanced ROS generation (55, 56). 
To determine if the observed functional alterations of the intact vessel on the wounded 
leg could be due to compensation for the loss of the ligated vessel we utilized a 
computational model to simulate the flow capacity of the remodeled lymphatic chain (177). 
We could independently control factors in the computational model and determine how 
they may contribute to the overall function of the pump to transport fluid against and 
adverse pressure gradient as would be encountered through hydrostatic loading in vivo. 
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Our results suggest that the decreased stiffness of the remodeled vessel, coupled with the 
increase in contractile force generation, and increased intrinsic contractile frequency would 
all elevate its predicted flow rate. Interestingly, the elevation in the predicted flow rate of 
the remodeled vessel falls very close to what would be expected in a limb in which one 
lymphatic vessel must handle the fluid load of what used to be two vessels draining the 
tissue space. On the other hand, when the average in-vivo frequencies assessed via NIR 
imaging at day 42 are used in the computational model, the predicted flow rate of the 
remodeled vessels falls to roughly half of control. Taken together, these results suggest that 
the vessels from the wounded leg alter their intrinsic contractile function to elevate their 
flow to compensate for the increased fluid load caused by damage to a vessel draining the 
same tissue space; however, in an in-vivo context, mechanical or soluble factors may 
inhibit the contractile frequency of the remodeled vessel. This could be caused by elevated 
lymph load in the wounded leg that could increase extrinsically driven lymph flow and 
subsequently decrease the intrinsic contractile frequency of the vessel (63, 171, 172).  Thus, 
it is possible that total lymph drainage is elevated in-vivo despite the observed decrease in 
the contractile frequency, which would explain the lack of swelling observed in the model. 
In conclusion, this study is the first of its kind to demonstrate that an injury to a single 
collecting lymphatic vessel can have broader impacts on the remaining intact lymphatic 
network. Specifically, the uninjured vessel can compensate in vivo by altering its intrinsic 
functional response and structure. However, through this process, the collecting lymphatic 
muscle experiences increased oxidative stress due to increased contractility. This raises the 
question of when or if this increase in oxidative stress would later result in lymphatic 
muscle fatigue and subsequent dysfunction. One of the most important implications for this 
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is in the context of the pathogenesis of secondary lymphedema, where patients undergo a 
primary surgical insult to the lymphatic network draining the tissue space. It has been 
observed that these patients have intact and functional collecting lymphatic vessels (157). 
In fact, in these scenarios, it has even been suggested that overworked lymphatic vessels 
due to excess fluid load may be indicative of later lymphedema development (15, 47). Our 
data supports these hypotheses by demonstrating functional compensation by intact 





CHAPTER 5. CONCLUSIONS AND FUTURE IMPLICATIONS 
 Despite being an integral driver of lymphatic transport, relatively little is known 
about how lymphatic pump function and remodeling is affected following injury that 
results in a loss of lymphatic drainage pathways. In some cases, this loss ultimately results 
in chronic lymphedema whereas in others it does not. It is possible that predisposing factors 
that impact baseline lymphatic pump function become exacerbated by increased fluid loads 
due to surgical insult, ultimately manifesting in lymphedema. Alternatively, in scenarios 
where lymphedema does not immediately develop, it is unclear how collecting lymphatic 
vessels are able to alter their structure and function to compensate for losses in lymphatic 
drainage pathways. It was therefore the goal of this scholarly work to develop and validate 
novel NIR imaging methods that enable non-invasive phenotyping of lymphatic pump 
performance and subsequently to use these techniques to provide biological insight into the 
functional and remodeling response of the collecting lymphatic vessels to surgical 
disruption of lymphatic drainage pathways. 
In Chapter 2, we presented the development of novel NIR imaging techniques that 
enable holistic characterization, or phenotyping, of collecting lymphatic function during 
disease. To this end, we created a method to quantify lymphatic pumping pressure using 
NIR imaging in conjunction with an automated feedback-controlled occlusion cuff. The 
results of the study not only demonstrated the utility of the technique but also provided 
novel insight into the regulation of collecting lymphatic physiology. Specifically, we 
discovered that chains of lymphangions contracting in series are essential in generating the 
pressures necessary to propel lymph up the adverse hydrostatic pressure gradients in the 
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body. Moreover, we found that a modulator of lymphatic contractility that is commonly 
associated with inflammation, nitric oxide, directly regulates collecting lymphatic pump 
physiology via impairment of contractile force generation in addition to its previously 
described effects on contractile frequency. It was these discoveries that helped to enhance 
the physiological relevance of the metric and enabled our subsequent line of questioning 
regarding pump dysfunction in the context of lymphatic disease. By combining the novel 
pumping pressure measurement technique with previously established packet performance 
metrics, we enabled the unique ability to non-invasively distinguish underlying modalities 
of lymphatic pump failure. To demonstrate this, we utilized two models that were known 
to possess deficiencies in lymphatic transport, but the involvement of the collecting vessel 
pump had not been described, and thus their appropriateness as a therapeutic target had 
remained elusive. These included a mouse lacking lymphatic endothelial epsins and a 
model of diet-induced obesity.   
In using our functional phenotyping approaches on LEC-DKO mice, we detected 
several abnormalities in lymphatic network, despite the histological appearance of 
structurally “normal” lymphatic vessels and valves. This appeared to be caused by the 
profound dysfunction of the collecting lymphatic vessels, which exhibited no detectable 
contractile activity in addition to valve incompetency. The results of the LEC-DKO study 
have subsequently raised a novel line of questioning regarding the role of lymphatic 
endothelial epsins in the regulation of lymphatic physiology and the development of 
lymphedema. To this end, the work presented in this thesis motivated the use of an 
inducible lymphatic endothelial epsin knockout model, coupled with the disease 
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phenotyping techniques described here, that enables investigation into the post-
developmental role of epsins in regulating lymphatic function and remodeling.  
In contrast with the profound dysfunctional phenotype discovered in the LEC-DKO 
model, we found that obese mice exhibited only modest declines in lymphatic packet 
frequency. In fact, this highlighted the primary contribution of our functional phenotyping 
techniques. If we had only assessed packet frequency as the sole metric of collecting 
lymphatic function in these two disease models, we would not have elucidated the stark 
differences in pumping pressure that suggest a more profound impairment in lymphatic 
function associated with the genetic loss of lymphatic endothelial epsins. Despite our 
findings that obesity only appears to have modest effects on collecting lymphatic pump 
function, it is well known that obesity increases the risk of lymphedema development and 
the subsequent severity of the disease after surgical insult to the lymphatic vasculature. 
This raised the question of if these baseline declines in collecting lymphatic packet 
frequency, caused by obesity, induce a “tipping point” following lymphatic injury in which 
lymphatic transport declines further and lymphedema pathogenesis occurs. It was therefore 
the goal of my work presented in Chapter 3 to investigate the specific collecting lymphatic 
failure modes involved in lymphedema pathogenesis during obesity.  
To accomplish the study presented in Chapter 3, we utilized the functional 
phenotyping techniques discussed in Chapter 2 in conjunction with a single vessel 
lymphatic vessel ligation model to induce lymphedema in obese mice and subsequently 
assess the functional response of the remaining intact lymphatic vessel over the course of 
the disease. The results of the study demonstrate that obesity differentially impairs the 
contractile function of that intact collecting lymphatic vasculature during lymphedema. 
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More specifically, we found that obesity significantly delays the recovery of collecting 
lymphatic pumping pressure during lymphedema and that this effect persists despite the 
resolution of tissue swelling. The etiology of this decline in pumping pressure is, so far, 
unclear; however, we hypothesized that this could be a result of obesity differentially 
decreasing lymphatic contractile frequency to a point that the lymphatic vessel chain is no 
longer able to maintain pressure generating abilities. Given that CD4+ T-cells have been 
shown to be an essential mediator of the tissue changes associated with lymphedema 
development during obesity, we sought to determine if inhibiting activation and 
differentiation of these cell types with tacrolimus would protect against the functional 
declines that we observed. We subsequently demonstrated that tacrolimus, protects against 
losses in packet frequency and pumping pressure following lymphedema development in 
obese mice.  
Taken together, the results from Chapter 3 suggest that obesity induces differential 
declines in the functional response of the collecting lymphatic vessels during lymphedema 
and that this response is likely T-cell mediated. Although it is apparent from this study that 
collecting lymphatic dysfunction is associated with obesity during lymphedema, the degree 
that lymphatic dysfunction my influence lymphedema development during obesity is 
unclear. This study pathed the way for future work seeking to investigate causality within 
this relationship. In fact, given that our functional phenotyping techniques provides a 
wealth of functional metrics at various timepoints throughout the studies, it seems 
reasonable to believe that these “features” could be incorporated into machine learning 
models that seek to predict the severity of lymphedema at later time points. In addition to 
this, it would be beneficial for future work to investigate the biological mechanisms that 
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are driving the functional declines observed in this study. For example, knowledge of the 
degree that these changes are being caused by direct remodelling of the vessels versus 
soluble functional mediators would be invaluable for determining therapeutic targets that 
seek to improve collecting vessel function.  
 Unlike mouse lymphedema models, human lymphedema typically does not 
manifest immediately after surgery. In fact, in a clinical setting the lymphatic vasculature 
is routinely damaged during surgery and yet, in many cases, lymphedema will never 
develop.  Therefore, we hypothesized that surgical ligation of a collecting lymphatic vessel 
will induce a compensatory functional and remodeling response from an undamaged vessel 
draining the same tissue space when lymphedema does not develop. We believed that 
sheep, given their size similarities to humans, may provide a more clinically relevant model 
for assessing lymphatic pump function and remodeling response to lymphatic injury. 
Because of this, in study described in Chapter 4, we adapted the tools and techniques 
described in Chapters 2 and 3 for use in sheep. This was accomplished by developing a 
sheep lymphatic injury model, that involved surgical ligation of a single collecting 
lymphatic vessel in the hind limb while leaving the other vessel intact.  
We discovered that following surgical damage to lymphatic vessel, the intact 
collecting vessel draining the same tissue space alters its functional response and 
subsequently remodel to compensate for the increased fluid loads caused by the injury. 
NIR functional imaging revealed that this intact vessel exhibits declines in packet 
frequency, packet transport, and pumping pressure 28 days after surgery, that subsequently 
recovers by day 42. Ex-vivo testing of these intact isolated vessels revealed that they had 
enhanced intrinsic contractility compared to controls in conjunction with decreased flow-
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mediated contractile inhibition. Proteomic analysis of the lymphatic smooth muscle cells 
from these revealed an upregulation of pathways associated with oxidative phosphorylation 
and mitochondrial dysfunction caused by oxidative stress, which complements the 
observed increase in the contractile frequency of isolated vessels. This study is the first of 
its kind to demonstrate that an injury to a single collecting lymphatic vessel can have 
broader impacts on the remaining intact lymphatic vessels in scenarios that lymphedema 
does not develop. Moreover, it appears that the intact lymphatic vessels compensate in vivo 
by altering its intrinsic functional response and structure. However, through this process, 
the collecting lymphatic muscle experiences increased oxidative stress due to increased 
contractility, which raises question of when or if this increase in oxidative stress would 
later result in collecting lymphatic dysfunction. It would be beneficial for future work to 
investigate the role oxidative stress in collecting lymphatic pump failure along with the 
mechanisms that drive this process. Additionally, given that these muscle cells have 
increased oxidative stress, it would be beneficial to investigate if an additional challenge 
(surgical or inflammatory) overloads the fluid draining capacity of the vessels ultimately 
resulting in lymphedema.  
In conclusion, the results of the studies presented in this scholarly work offer one of 
the first glimpses into the functional and remodeling response collecting lymphatic vessels 
to disruptions in lymphatic drainage pathways. Specifically, we demonstrate that diet-
induced obesity adversely impacts collecting lymphatic contractility and pump function 
during lymphedema in a mouse model. Further, in a clinically relevant sheep model, we 
demonstrate that the uninjured vessel can compensate in vivo by altering its intrinsic 
functional response and structure; however, through this process, the collecting lymphatic 
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muscle experiences increased oxidative stress due to increased contractility. One of the 
most important findings from these studies is that injury to the lymphatic vasculature 
produces lasting structural and functional alterations to the remaining intact collecting 
lymphatic vessels, which occurs independently of direct mechanical damage. It is possible 
that these lasting alterations may influence the development of lymphedema upon later 
harmful stimuli that subsequently overloads the fluid drainage capacity of these vessels. 
Future work is needed to investigate the potential adverse consequences of these functional 
and remodeling responses, and if or how they may influence the development of 



















%Pumping Pressure Measurement 
%Pressure and intensity data will be imported from text files (tab 
delimited)  
%and will be analyzed to determine the measured pumping pressure. 
%Browse for pressure and intensity files 
[pFileName, pPathName] = uigetfile('*.txt','Select the pressure 
data','C:\Users\'); 
[iFileName, iPathName] = uigetfile('*.txt','Select the intensity 
data','C:\Users\'); 
%Full file names for the pressure and intensity files 
pressureFile = strcat(pPathName,pFileName); 
intensityFile = strcat(iPathName,iFileName); 
%Input frame where pumping pressure measurement started to adjust time 
data 
%for pressure measurement 
prompt = 'Which frame did the pumping pressure measurement start on?'; 
dlg_title = 'Input Frame'; 
num_lines = 1; 
PressureFrameStart = inputdlg(prompt,dlg_title,num_lines,{'0'}); 
PressureFrameStartNum = str2double(PressureFrameStart{1}); 
%Read in data from pressure file, and separate out adjusted time data 
and 
%the pressure data 
PressureWksht = tdfread(pressureFile); 
PressureFieldNames = fieldnames(PressureWksht); 
PressureTimeData = 
PressureWksht.(PressureFieldNames{1})+PressureFrameStartNum; 
PressureData = PressureWksht.(PressureFieldNames{2}); 
%Read in data from intensity file, and separate out time data and the 
%intensity data 
IntensityWksht = dlmread(intensityFile, '\t'); 
%IntensityFieldNames = 'intensity'%fieldnames(IntensityWksht); 
% IntensityTimeData = IntensityWksht.(IntensityFieldNames{1}); 
% IntensityData = IntensityWksht.(IntensityFieldNames{2}); 
IntensityData = IntensityWksht; 
IntensityTimeData=zeros(1,length(IntensityData))'; 
for k=2:length(IntensityData) 
    IntensityTimeData(k) = IntensityTimeData(k-1)+1; 
end 
%Filter Intensity Data using a moving average filter (averaging over 15 
%points) 
timeIntervalFilter = 5; 
FilterMat = ones(1,timeIntervalFilter)/timeIntervalFilter; 
IntensityDataFiltered = filter(FilterMat, 1, IntensityData); 




% hold on 
% plot(IntensityTimeData,IntensityData) 
% plot(IntensityTimeData,IntensityDataFiltered) 
% legend('Intensity Data','Intensity Data Filtered') 
  
%% 
%Determining Pumping Pressure Value 
count = 0; 
%Find time point where pressure first goes above 80 mmHg (t1) and when 
it 
%decreases below 60 mmHg after holding the pressure at 80 mmHg (t2) 
for i=1:length(PressureData) 
    if PressureData(i)>80 && count==0 
        t1_P = floor(PressureTimeData(i)); 
        [Val1, t1] = min(abs(IntensityTimeData-t1_P));  
        count = 1; 
    elseif PressureData(i)<60 && count==1 
        t2_P = floor(PressureTimeData(i)); 
        [Val2, t2] = min(abs(IntensityTimeData-t2_P)); 
        count = 2; 
    elseif PressureData(i)<1 && count==2 
        t3_P = floor(PressureTimeData(i)); 
        [Val3, t3] = min(abs(IntensityTimeData-t3_P)); 
        break; 
    end 
end 
%Find max intensity after t2 and find index of value in 
%IntensityDataFiltered 
[maxIntensity, maxIntIndex_NA] = max(IntensityDataFiltered(t2:t3)); 
maxIntIndex = length(IntensityDataFiltered) - 
length(IntensityDataFiltered(t2:end)) + maxIntIndex_NA; 
%Find min intensity after t1 and find index of value in 
%IntensityDataFiltered 
[minIntensity, minIntIndex_NA] = 
min(IntensityDataFiltered(t2:maxIntIndex)); 
minIntIndex = length(IntensityDataFiltered) - 
length(IntensityDataFiltered(t2:end)) + minIntIndex_NA; 
%Average min and max intensity to find the mid intensity 
midIntensity = mean([minIntensity maxIntensity]); 
%Find the index and time where the intensity data is closest to the mid 
%intensity 
[midIntVal, midIntIndex_NA] = 
min(abs(IntensityDataFiltered(minIntIndex:maxIntIndex)-midIntensity)); 
midIntIndex = length(IntensityDataFiltered) - 
length(IntensityDataFiltered(minIntIndex:end)) + midIntIndex_NA; 
midIntTime = IntensityTimeData(midIntIndex); 
%Find the index and pumping pressure where the intensity data is 
closest to 
%the mid intensity 
if (maxIntensity-minIntensity)>100 
    [pressPumpVal, pressPumpIndex] = min(abs(PressureTimeData-
midIntTime)); 
    PumpingPressure = PressureData(pressPumpIndex); 
else 








%Find how quickly the intensity decreases to its minimum value 
[maxIntEmpRate, maxIntEmpRateIndex_NA] = 
max(IntensityDataFiltered(t1:t2)); 
maxIntEmpRateIndex = length(IntensityDataFiltered) - 
length(IntensityDataFiltered(t1:end)) + maxIntEmpRateIndex_NA; 
minThreshold = 1.05*minIntensity; 
for j=maxIntEmpRateIndex:t3 
    if IntensityDataFiltered(j)<minThreshold 
        threshIntIndex = j; 
        break; 












title('Pumping Pressure Measurement') 
yyaxis right 
plot(PressureTimeData,PressureData) 
axis([0 max(max(PressureTimeData),max(IntensityTimeData)) -5 90]) 
xlabel('Time (s)') 
ylabel('Pumping Pressure (mmHg)') 
yyaxis left 
plot(IntensityTimeData,IntensityDataFiltered) 
%Line to denote the pumping pressure on the graph 
if PumpingPressure>0 





















threshold = 0.001; %change 
  
%Packet Processing 
%Intensity data will be imported from text files (tab delimited)  
%and will be analyzed to determine the functional metrics. 
%Browse for intensity file 
[FileName, PathName] = uigetfile('*.txt','Select the intensity data', 
'C:\Users\'); 
%Full file names for the intensity file 
intensityFile = strcat(PathName,FileName); 
  











if maxtab2(1,1) < min2(1,1) 
    maxtab2 = maxtab2(2:end,:); 
end 
  
if maxtab2(end,1) > min2(end,1) 





    index=min2(n); 
    while y2(index) <= min2(n,2)*(1+threshold) 
        index=index-1; 
    end 
    mintemp2(1,1)=index;mintemp2(1,2)=y2(index); 
    index=min2(n); 
    while y2(index) <= min2(n,2)*(1+threshold) 
        index=index+1; 
    end 
    mintemp2(2,1)=index;mintemp2(2,2)=y2(index); 











    packet_width2 = [packet_width2 mintab2(n+1,1)-mintab2(n,1)]; 






    packet_line_x2 = mintab2(n*2-1,1):mintab2(n*2,1); 
    packet_slope2 = (mintab2(n*2,2)-mintab2(n*2-1,2))/(mintab2(n*2,1)-
mintab2(n*2-1,1)); 
    packet_offset2 = mintab2(n*2-1,2) - packet_slope2 * mintab2(n*2-
1,1); 
    for index=1:length(packet_line_x2) 
        packet_line_y2(index) = packet_line_x2(index)*packet_slope2 + 
packet_offset2; 
    end 
    packet_line2 = [packet_line_x2; packet_line_y2]; 
    packet_line2 = packet_line2'; 
    packet_boundary2 = [packet_boundary2;packet_line2]; 
  
    packet_amplitude2(n) = maxtab2(n,2) - mean_packet_min2(n); 
    packet_amplitude_perdiff2(n) = 
packet_amplitude2(n)/mean_packet_min2(n); 
for index = mintab2(n*2-1,1):mintab2(n*2,1) 
        integral_y2=[integral_y2;y2(index)]; 
    end 
    for index = 1:length(integral_y2) 
    packet_integral2(n) = packet_integral2(n) + integral_y2(index)-
packet_line_y2(index); 
    end 
    packet_integral_norm2(n) = packet_integral2(n)/mean_packet_min2(n); 
    packet_line_y2=[]; 
    integral_y2=[]; 
end 
  
fig2 = figure; 






%title([filename ' Plot 2']); 
  
  





%packets per min, assuming 10fps 
packet_frequency2 = length(maxtab2)/(mintab2(end,1)-mintab2(2,1))*600; 
  
avg_packet_width2 = mean(packet_width2); 
avg_packet_amplitude2 = mean(packet_amplitude2); 
avg_packet_amplitude_perdiff2 = mean(packet_amplitude_perdiff2); 
avg_packet_integral2 = mean(packet_integral2); 
avg_packet_integral_norm2 = mean(packet_integral_norm2); 
  

































APPENDIX C. PROTEOMIC ANALYSIS OF SHEEP LYMPHATIC 
SMOOTH MUSCLE CELLS 
Table 2 – Summary of protein expression fold changes and associated genes 
Fold Changes 
Wounded/Ctrl 












-1.028 ACLY ATP citrate lyase Cytoplasm enzyme 
1.117 ACTB actin beta Cytoplasm other 













aldehyde dehydrogenase 1 







acidic nuclear phosphoprotein 
32 family member B 
Nucleus other 















ATPase Na+/K+ transporting 





ATPase Na+/K+ transporting 


















calmodulin 1 Cytoplasm other 
0 CAPN3 calpain 3 Cytoplasm peptidase 
-1.181 CAST calpastatin Cytoplasm peptidase 










1.113 CNN1 calponin 1 Cytoplasm other 
2.444 COX7A1 









-4.689 CRYAB crystallin alpha B Nucleus other 












  CSTB cystatin B Cytoplasm peptidase 
2.052 CTSB cathepsin B Cytoplasm peptidase 
-1.171 CTSD cathepsin D Cytoplasm peptidase 
  CTSL cathepsin L Cytoplasm peptidase 
1.309 CYCS cytochrome c, somatic Cytoplasm transporter 
  CYP11A1 
cytochrome P450 family 11 
subfamily A member 1 
Cytoplasm enzyme 




  DYNLT3 dynein light chain Tctex-type 3 Cytoplasm other 
1.23 EEF1D 
eukaryotic translation 




-3.527 FTH1 ferritin heavy chain 1 Cytoplasm enzyme 
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0 GGCX gamma-glutamyl carboxylase Cytoplasm enzyme 
-1.131 H2AFZ H2A histone family member Z Nucleus other 







(NADP(+)) 1, cytosolic 
Cytoplasm enzyme 
-3.287 IGFBP4 
insulin like growth factor 






























-1.064 MT-ATP6 ATP synthase F0 subunit 6 Cytoplasm transporter 
1.094 MT-CO2 
cytochrome c oxidase subunit 
II 
Cytoplasm enzyme 
1.476 MT-CO3 cytochrome c oxidase III Cytoplasm enzyme 
1.507 MT-ND3 
NADH dehydrogenase, 




subunit 5 (complex I) 
Cytoplasm enzyme 
-2.212 MYLK myosin light chain kinase Cytoplasm kinase 
-1.349 PDXK 
pyridoxal (pyridoxine, vitamin 
B6) kinase 
Cytoplasm kinase 








-2.509 PLP2 proteolipid protein 2 Cytoplasm transporter 





protein kinase cAMP-activated 
catalytic subunit alpha 
Cytoplasm kinase 




-1.282 PYGB glycogen phosphorylase B Cytoplasm enzyme 
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1.262 RPL10 ribosomal protein L10 Cytoplasm other 
1.072 RPS25 ribosomal protein S25 Cytoplasm other 
1.134 RPS26 ribosomal protein S26 Cytoplasm other 
1.069 RPSA ribosomal protein SA Cytoplasm 
translation 
regulator 




-1.817 SFN stratifin Cytoplasm other 















  SLC2A1 




















superoxide dismutase 1, 
soluble 
Cytoplasm enzyme 
1.021 SORD sorbitol dehydrogenase Cytoplasm enzyme 


























-1.499 TXN thioredoxin Cytoplasm enzyme 
1.103 UBA52 
ubiquitin A-52 residue 







1.023 VIM vimentin Cytoplasm other 
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